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Increasing demand for health services and resource constraints have affected 
access to prescribing services in primary care. Some countries, including New 
Zealand (NZ), have introduced non-medical prescribing (NMP) to facilitate timely 
access to medicines. This shift in roles utilises the skills of health professionals 
including pharmacists to improve patients’ access to prescribing services. NMP in 
NZ is a relatively new health service, and little is known about the uptake, 
utilisation and perceptions of this service from both the public and pharmacists. 
 
Aim 
To investigate non-medical prescribing in New Zealand, and how pharmacists fit 
into this prescribing landscape in primary care. 
 
Method 
This thesis was conducted in five stages: 
1. A literature review to establish an overview of NMP research conducted in NZ, 
and to identify knowledge gaps.  
2. A review of data from a variety of NZ sources (NZ legislation, information from 
professional and regulatory organizations, policy documents, information from 
education providers, and grey literature) to provide an updated overview of 
NMP in NZ. 
3. A pharmacoepidemiology study, utilising the NZ National healthcare collections 
to identify NMP trends in NZ primary care. 
4. A discrete choice experiment to determine community pharmacists’ 
preferences for providing prescribing services in primary care in NZ. 
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5. A discrete choice experiment to determine the NZ publics’ preferences for 
utilising pharmacist prescribing services in primary care in NZ. 
 
Main findings 
1. There is a paucity of NZ research regarding non-medical prescribing. Little is 
known in NZ about the current state of NMP and how this service is being 
utilised. NZ research has yet to explore the place of pharmacist prescribers 
within primary care.  
2. There is variation in the regulation, educational programmes and prescribing 
competencies used by the different prescribing health professionals involved in 
NMP in NZ. 
3. NMP is not widely utilised in NZ, and nurse prescribers are the major NMP 
providers in primary care. Pharmacist prescribers are not well utilised and 
have the potential to contribute more to the NMP service in NZ.  
4. NZ community pharmacists are willing to provide prescribing services in 
primary care in NZ using a variety of autonomous prescribing models in 
community pharmacies.  
5. The NZ public are willing to use various models of pharmacist prescriber 
services in primary care if they are accessible when required, are open for 
longer hours, and cost less than a GP consultation.  
 
Conclusion 
Compared to the other countries, NMP in NZ is inconsistently implemented and 
underutilised. An overarching NMP policy should be developed to enable 
consistency in the various aspects of NMP. The DCEs signalled that NZ community 
pharmacists see themselves as part of the prescribing team, and that the NZ public 
are willing to utilise pharmacist prescribing services in primary care. As demand 
for healthcare in NZ increases, pharmacists have the potential to be part of the 
solution within the NMP framework in primary care. Policy makers and funders 
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have the opportunity to utilise the outputs of this thesis to evolve the traditional 
role of pharmacists—to develop pharmacist prescribing services in NZ that enable 
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Chapter 1: Introduction 
Healthcare systems around the world face a number of concerns regarding their 
financial and operational viability. These concerns include the increased cost of 
new pharmaceuticals, evolving technologies, the growing needs of aging 
populations, the impact of chronic disease, and a significant workforce crisis [1]. 
People’s access to medicines is also an important factor as drug therapy is the most 
common health intervention in modern healthcare systems [2]. The activity of 
prescribing medicines for a patient has traditionally been the responsibility of a 
physician. The main prescribers within healthcare systems are medical 
practitioners, particularly those in primary care, and the international shortage of 
medical practitioners has affected access to prescription medicines by populations 
in many countries [2]. This problem has been identified, particularly in developed 
countries, as the burdens of chronic disease and aging populations threaten to 
overload already struggling healthcare systems [2]. Many countries have extended 
the authority of prescribing medicines to include other health professionals in an 
attempt to address this problem. 
 
1.1 The aim behind non-medical prescribing 
Extending prescribing rights to other health professionals can allow more patients 
to be assessed and treated in a timely manner. In the United Kingdom (UK), the 
socioeconomic and political demands on their healthcare system has seen the 
extension of prescribing right to groups of healthcare professionals, other than 
medical doctors [3]. The aim of non-medical prescribing in the UK was to improve 
patient care without compromising patient safety, make it easier and quicker for 
patients to get the medicines they need, increase patient choice in accessing 
medicines, make better use of the skills of health professionals, and contribute to 
the introduction of more flexible team-working across the health service [4]. Other 
countries have also extended prescribing rights to other healthcare professionals 
including the USA, Canada, Australia, the UK, Ireland, and Sweden [5,6]. New 
Zealand (NZ) also currently utilises non-medical prescribing. 
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1.2 What is non-medical prescribing and what health professions 
are involved? 
Traditional implementers of prescribing were healthcare professionals who held a 
medical degree and dentists. Non-medical prescribing is a term that describes the 
prescribing of medicines to a patient by a health professional who does not have a 
medical degree, but they do have the legislative right to prescribe prescription 
medicines. There are various definitions used to describe this internationally, 
however the term, non-medical prescribing (NMP) seems to have originated in the 
UK [7]. In the UK, NMP is defined as prescribing by specially trained nurses, 
optometrists, pharmacists, physiotherapists, podiatrists and radiographers, 
working within their clinical competence as either independent or supplementary 
prescribers [8]. Health professionals that have prescribing rights in many 
countries include chiropodists, dietitians, midwives, nurses, optometrists, 
pharmacists, physiotherapists, podiatrists, and radiographers, and are termed non-
medical prescribers [9]. It is recognised that the UK has the most extensive non-
medical prescribing rights internationally [3,10,11]. Currently, Australia has only 
extended prescribing rights to dentists, midwives, nurses, optometrists, 
podiatrists, and physiotherapists [12]. 
 
1.3 Models of non-medical prescribing 
A non-medical prescribing model describes how a non-medical prescriber is 
allowed to prescribe within their scope of practice. Non-medical prescribing 
models vary between countries. The UK has had the most significant policy and 
regulation reform, and has three main non-medical prescribing models which 
include: 
• independent prescribing, defined as prescribing by a practitioner, who is 
responsible and accountable for the assessment of patients with undiagnosed 
or diagnosed conditions and for decisions about the clinical management 
required, including prescribing [13]. In the UK this includes pharmacists, 
nurses, chiropodists/podiatrists, optometrists and physiotherapists [14]. 
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• supplementary prescribing, defined as a voluntary partnership between the 
independent prescriber (a doctor or dentist) and a supplementary prescriber 
to implement an agreed patient-specific clinical management plan, with the 
patient’s agreement [13]. In the UK this includes pharmacists, midwives, 
nurses, chiropodists, podiatrists, physiotherapists, radiographers, optometrists 
[14]. 
• limiting prescribing to a restricted formulary, which relates to prescribing by 
community practitioners such as school nurses from a specified formulary [13]. 
Many countries including New Zealand have adapted the UK model and have also 
introduced NMP. Various literature reviews have found that pharmacist 
prescribing models in other countries included independent and supplementary 
prescribing models [15], as well as other prescribing models (i.e. 8 types of 
prescribing models were identified) [16]. Non-medical prescribers work in a 
variety of settings in primary care and secondary care. In many countries non-
medical prescribers work in medical centres, acute settings such as an accident 
and emergency departments, primary and secondary care clinics including 
condition-specific clinics such as diabetes and mental health, family planning, and 
community pharmacies. 
 
1.4 Non-medical prescribing training and prescribing 
competencies 
Non-medical health professionals, with the exception of dentists, are usually 
required to complete further training to enable them to become non-medical 
prescribers. Training programmes for non-medical prescribers are provided by 
higher education institutions [17]. Non-medical prescriber educational training 
requirements vary between countries and can also be dependent on the non-
medical prescriber’s model of practice. Prescribing is a complex process and 
teaching prescribing can be difficult [18,19]. Evaluation of non-medical prescribing 
training programmes is important to ensure that it is of the same standard that 
applies to medical prescribers. The WHO Guide to Good Prescribing and Teacher's 
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Guide to Good Prescribing are important resources that are incorporated into 
many curricula to teach prescribing to medical and non-medical prescribers [18-
21]. 
Prescribing competencies are seen as an important aspect of prescribing that 
relates to all prescribers. Medical and non-medical prescribers are required to 
regularly review their practice to ensure competence and this should also include 
prescribing [17]. Prescribing competencies are considered a tool to ensure 
responsible prescribing, thereby increasing patient safety. Continuing education 
programmes and competence frameworks are usually the responsibility of a health 
professional’s governing body, but other regulatory organisations may also be 
involved. In Australia, the Prescribing Competencies Framework was produced by 
one organisation and it applies all health professionals with prescribing rights 
[22]. This document provides prescribing competencies that can be incorporated 
into existing professional competencies, standards, and education and assessment 
systems [23]. The UK also has a single competency framework that applies to all 
prescribers in the UK [24]. The UK prescribing competency framework was 
originally published in 2012  [25], and was updated during 2015 [26], with its 
current version published in 2016 [27]. The single prescribing competency 
frameworks developed in the UK and Australia are aligned with the WHO Guide to 
Good Prescribing model [18]. Past research in the UK has identified that the 
development of a validated prescribing competency tool is required for consistent 
assessment of prescribing competency [28]. 
 
1.5 Evaluation and development of NMP models 
Evaluation is an important tool used in many areas including healthcare and is 
often lacking in this sector. Evaluation enables assessment of an issue and allows 
positive and negative aspects to be identified. Identification of positive aspects 
enables further improvement, whereas identification of negative aspects enables a 
problem to be addressed and rectified. Non-medical prescribing is occurring in 
many countries, and this has resulted in research on the subject of non-medical 
prescribing. Research is one mechanism of evaluation. Non-medical prescribing 
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research exists in many countries, is extensive, and continues to grow as non-
medical prescribing increases. Much of the NMP research has been initiated and 
funded by Government Departments of Health and includes evaluation of non-
medical prescribing overall, patient and physician responses to non-medical 
prescribing, education and continuing education for non-medical prescribers 
[3,8,11,29-32]. Existing research also includes evaluation of, education and patient 
responses to individual health professions providing non-medical prescribing [33-
35]. Grey literature relating to non-medical prescribing is available in some 
countries [7,8,13,23]. 
A Cochrane review of international research found that non-medical prescribing, 
including that by nurses and pharmacists, provided outcomes comparable to 
medical prescribers when treating chronic health conditions such as high blood 
pressure, diabetes, high cholesterol, and helping patient adherence [9]. The review 
also found that patient satisfaction and health-related quality of life measures with 
non-medical prescribers was comparable with that for medical prescribers [9]. 
Positive outcomes have been identified from UK economic evaluation of the NMP 
service, including evidence that the addition of just one non-medical prescriber in 
some GP practices could add value contributions of around 270 million pounds 
(GB) annually [36]. Another UK evaluation, which included health preference 
methodology, indicated that nurse and pharmacist prescribing was well-integrated 
in the health system, was safe and clinically appropriate, had high patient 
satisfaction, and that NMP was viewed positively by other health professionals 
[37]. The UK evaluation also noted that ensuring nurses and pharmacists were 
adequately prepared to prescribe for patients with co-morbidities was a key issue 
to consider when developing expanded prescribing services from these providers 
[37]. Cost effectiveness analyses demonstrated the value of Canadian pharmacist 
prescribing services to manage the long-term conditions of hypertension and 
cardiovascular risk [38,39]. Canadian research concluded that while GPs were 
hesitant about pharmacist prescribing, they were more accepting of the role when 
they had a collaborative and trust-worthy working relationship with the 
pharmacist [40]. Canadian health preference research demonstrated higher 
patient preferences for a collaborative pharmacist prescribing service that 
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included a doctor, compared to an independent pharmacist prescribing model, 
when treating a chronic health condition [41]. 
 
1.6 The New Zealand context 
Non-medical prescribing is still a comparatively new area in New Zealand, and as a 
result, it is changing significantly since first implemented. The type of non-medical 
health professionals that have prescribing rights in New Zealand is expanding and 
these health professionals are now working in a variety of practice settings. The NZ 
Pharmaceutical Collection data has identified that medicines have been dispensed 
from prescriptions written by various non-medical prescribers, where it is unclear 
if they have prescribing rights e.g. chiropractors and psychologists [42]. It would 
be useful to clarify and identify which non-medical health professionals currently 
have prescribing rights in NZ, and their practice settings.  
Prescribers in NZ, including non-medical prescribers, fall into three legal 
categories, namely authorised prescribers, designated prescribers, or delegated 
prescribers [43]. Prescribing models in New Zealand have included various 
versions of independent prescribing, supplementary prescribing, and restricted 
formulary prescribing. It would be beneficial to identify and understand which 
prescribing models NZ non-medical prescribers are currently using. Training 
requirements to enable prescribing by non-medical prescribers in NZ varies 
between the different health professions. Exploring the educational requirements 
of non-medical prescribers in NZ would be constructive in being able to identify 
the use of prescribing competencies (if any) when preparing for and implementing 
non-medical prescribing. Research on non-medical prescribing in New Zealand is 
also in its infancy compared to other countries. As the non-medical prescribing 
environment in New Zealand progresses, there is no single resource to provide 
updated information of how the overall NMP health service is evolving, and who is 
involved in its provision. This type of information is vital to effective 




1.7 New Zealand pharmacists and prescribing 
Pharmacists are frequently described as the most accessible healthcare 
professional in primary care [44,45]. Community pharmacists in NZ are often the 
health professional that people have the most regular contact with and are the 
easiest to access in primary care [46]. There are approximately 1000 community 
pharmacies in NZ, which are visited by over 1.3 million people each month [46]. 
Current workforce data indicates that 79% (3071 out of 3889) of practising 
pharmacists work in community pharmacies [47]. Although urban areas in NZ 
have more access to pharmacists than rural areas [47], a sizable pharmacist 
workforce delivers healthcare services to rural communities. Māori have higher 
proportions living in small urban and rural areas in NZ compared with the total 
population [48]. NZ research has shown that in rural areas, greater than 96% of 
the more deprived populations (i.e. decile 5–10 on the NZ Index of Deprivation), 
are located within a reasonable distance of a community pharmacy (i.e. 25 
kilometre radius) [49]. For many of these rural areas, a community pharmacy is 
the only option for healthcare services as there may be no GP or other primary 
care service easily available. The pharmacist workforce has the capacity and 
potential to be further utilised to improve access to prescribing services and 
medicines in rural NZ and in our priority health populations. 
Community pharmacists are an integral part of the healthcare system. In NZ they 
are involved in providing additional professional services in primary care such as 
immunisation and nicotine replacement therapy. NZ pharmacists are well 
equipped to further integrate into primary care prescribing services as their 
undergraduate programme provides with them with extensive knowledge of 
pharmacology and pharmaceutics. 
To cope with the increasing demand for prescribing services, other countries 
including the UK, USA, and Canada have made use of the accessibility and 
knowledge of community pharmacists to deliver prescribing services in primary 
care [9]. In contrast, pharmacist prescribers in NZ are based in GP practices and 
are a very small workforce. NZ pharmacist prescribers utilise a collaborative 
prescribing model where the GP/authorised prescriber makes the initial diagnosis, 
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and the pharmacist prescriber independently prescribes from a list of specified 
prescription medicines for that condition only [50]. While community pharmacists 
in NZ are not considered prescribers, their scope of practice does enable them to 
provide medicines that are classified as restricted medicines (i.e. pharmacist only 
medicines) to patients [50].  
Prior to further developing pharmacist prescribing services in NZ, there are 
knowledge gaps that need to be addressed. Firstly, there is no information 
regarding the prescribing services that NZ pharmacists are willing to provide. 
Secondly, there is no information on whether the NZ public are willing to use 
pharmacist prescribing services. Understanding health provider and public 
preferences would be beneficial when developing NZ pharmacist prescribing 
services, moving forward. 
As NZ healthcare system grapples with the increasing strain on its services, there is 
opportunity to make better use of this accessible and knowledgeable workforce of 
community pharmacists to help share the prescribing workload in primary care. 
 
 1.8 Structure of this thesis 
This thesis is organised and presented as follows: 
• Chapter 1: Introduction 
• Chapter 2: Narrative literature review 
• Chapter 3: Current overview of non-medical prescribing in NZ (contains 
published manuscript) 
• Chapter 4: Non-medical prescribing trends in NZ (contains submitted 
manuscript) 
• Chapter 5: Identifying community pharmacist preferences for prescribing 
services in primary care in New Zealand (contains published manuscript) 
• Chapter 6: Identifying New Zealand public preferences for pharmacist 
prescribers in primary care (contains submitted manuscript) 
• Chapter 7: Discussion and conclusion 
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Some of the topics in this Introduction section are covered in more detail in the 





Chapter 2:  Literature Review: Non-medical prescribing in 
New Zealand 
Non-medical prescribing (NMP) research in New Zealand (NZ) is in its infancy. The 
literature review, presented below, aims to enable a comprehensive overview of 
the body of NMP research in NZ. A narrative review method [51] was selected due 
to the heterogeneity of the methods utilised and the variety of topics within NZ 
NMP research.  
 
2.1 Objective 
A narrative literature review was conducted on “non-medical prescribing in New 
Zealand” with the following objectives: 
• To establish an overview of research conducted in New Zealand on non-
medical prescribing.  
• To inform the investigations undertaken in this thesis. 
 
2.2 Method 
2.2.1 Literature review 4 March 2017 





These four databases were selected as their individual and overlapping subject 
areas, and content created an expansive source of information. The four databases 
also enable a comprehensive search strategy that utilise a combination of subject 
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headings and key word searching. The Medline and Embase databases utilise both 
subject headings and key words in the searches. The CINAHL database utilises only 
subject headings, and the Scopus database utilises only key words.  
Inclusion and exclusion criteria were developed to screen the results from the 
search strategy to ensure research articles met the parameters of the literature 
review and are listed below.  
Inclusion criteria: 
Articles must 
• Relate to non-medical prescribing in NZ, which is defined as the legislative 
authority to prescribe medicines that are legally classified as prescription 
medicines in NZ for use in people; 
• Include original NZ data; 
• Be written in English;  
• Be full research articles only (no abstracts or conference presentations). 
 
Exclusion criteria: 
• Articles that focused on the provision of medicines by health professionals via 
standing orders, or medicines classified as ‘pharmacist only’ (‘restricted’), 
pharmacy only, or general sale medicines; 
• Magazine-type articles or editorials; 
• Results lacking original NZ data relating to NMP. 
‘Pharmacist only' medicines (also known as ‘restricted’ medicines) relate to 
specific prescription medicines that have been re-classified to the 'pharmacist 
only' designation in NZ. This medicine classification in NZ enables pharmacists to 
supply and dispense these medicines without a prescription, and further training 
is required to supply some of these medicines [52]. 
The search strategy and search terms used are outlined Table 1. 
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Table 1 Literature search strategy (format adapted from the University of Otago search strategy 
worksheet [53]) 
Date Database Coverage Search string / terms and limits Notes 
04.03.17 Medline 1946 to 
4 March 
2017 
(Drug prescriptions/ OR non-
medical prescribing.mp OR non 
medical prescribing.mp) AND 
(Dentists/ OR Midwifery/ OR 
Nurse Practitioner/ OR Nurses/ OR 
Optometry/ OR 
Pharmacists/ OR Nutritionists/) 
AND (New Zealand/ OR New 
Zealand.mp) 
“/” denotes medical subject heading 
“mp” denotes keyword 
39 hits 






(drug therapy/ OR prescription/ OR 
non-medical 
prescribing.mp OR non medical 
prescribing.mp) AND 
(dentist/ OR midwife/ OR nurse 
midwife/ OR nurse 
practitioner/ OR nurse/ OR 
optometry/ OR pharmacist 
attitude/ OR pharmacist/ OR 
dietitian attitude/ OR 
dietitian/) AND (New Zealand/ OR 
New Zealand.mp) 
Limited to: English language, 
human. 
“/” denotes medical subject heading 
“mp” denotes keyword 
160 
hits 
04.03.17 CINAHL 1981 to  (MH “Prescriptive Authority OR MH 






MH “Prescribing Patterns” OR “non-
medical prescribing OR 
“non medical prescribing”) AND 
(MH “Dentists” OR MH 
“Nurse Midwives” OR MH “Nurse 
Practitioners” OR MH 
“Registered Nurses” OR MH 
“Optometry” OR MH 
“Pharmacists” OR MH “Dietitians”) 
AND (MH “New Zealand” 
OR “New Zealand”) 
“MH” denotes medical subject 
heading. 
04.03.17 Scopus 1823 to  
4 March 
2017 
(non-medical prescrib* OR non 
medical prescrib* OR 
nonmedical prescrib* OR prescrib*) 
AND (dentist OR midwife 
OR nurse practitioner OR nurse OR 
optometrist OR 
pharmacist OR dietitian) AND (New 
Zealand) 







The articles retrieved were screened using the defined inclusion and exclusion 
criteria to eliminate irrelevant material (see Fig 1).  PhD candidate RR removed 
inappropriate articles that did not meet the inclusion criteria: duplicates and 
articles appearing irrelevant on examination of the title and/or abstract. 
Potentially relevant articles were retained for further review. Further reading 
identified any remaining inappropriate articles and some of uncertain fit. The 
latter were discussed with a supervisor AS, and those agreed inappropriate were 
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removed. Reasons for removal included, studies were not focused on NMP in NZ or 
did not contain original research. The selected published papers included in the 
review were categorised by health profession involved and the type of research, 
and examined for their findings, strengths, and limitations.   
The international literature was identified using various international systematic 
reviews of NMP, pharmacist prescribing services, and health preference 
methodology (including discrete choice experiments (DCEs)) which provided a 
large dataset of published research to identify international literature. A snowball 
technique was also used where further literature was identified from the 
references of already identified published international literature. This combined 











2.2.2 Literature review update  
The literature review search strategy was re-run on 29 September 2020 in the 
same four databases (Medline, Embase, CINAHL, and Scopus), and limited to the 
period 5 March 2017–29 September 2020 to capture any recent NMP research in 
NZ. The updated literature search provided 145 hits, which were reviewed against 
the same literature review inclusion and exclusion criteria stated above (results 
shown in section 2.7.1 Literature review update). 
 
2.3 Results 
The final set of literature from the March 2017 search included twenty-one 
research articles. Table 2 provides a summary of these articles in terms of 




Table 2 Summary of final set of NZ NMP published studies from literature review conducted on 4 March 2017 




Research category Participants Strengths and 
limitations 
NZ NMP OVERALL: 
Hale 2012 [54]  












NMP Evaluation framework 




to develop an 
evaluation 
framework. 
Unclear how data 














Dentist Dentists’ understanding 
and practice of 
antibiotic prophylaxis 














relevance of safe 
medication practice 
tutorials as a course 
for pharmacist 












Likert scaling used to 









provides insight into 
education 
intervention. 
Small sample size 
limits the 
generalisability to all 
clinical pharmacists. 





exploration of a role 























perceptions of the 
participants in the 







Sample bias, which 
limits ability to 
generalise results of 
study to other health 
professionals in NZ. 





















perceptions of the 
GPs in the study, 
including their 
changing/positive 




Small sample size 
and sample bias, 
which both limit the 
ability to generalise 
results of study to 
other GPs in NZ.  
















perceptions of the 




views of pharmacists' 
current and potential 
contributions to 
medication review 








Small sample size 
and sample bias, 
which both limit the 
ability to generalise 
results of study to 
other GPs in NZ. 
Shaw 2013 [60] 
(NZ)  
















provides insight into 






Sample bias as 
narrative only 






Mackay 2003 [61]  
(NZ) 
General practitioners' 
perceptions of the 
nurse practitioner 

















captured the full 
spectrum of 
perceptions of the 






Small sample size 
and sample bias 
limits the 
generalisability of 
study results to all 
GPs in NZ. 
Kenealy 2004 [62] 
(NZ) 
Diabetes care: 















(n=86 in 1990 and 
n=155 in 1999) 
Provides insight into 
how registered 
nurses’ practice and 
perceptions in 
diabetes care have 
changed over a 
specified period. 





study results to all 
registered nurses in 
NZ. 






nurse for prescribing 























Small sample size 
and sample bias 
limits the 
generalisability of 
study results to all 
student nurse 
practitioners in NZ. 




practicum within a 
Master's degree in 
Qualitative—
interviews and 






















Small sample size 







study results to all 
these stakeholders in 
NZ. 
Jacobs 2008 [65] 
(NZ) 
The genesis of 
advances nursing 
practice in New 
Zealand: policy, 
politics and education 
Qualitative— 
narrative utilising 






Review of nurse 
practitioner prescribing 
None.  
Data collected from 





and collation from a 
wide range of data 
sources into one 
document. 
Sample bias as 
narrative only 
provides the views of 
the study researcher. 
Chaston 2009 [66] 
(NZ) 
Mental health nurse 
prescribing in New 












(comparison of nurse 
practitioner educational 
pathways between NZ 
and the UK) 
None.  
Data collected from 





and collation from a 
wide range of data 








Sample bias as 
narrative only 
provides the views of 






framework to nurses: 
Lessons from the past 
Qualitative—
narrative utilising 




nurses & nurse 
practitioners) 
Review of nurse 
prescribing in NZ 
None.  
Data collected from 





and collation from a 
wide range of data 
sources into one 
document. 
Sample bias as 
narrative only 
provides the views of 
the study researcher. 
Pirret 2012 [68] 
(NZ) 
A critical care nurse 
practitioner's 
prescribing using 
standing orders and 
authorised 
prescribing when 






Clinical audit of nurse 
practitioner prescribing 
Audit data from 
one nurse 
practitioner in a 
single NZ tertiary 
hospital intensive 
care unit (ICU) 
(n=1061 patient 
visits) 
Audit tool provides a 
snapshot of 
frequency of 
prescribing and types 
of medicines 
prescribed by nurse 
practitioner in 
critical care unit. 
Sample bias could 
have influenced 
results as nurse 
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care outreach role: A 
clinical audit 
practitioner collected 
their own audit data. 
Small sample size (i.e. 
audit captures data 
from one nurse 
practitioner in a 
single hospital unit) 
limits the 
generalisability of 
study results to all 
critical care nurse 
practitioners in NZ. 
Kroezen 2012 [69] 
(Netherlands) 
Nurse prescribing of 
medicines in Western 
European and Anglo-
Saxon countries: A 









Comparative study of 
aspects of nurse 
prescribing between 
selected countries  (NZ 













between the selected 
countries. 
Small sample size 






Lim 2014 [70] 
(NZ) 

























perspectives of the 
educational 
programme. 
Small sample size 
and sample bias 
limits the 
generalisability of 
study results to all 
registered nurses in 
NZ. 
Lim 2014 [71] 
(NZ) 
Nurse prescribing: 









Overview of nurse 
prescribing in NZ 
None.  
Data collected from 





and collation from a 
wide range of data 
sources into one 
document. 
Sample bias as 
narrative only 
provides the views of 


















































utilised a variety of 
methods to capture 
various data from all 
stakeholders 
involved to provide a 
comprehensive 
evaluation of the 
diabetes nurse 
prescriber project. 
Sample bias may 
exist, as some of the 
evaluation tools 
required a judgement 
call from individuals. 
The small sample size 
for some of the data 
collection limits 
ability to generalise 
results of study to 
other stakeholders in 







Lim 2015 [73] 
(NZ) 
Learning to become a 
nurse prescriber in 
New Zealand using a 
constructivist 























Small sample size 
and sample bias 
limits the 
generalisability of 
study results to all 









intentions of nurses 
working in primary 


















similar to wider 
nursing workforce. 
Quantitative tests 
were able to show an 
association with 
some models of 
nurse prescribing 





Small sample size 
limits the 
generalisability of 
qualitative work to 
all registered nurses 
in NZ (i.e. the study 
indicated population 
of registered nurses 






Only one article of the twenty-one research articles related specifically to the 
overall subject of NMP in NZ [54], while the rest related to prescribing by a specific 
health profession. Of the twenty profession-specific studies, the majority related to 
nursing prescribers (14 studies i.e. 70%) [61-74], followed by pharmacist 
prescribers (5 studies i.e. 25%) [56-60], and dentists (1 study i.e. 5%) [55].  
The educational aspects of prescribing (e.g. the development and/or evaluation of 
an educational programme) and perceptions of health professionals towards non-
medical prescribing were the most studied topics. Seven out of twenty-one studies 
were related to the educational aspect of prescribing and of these seven, two 
studies were about pharmacists [56,60], one about registered nurses [70], and four 
about nurse practitioners [63,64,66,73]. Six of the twenty-one studies related to 
the same [62,74], or another health professionals’ perceptions of the prescribing 
by a specific type of non-medical prescriber [57-59,61] .  
Three studies provided a review or overview of nurse prescribing from an 
examination of grey literature and secondary data [65,67,71]. Two studies 
evaluated prescribing practice including evaluating dentists’ understanding and 
practice of antibiotic prophylaxis [55], and a clinical audit of a nurse practitioner’s 
prescribing practice [68]. Three studies focused on a variety of research categories 
including developing an evaluation framework for NMP research [54], a 
comparative study of nurse prescribing between selected countries (including NZ) 
[69], and the evaluation of a diabetes nurse prescribing project [72]. 
 
2.3.1 Overall NZ NMP research   
The single study that focused on NMP overall in NZ developed an evaluation 
framework for NMP research [54]. This study utilised a variety of pharmacist 
prescribing models and settings to develop a NMP framework that could be 
applied to all non-medical prescribers, with the intention of enabling consistency 




2.3.2 NZ NMP research relating to nurses 
The majority of the NZ NMP studies related to nurse prescribing (14 out of 21 
studies). About a third of these (5 out of 14 studies) related to education. Three 
studies explored nurse prescribers’ perceptions of the educational 
framework/programme using standardised University surveys [63], and 
qualitative survey and/or interview methods [70,73]. One study explored the 
perceptions of the educational framework/programme from other stakeholders 
[64], and one study compared the nurse practitioner pathways of NZ and the UK 
[66]. The latter highlighted the lengthy pathway taken by nurse practitioners in 
NZ, as well as the difficulty of extending their nurse prescribing rights (i.e. moving 
from the designated prescriber to authorised prescriber status) [66]. However 
since that study, changes to the Medicine Act in NZ in July 2014 have granted nurse 
practitioners the same prescriber status as general practitioners (i.e. authorised 
prescriber) [75]. In addition, the educational pathways have become more 
streamlined [76].  
Nurse prescriber and other stakeholder perceptions about the nurse prescriber 
educational programmes/framework generally indicated positive experiences; 
however, they also highlighted the challenges of nurses' experiences as 
postgraduate students engaging in the new and unfamiliar material of 
pharmacology and therapeutics and provided insight into how to deal with these 
challenges [63,70,73]. Perceptions of nurse prescribers and other stakeholders 
regarding the nurse practitioner prescribing practicum were also positive [64]. 
However, the latter also highlighted the challenges faced by the nurses as well as 
their medical supervisors, which included a clear understanding of roles, a 
supportive supervisory environment, and orientation of the medical supervisors 
[64].  
The three studies that focused on health professionals’ perceptions of nurse 
prescribers found nurses had positive perceptions of registered nurse prescribing 
roles [62,74], but general practitioners (GPs) had less favourable views [61].  The 
diabetes care study (comparing surveys of practice nurses views in 1990 and 
1999) concluded that practice nurses were under-trained for future diabetes care 
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roles and that future research should investigate whether implementing such roles 
would translate into improved outcomes for patients [62]. Concerns raised by 
these studies included adequate funding to undertake nurse prescriber training, as 
well as improved education for medical prescribers, and adequate support for 
nurse prescribers [61,74].  
The review articles on nurse prescribing provided useful insight into the historical 
progression of nurse practitioner prescribing roles [65] and registered nurse 
prescribers in NZ [71]. Three studies highlighted the challenges such as education 
requirements and barriers towards implementation of these roles, as well as how 
these challenges could be/have been overcome [65,67,71]. Lessons learned from 
the development and implementation of the nurse practitioner role in NZ have 
helped the successful evolvement of the registered nurse prescriber role [67,71].  
Two NZ studies evaluated nurse prescribing in practice including twelve diabetes 
nurse prescribers in a specialist diabetes service setting [72] and one critical care 
nurse practitioner in an intensive care unit hospital setting [68]. While both 
studies utilised a clinical audit tool, the diabetes nurse prescriber study also 
utilised quality audit tools, clinical data and prescribing logs, and satisfaction 
surveys and input from the diabetes nurse prescribers, diabetes team members, 
GPs, and patients [68,72]. The critical care nurse practitioner prescribed a greater 
number and wider range of medications when they utilised the authorised 
prescribing model (in 2007-2008) compared to when previously using standing 
orders to prescribe (in 2006-2007) [68]. The range of medicines that were newly 
prescribed by the nurse practitioner included diuretics, anti-arrhythmics, 
antibiotics, and medicines categorised as ‘other’ which included insulin, 
loperamide, nicotine patches and vitamin K [68]. The evaluation of the diabetes 
nurse prescribing service indicated that the service was safe, of high quality and 
appropriate. It also highlighted that adequate training and access to supportive 
clinical supervision was important, as nurses are novices in the prescribing role at 
this stage [72].  
A comparative study of nurse prescribing between several countries (including 
New Zealand) highlighted that the legal, educational and organisational conditions 
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under which nurses prescribe medicines varied considerably between countries, 
and provided useful comparisons between the countries and context for NZ nurse 
prescribing roles at the time [69]. 
 
2.3.3 NZ NMP research relating to pharmacists   
Five out of the twenty-one NZ NMP studies related to pharmacist prescribers. 
Three related to health professionals’/patients’ perceptions of pharmacist 
prescribers [57-59]. One study found that the perceptions of health professionals 
(including psychiatrists, mental health pharmacists, and nurse practitioners) and 
patients of pharmacist prescribers in the mental health team were positive and 
supportive of the pharmacist prescriber role [57]. In contrast, other researchers 
found GPs were more accepting of pharmacists being involved in medication 
review roles and less supportive of pharmacists practising screening, monitoring, 
and prescribing [58,59]. Some of the GP concerns were related to pharmacist 
prescribers making diagnoses [58,59]; however, diagnosing patients is not within 
the NZ pharmacist prescriber’s current scope of practice. Of the GPs who were 
supportive of pharmacist prescribing roles, the collaborative pharmacist 
prescribing models (where prescribing occurred under agreed protocols or 
guidelines for a limited number of diseases and conditions), with appropriate 
training and close monitoring was more acceptable [59]. While the GPs 
acknowledged that pharmacist prescribing could potentially compete with the GPs’ 
own work, they indicated that it would not be a problem due to doctor workforce 
shortages in NZ [59]. Solutions to concerns identified from other health 
professionals and/or patients included a strategic plan with effective 
communication and education to these sectors about the pharmacist prescribers’ 
roles and responsibilities [57-59]. Supportive training environments for the 
pharmacist prescribers were also important to encourage pharmacists to take up 
these extended roles [57].  
Two out of the five pharmacist prescriber studies related to education. A sample of 
clinical pharmacists investigated Safe Medication Practice Tutorials, which 
highlight error prone conditions and common errors within the healthcare system 
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[56]. They found they were relevant and useful to increase the awareness of 
prescribing errors and improve safe prescribing practices, and could be considered 
as a component of future NMP training [56]. The second study documented the 
development, implementation, and evaluation of a University level educational 
programme for pharmacist prescribers, that was accredited and enabled graduates 
of the educational programme to register and practise as pharmacist prescribers in 
NZ [60]. The student pharmacist prescribers (who were experienced practising 
pharmacists) found aspects of the course assessment challenging—including the 
reflective portfolio (which was pass or fail), the objective structured clinical 
examination (OSCE), and the individual oral component detailing their activities 
and experiences as a trainee prescriber, all of which were considered to be very 
stressful [60].  
 
2.3.4 NZ NMP research relating to dentists 
One of the twenty-one NZ NMP studies evaluated NZ dentists’ understanding and 
practise of prescribing parenterally administered antibiotic prophylaxis [55]. The 
study found that most dentists followed the National Heart Foundation of New 
Zealand (NHFNZ) guidelines regarding antibiotic prophylaxis [55]. However, it also 
noted that there were antibiotic prophylaxis guidelines available from other 
organisations such as the American Heart Association, British Society for 
Antimicrobial Chemotherapy, and Australian Dental Association, and that a review 
of the NHFNZ antibiotic prophylaxis guidelines may be required to ensure that 
they reflected current scientific opinion and were consistent with those used in 
other countries [55]. 
 
2.3.5 Research methods employed in NZ NMP research 
The research methodologies employed were heterogenic with two of the studies 
using only a quantitative method [55,68], fourteen studies used only a qualitative 
method [54,57-60,63-67,69-71,73], and five studies used a combination of both 
methods [56,61,62,72,74].  
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Overall, five of the twenty-one studies utilised a quantitative method in their mixed 
method approach, and nineteen out of the twenty-one studies included a 
qualitative research method component. The two studies that only used a 
quantitative method utilised a cross-sectional survey and a clinical audit 
respectively. The qualitative studies employed a variety of data collection methods 
including focus groups, electronic or postal self-administered surveys, and semi-
structured interviews, and thematic analysis was used to analyse the data from 
these studies. The five studies that incorporated quantitative analyses into their 
mixed method approach typically added descriptive cross-sectional analyses to 
their qualitative thematic analyses. 
 
2.3.6 Literature review update  
As discussed earlier, the literature search was repeated in September 2020 with 
145 new hits obtained. This led to a further seven papers being included in the 
thesis [77-83]. The results of the literature review update are summarised in 
Supplementary Table S1 (see Literature Review Supplementary Material 1 at the 
end of this chapter) and are discussed in the relevant chapters of the thesis. 
 
2.4 Discussion 
2.4.1 NMP research in NZ 
There was a small body of research relating to NMP in NZ, and the final set of 
twenty-one studies reflected this. Analysis indicated that only one of the studies 
related specifically to the evaluation of NMP in NZ [54], and the remainder related 
to specific health professionals who are non-medical prescribers in NZ. This 
indicates that the context of overall NMP in NZ as a subject has not yet been well 
studied, and current research is very profession-specific. The majority of current 
NZ NMP research has occurred in silos, where the research topic is investigated 
and discussed within the confines of each of the different prescribing health 
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professionals (e.g. only nurses, or only pharmacists, and so forth), and does not 
explore the research topic with regard to the overall context of NMP in NZ.  
The final data set of the literature review included studies relating to nurse 
practitioners, diabetes nurse prescribers, registered nurse prescribers, pharmacist 
prescribers, and dentists. There were no studies that related to midwives, 
optometrist prescribers, or dietitian prescribers, although the latter only gained 
prescribing rights in NZ in 2015.  
 
2.4.2 NMP frameworks 
A single study focused on overall NMP in NZ and developed an NMP evaluation 
framework that could be applied to all non-medical prescribers, with the intention 
of enabling consistency when evaluating NMP services and research [54]. 
However, this framework does not seem to be widely used in the NMP research 
field, with only four NMP studies citing the framework [84,85,34,86]. 
A single prescribing competency framework for all prescribers, not just non-
medical prescribers, exists in the UK and Australia [27,23]. A specific prescribing 
competency framework is a common set of competencies that is specific to 
prescribing regardless of the background of the health professional [27]. These 
prescribing competency frameworks have a wider range of uses compared to the 
evaluation framework developed for NMP research in the NZ study [54]. The UK 
and Australian  prescribing competency frameworks provide a consistent 
framework that can be used by prescribers to evaluate their prescribing 
competency, and by regulators, education providers, professional organisations 
and specialist groups to inform standards, develop education pathways, and 
inform guidance and advice [27]. The availability of a single prescribing 
competency framework could be a reason for the widespread implementation of 
the NMP service in the UK, which utilises various health professionals and has 




2.4.3 Stakeholders views on NMP educational programmes 
The educational aspects of prescribing (e.g. the development and/or evaluation of 
an educational programme) was one the two most studied topics in NZ NMP 
research. Seven out of twenty-one studies related to the educational aspect of 
prescribing and of these seven, two studies related to pharmacists [56,60], and five 
related to nurse prescribing [63,64,66,70,73]. 
Nurse prescriber and other stakeholder perceptions about the nurse prescriber 
educational programmes/framework generally indicated positive experiences, 
however they also highlighted the challenges of nurses' experiences as 
postgraduate students engaging in the new and unfamiliar material of 
pharmacology and therapeutics, and provided insight into how to deal with these 
challenges [63,70,73]. Similar positive experiences and challenges were noted in 
UK research relating to nurse prescriber education programmes [87,35,88]. The 
UK studies [87,35] also highlighted the same additional challenges faced by the 
nurses in the NZ studies [64], which included a clear understanding of roles, a 
supportive supervisory environment, and accessible medical supervisors. 
Amendments have been made to the nurse prescribing practicums in NZ to enable 
supportive environments and appropriate supervisors, which includes nurse 
practitioners now allowed to be designated authorised prescriber supervisors for 
nurse practitioners and registered nurse prescribers undertaking their prescribing 
practicum [76].  
One of the two NZ pharmacist prescriber studies relating to education found that 
the student pharmacist prescribers (who were experienced pharmacists) generally 
thought the content and delivery methods of the prescribing programme was 
appropriate [60]. Nevertheless, these students found aspects of the course 
assessment challenging [60]. Similarly, UK research into pharmacist 
supplementary prescribing, found pharmacist prescribers were generally positive 
about the prescribing educational programme [89,90]. Useful aspects of the UK 
programme included understanding legal aspects of prescribing and learning 
consultation and examination skills [89], while negative aspects included covering 
pharmacology knowledge that pharmacists were already familiar with [89], the 
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large workload and tight timeframes [90].  Although pharmacist prescribing does 
not exist in Australia, some of their researchers have developed and/or 
implemented and evaluated an existing pharmacist prescribing education 
programme [91,92]. A prescribing education programme developed for a mixed 
cohort of physiotherapists and pharmacists was positively received [91]. It also 
highlighted the importance of the designated medical practitioner, and 
improvements in the content and delivery of the programme [91]. Australian 
researchers found positive experiences from the hospital pharmacists who had 
completed a UK accredited pharmacist independent prescribing course, and 
concluded it could be used to help develop an accredited course for Australian 
pharmacist prescribers [92].    
 
2.4.4 Perceptions of health professionals/public on non-medical 
prescribers 
The perceptions of health professionals towards non-medical prescribing was the 
second most common topic in NZ NMP research. Six of the twenty-one studies 
related to the same [62,74], or another health professionals’ perceptions [57-
59,61] of the prescribing by a specific type of non-medical prescriber.  
The three NZ studies that investigated GPs’ perceptions of possible nurse and 
pharmacist prescribing roles concluded that while some GPs were supportive, 
others had concerns [58,59,61].  These studies were conducted when there were 
relatively few nurse practitioners and before there were any registered pharmacist 
prescribers in NZ. Similarly, UK research found GPs were positive about nurse and 
pharmacist prescribers in practice [93,94]. UK GPs’ initial reservations towards 
pharmacist prescribing [95]  have changed over time, and later studies have 
indicated GP support for pharmacist prescribing roles [37,96]. Canadian research 
also concluded that while GPs were hesitant about pharmacist prescribing, they 
were more accepting of the role when they had a collaborative and trust-worthy 
working relationship with that pharmacist [40].  UK research mirrors NZ research 
in terms of the favourable perceptions of nurses towards nurse prescribing [93] 
and of pharmacists towards pharmacist prescribing [95,37]. UK research is similar 
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to NZ research [57,61,74] by identifying nurse and pharmacist prescribers’ 
concerns regarding adequate funding to undertake prescriber training, and for on-
going support in the prescribing environment [93,95].   
While there is no research into patient perceptions of non-medical prescribing in 
NZ, there is abundant research in the UK and Canada concluding positive patient 
and/or consumer perceptions/experiences of nurse and pharmacist prescribing 
services [95,37,38,97-100]. Health preference methodology such as stated 
preference studies have been utilised in Canada and the UK to determine patient 
preferences for pharmacist services [41], and patient preferences for nurse and 
pharmacist prescribing services [101,102]. 
 
2.4.5 Challenges with implementing NMP  
NZ NMP research has identified challenges/barriers and possible solutions to 
implementing NMP in NZ. The review articles on nurse prescribing in NZ [65,71] 
highlighted the challenges such as education requirements and 
systematic/legislative barriers towards implementation of nurse prescriber roles, 
as well as how these challenges could be/have been overcome [65,67,71]. The 
evolvement of the nurse practitioner role in NZ, especially from being a designated 
prescriber to its current authorised prescriber classification, has helped to 
successfully develop and implement the registered nurse prescriber role in NZ 
[67,71]. Following recent legislative changes in NZ [103,104], there are now three 
scopes of practice for registered nurse prescribers: registered nurse prescriber in 
primary health and specialty teams, diabetes nurse prescriber, and registered 
nurse prescriber in community health [105]. 
Three pharmacist prescriber studies in NZ identified challenges and possible 
solutions to allay concerns from other health professionals and/or patients about 
pharmacist prescribers [57-59]. These included a strategic plan with effective 
communication and education to these sectors about the pharmacist prescribers’ 
roles and responsibilities [57-59]. Supportive training environments were 
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identified an important facilitator to encourage pharmacists to take up these 
extended prescribing roles [57].  
International research has also investigated barriers and facilitators for NMP and 
found similar findings to NZ NMP research. Identified facilitators of NMP included 
supportive training and prescribing environments, perceived improved patient 
care, professional autonomy, and job satisfaction [37,106-108]. Identified barriers 
of NMP included lack of defined roles, organisational barriers, and service funding 
[37,106-108].  
 
2.4.6 Research methods employed in NZ NMP research 
The studies from the literature search were categorised by research type i.e. 
qualitative, quantitative, or a combination of both methods. Qualitative research 
methods use flexible methods and are useful for gaining an in-depth understanding 
of the views/practices of individual participants, while quantitative research 
methods quantify measurable variables to give an overview about the sample 
frame and/or quantify trends of the quantitative variables [109-111]. Using a 
combination of qualitative and quantitative methods can fulfil different yet 
complementary purposes to answer the research question [111]. Sample size and 
sample bias are issues that affect the generalisability of study results for both types 
of research [112]. Larger sample sizes and/or matching sample frame 
characteristics to the population characteristics are used to combat the size of 
sampling error (i.e. the gap in the sample’s representativeness of the population 
characteristics) [109,112]. While sample size is not always an issue with 
qualitative research due to its intentions, small sample sizes raise the question of 
study credibility—whether the study enables the widest possible coverage of the 
research subject’s perceptions or opinions [110,112,113]. 
The final set of twenty-one articles from the literature search highlighted the 
distinct lack of quantitative research on NMP in NZ, and this could reflect the small 
numbers of non-medical prescribers in NZ at that time. Two of the studies used 
only a quantitative method [55,68], and five of the studies utilised a quantitative 
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method in their mixed method approach [56,61,62,72,74]. Only the dentist study 
[55] comments on its sample size. All these studies have the limitations associated 
with small sample sizes and sample bias, which limits the generalisability of each 
study’s findings.   
This narrative review found the majority of NMP research in NZ used a qualitative 
method. Fourteen out of the twenty-one studies used only a qualitative method, 
and overall nineteen studies include a qualitative research method. The different 
data collection and analyses methods utilised for the qualitative component of 
these studies, especially the thematic analysis [109,110], can be time consuming 
and labour intensive. This qualitative approach provides a detail-rich narrative, 
which helps to understand perceptions, processes and phenomena which cannot 
be reduced to quantifying variables [109].  As seen with the quantitative studies, 
all the studies that used a qualitative research method have the limitations 
associated with small sample sizes and sample bias, which limits the 
generalisability of each study’s findings.  
 
2.4.7 NMP research in other countries 
This small body of research relating to NMP in NZ is in stark contrast to NMP-
related research in other countries. Identifying the NMP research areas in other 
countries highlights potential areas for research in NZ. 
Research relating to NMP in Australia includes evaluation of NMP overall [31] and 
specific non-medical prescribers such as pharmacists [12,114], podiatrists [33] 
and physiotherapists [34]—some of which have not yet been explored in NZ.  
Research relating to NMP in the UK is more abundant than in NZ or Australia. This 
is not surprising as the UK is recognised as having the most extensive non-medical 
prescribing rights internationally [11,115]. UK studies include various research 
aspects that relate to the overall NMP service and includes studies that evaluate 
the economic aspect of NMP, patient and physician responses to NMP, education of, 
and continuing education for non-medical prescribers 
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[11,3,8,29,30,32,116,117,36]. Research that evaluates these aspects of the overall 
NMP service in NZ is lacking.  
UK research also relates to the specific health professionals involved in NMP (i.e. 
nurses, pharmacists, and so forth), and studies include evaluation of, education of, 
and perceptions of health professionals/patients to the individual NMP providers 
[87,35,33,118,101,119-121]. While there is some research in NZ that relates to 
these aspects, they are explored only within the confines of each prescribing health 
profession rather than also within the context of NMP in NZ. There is some analysis 
of the rate of prescribing errors by pharmacist prescribers in the UK [122,123], 
and whether nurse and pharmacist independent prescribers are making clinically 
appropriate prescribing decisions [124]. There is some initial NZ research 
investigating potentially inappropriate prescribing by nurse practitioners in NZ 
[81]. 
As highlighted earlier in this chapter, research is a mechanism that can be used to 
evaluate a service. The sparseness of research relating to NMP in NZ, compared to 
countries such as the UK, suggests that evaluation of various aspects of NMP in NZ 
is lacking. UK research has been able to quantify prescribing in primary care that 
can be attributed to non-medical prescribers [125], as well as gauging how many 
nurse and pharmacist prescribers are providing prescribing services [9,37]. 
Preliminary NZ research indicates that between 2008 and 2015, NMP accounted 
for approximately 2–4% of all medicines dispensed in NZ each year [126]. 
However, we do not have updated information as to whether the use of NMP in NZ 
is increasing, who is prescribing, what they are prescribing, and whether more 
non-medical prescribers should be trained for the workforce in NZ. 
In the UK, the health service routinely provides information to patients and 
consumers about non-medical prescribing services and the health professionals 
involved, and examples include NMP patient/consumer information leaflets 
produced by most regional organisations of National Health Service (NHS) 
[127,128]. However, there is limited NMP patient/consumer information in NZ 
[129-131]. Research in NZ is also required to establish whether New Zealanders 
are aware that NMP is already part of the NZ health service, and if they understand 
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how this service works and who can provide it. We also do not know if New 
Zealanders are willing to use NMP services. 
A large proportion of the UK primary care workforce includes nurses and 
pharmacists, and UK data indicate that nurse and pharmacist prescribers’ 
predominant practice setting is primary care, presumably to address the increased 
demand for prescribing services in that sector [37]. Pharmacist prescribers are 
well established within NMP in the UK, and research has utilised various 
methodologies to evaluate the preferences of health professionals, patients, and/or 
the public to pharmacist prescribing services in primary care 
[100,101,120,102,132,133]. Canadian research has also used various 
methodologies, including health preference research, to explore aspects of 
pharmacist services in primary care, including prescribing [38,97,134,39]. This 
type of research helps to address health workforce needs, including pharmacist 
prescriber workforce development and allocation in areas such as primary care 
[9].  
This narrative literature review identifies five published papers relating to NZ 
pharmacist prescribing within the NMP dimensions and all were qualitative in 
nature, indicating a lack of quantitative NZ research evaluating pharmacist 
prescribing. While pharmacists have been identified as having an increasingly 
important role in the primary care team in NZ [135], NZ research has yet to 
explore pharmacist prescribing services within NMP in primary care in NZ. 
 
2.5 Conclusion 
Non-medical prescribing is growing in New Zealand, and several non-medical 
health professional groups are engaged in NMP in NZ. However, in terms of 
research to help evaluate this service, the literature review highlighted the paucity 
of research in NZ. Current research evaluated different aspects of NMP in NZ, but 
focused on individual health professional groups, and the majority of this research 
utilised qualitative methods. As NMP in NZ progresses, it is imperative to evaluate 
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some key aspects of this service to ensure that it remains safe to patients, is useful 
in delivering beneficial health outcomes for the NZ public, and economically viable. 
The narrative literature review identified the following research deficits regarding 
NMP in NZ. It is difficult to evaluate the NMP service in NZ, as information is only 
available within the silos of the various health professionals who have prescribing 
rights within NMP in NZ. There is no overall snapshot of how NMP currently exists 
in NZ, and very little information about how it is being utilised in NZ. NZ research 
has yet to explore the place of pharmacist prescribers within the prescribing 
landscape in primary care in NZ. The narrative review informed the objectives and 
projects for this PhD.  
 
2.6 Objectives and projects for this thesis 
The conclusions of this literature review informed this thesis and provided the 
rationale for the investigations. Based on the literature review above, the PhD aims 
to answer the following objectives: 
• Understand the current non-medical prescribing environment in NZ. 
• Determine NZ non-medical prescribing trends in primary care. 
• Ascertain preferences for pharmacist prescribing services in primary care in 
NZ. 
 
The following projects aim to address the objectives listed above: 
• Project 1: Create a current overview of non-medical prescribing in NZ. 
• Project 2: Identify non-medical prescribing trends in New Zealand from 2016–
2020. 
• Project 3: Identify community pharmacist preferences for prescribing services 
in primary care in NZ—a discrete choice experiment. 
• Project 4: Identify NZ public preferences for pharmacist prescribers in primary 
care—a discrete choice experiment. 
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Projects 1 and 2 will help gain insight into the current NMP landscape in NZ. 
Projects 3 and 4 utilise health preference methodology (namely discrete choice 
experiments) to determine provider preferences (i.e. community pharmacists) and 
consumer preferences (i.e. the NZ public) for pharmacist prescribing services. Both 
preference studies can inform the development of future pharmacist prescribing 
services and enable a better understanding of how pharmacists fit into the primary 





2.7 Literature Review Supplementary Material 1 
2.7.1 Literature review update    
The results of the literature review update run on 29 September 2020 are 
summarised in Supplementary Table S1 below. 
The literature review update run on 29 September 2020 indicates similar findings 
to the literature review conducted on 4 March 2017, in that the majority of the 
studies (5 out of 7 studies) were about nurse prescribers [78-82]. One study was 
about overall NMP in NZ [83], and one study was about optometrists [77]. Of the 
two studies that provide a review or overview, one related to NMP overall [83] and 
one related to nurse prescribers [78]. One study investigated the perceptions of 
health professionals within the same profession as the non-medical prescriber i.e. 
nurse prescribers [80]. The literature review re-run found three studies that 
related to nurses’ prescribing practice, and they included characterisation of nurse 
practitioner prescribing [82] , the evaluation of nurse practitioner prescribing 
practice [81], and the evaluation of nurse prescriber antibiotic prescribing practice 
[79]. The optometrist study provided an indication of the geographic distribution 
of optometrists in NZ to understand access to these services [77]. Three of the 
seven studies used a quantitative method [77,81,82], and four used a qualitative 
method [78-80,83]. The majority of the research captured from the literature 




Supplementary Table S 1 Summary of literature review update conducted on 29 September 2020 




Research category Participants Strengths and limitations 


















and grey literature  
 
NMP Overview of NMP None—see column 
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Flexible method enables 
exhaustive information 
capture and collation from a 
wide range of data sources 
into one consolidated 
document that provides 
comprehensive current 
overview of NMP in NZ. 
 
NMP in NZ will continue to 
evolve, and a limitation of 
the research is that it 
provides a snapshot of NMP 
in NZ at that date. 
NURSES: 


















Relatively complete large 
data set with 
comprehensive prescriber, 





Insights from a 
New Zealand study 
 
 Data set only captures 
subsidised dispensed 
medicines in NZ. It does not 
capture prescriptions that 
are written but not 
dispensed, nor does it 
capture the prescribing of 
unsubsidised medicines in 
NZ. Lack of accuracy as 
study captured dispensings 
that included repeat 
dispensing—a single 
prescription written by a 
nurse practitioner could 
have resulted in multiple 
dispensings depending on 
the number of dispensing 
on the prescription.  














Review of nurse 
prescribing in NZ 
Nurse practitioners 
(n=10) 
Flexible approach enables 
in-depth information 
capture from nurse 
practitioners. 
 
Small sample size and 
sample bias limits the 
generalisability of 
qualitative work to all nurse 




in New Zealand 





















Flexible approach enables 
in-depth information 
capture from nurse 
prescribers. 
 
Small sample size and 
sample bias limits the 
generalisability of study 
results to all registered 
nurse prescribers in NZ. 


























Relatively complete large 
data set with 
comprehensive prescriber, 
patient, and medicine 
details. 
 
Data set only captures 
subsidised dispensed 
medicines in NZ. It does not 
capture prescriptions that 
are written but not 
dispensed, nor does it 
capture the prescribing of 
unsubsidised medicines in 
NZ. Lack of accuracy as 
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study captured dispensings 
that included repeat 
dispensing—a single 
prescription written by a 
nurse practitioner could 
have resulted in multiple 
dispensings depending on 
the number of dispensing 
















Perceptions of health 





Flexible approach enables 
in-depth information 
capture from nurse 
prescribers. 
 
Small sample size and 
sample bias limits the 
generalisability of study 
results to all registered 













Optometrists Characterisation of 
optometrist 
workforce in NZ 
None. 
Data retrieved from 
regulatory 
organisations 
databases as at May 
2018 
Study provides an 
indication of the geographic 
distribution of optometrists 
in NZ to understand access 












 Limited by some of the 
assumptions made in the 
study and by the 
inaccuracies of the 
databases used to create 





Chapter 3: Current overview of non-medical prescribing in 
New Zealand 
3.1 Context 
The narrative literature review for this thesis confirms and highlights that 
research within the dimensions of non-medical prescribing (NMP) in New Zealand 
(NZ) is lacking. There is no easily accessible source of information about the 
current state of NMP in NZ for stakeholders, including health professionals 
themselves, the public, and policy makers, to understand this service in NZ.  
As described and included in the literature review in Chapter 2, non-medical 
prescribing in this thesis focuses on prescribing by non-medical prescribers that is 
defined as the legislative authority to prescribe medicines that are legally classified 
as prescription medicines in NZ for use in people. It does not focus on the 
provision of medicines via standing orders, or medicines classified as restricted 
(pharmacist only), pharmacy only, and general sale medicines by health 
professionals. 
 
3.2 Chapter aims  
The aim of this chapter is to provide an updated source of information that 
describes the current prescribing rights and educational requirements for non-
medical prescribers in New Zealand. 
 
3.3 Current overview of non-medical prescribing in New Zealand 
publication 
The manuscript entitled “Non-medical prescribing in New Zealand: an overview of 
prescribing rights, service delivery models and training” was published in 
Therapeutic Advances in Drug Safety in 2017 (See Appendix 1).  
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Citation: Raghunandan R, Tordoff J, Smith A. Non-medical prescribing in New 
Zealand: an overview of prescribing rights, service delivery models and training. 
Therapeutic Advances in Drug Safety. November 2017:349-360. 
doi:10.1177/2042098617723312.  
The manuscript is presented as published. However, aspects such as the 
numbering of the pages, figures and tables, and spelling have been adjusted to fit 
the overall style of the thesis. All references from the manuscript are found in the 
section ‘List of references’ at the end of the thesis. Journal permissions allow for 
the inclusion of the submitted/published manuscript in the thesis. 
 
3.3.1 Published manuscript: Statement of contribution  
PhD candidate, Rakhee Raghunandan (RR) and supervisor Dr Alesha Smith (AS) 
conceived and designed project and the data collection strategy. RR performed all 
data collection and data collation. RR, with assistance from AS and Assoc Prof June 
Tordoff (JT), conducted the analysis and interpretation of these data. RR drafted 
the manuscript, with all authors subsequently contributing to the review and 
revision of the manuscript. The final version of the manuscript was read and 





3.4 Published manuscript: Non-medical prescribing in New 
Zealand: an overview of prescribing rights, service delivery 
models and training 
Rakhee Raghunandan*1, June Tordoff1 and Alesha Smith1 
* Corresponding author 
1 School of Pharmacy, University of Otago, Dunedin, New Zealand 
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Key Points: 
• Non-medical prescribing (NMP) is being implemented in New Zealand in 
several health professional groups, and is evolving to address the increasing 
demands placed on the primary care sector. 
• There is no reliable and easily accessible information source regarding NMP in 
NZ for health professionals or the public. 
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• There is variation in the regulation, educational programmes and prescribing 
competencies used by the different prescribing health professionals involved in 
NMP in NZ. 
• A collaborative research network is required in NZ to evaluate and improve the 
NMP service in NZ. 
• NZ needs to develop overarching NMP policy to enable consistency in the 





Aim: In this paper, we aim to provide an updated source of information for non-
medical prescribing (NMP) in New Zealand (NZ). 
Method: A variety of NZ sources were used to collect data: legislation, policy 
documents and information from professional and regulatory organizations, and 
education providers.  
Results: In NZ, the legal categories for prescribers include authorised, designated, 
and delegated prescribers. Authorised prescribers include dentists, midwives, 
nurse practitioners, and optometrist prescribers. Designated prescribers include 
pharmacist prescribers, registered nurse prescribers, and dietitian prescribers. 
There are no delegated prescribers in NZ at this time. There is variation in the 
regulation, educational programmes and prescribing competencies used by the 
different prescribing health professionals involved in NMP in NZ.  
Conclusion: This update collates relevant information relating to NMP in NZ into 
one consolidated document and provides policy makers with a current overview of 
prescribing rights, service delivery models, training requirements, and prescribing 
competencies used for NMP in NZ. As NMP in NZ continues to expand and evolve, 
this paper will form a baseline for future NMP research in NZ. NZ needs to develop 
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overarching NMP policy to enable consistency in the various aspects of NMP, 
thereby delivering a safe and sustainable NMP service in NZ. 
Keywords: education, healthcare policy, non-medical prescribing, pharmacist 




Non-medical prescribing (NMP) was introduced in New Zealand (NZ), as in other 
countries, to address the threat of diminishing access to prescription medicines 
[4,115]. NMP is still a comparatively new practice in NZ, is changing significantly, 
and the number of non-medical health professional groups with prescribing rights 
is increasing. Furthermore, NZ pharmaceutical collection data have identified 
dispensed prescriptions written by non-medical prescribers where it is unclear if 
they have prescribing rights e.g. chiropractors and psychologists [42].  
This review focused on prescribing by non-medical prescribers that is defined as 
the legislative authority to prescribe medicines that are legally classified as 
prescription medicines in NZ for use in people. This review did not focus on the 
provision of medicines via standing orders, or medicines classified as restricted 
(pharmacist only), pharmacy only, and general sale medicines by health 
professionals. 
It is important to have current information about the prescribing models, practice 
settings, and educational aspects of NMP in an easily accessible source to enable: 
1). Patient safety: NZ health professionals need this information so they are aware 
of who can prescribe medicines in NZ and their scope of practice. Patients also 




2). Educational development: educators need to ensure that education curricula 
and training are appropriate to equip the health professional groups with adequate 
skills for prescribing. 
3). Policy development: policy makers require current information about non-
medical prescribers when developing strategies for delivering a safe NMP service. 
4). Workforce development: relevant authorities need to ensure the NZ NMP 
workforce is in adequate supply and suitably trained to deliver the health service. 
5). To facilitate the above, we plan to establish a snapshot of the range and scope of 
current NMP in NZ. 
 
3.4.3 Objective 
We aim to provide an updated source of information that describes the current 
prescribing rights and educational requirements for non-medical prescribers in 
New Zealand. 
We aim to determine the following: 
• which health professions have prescribing rights; 
• the prescribing model/s employed; 
• practice settings; 
• the training or education required; 
• use of prescribing competency framework (if any) by each profession. 
 
3.4.4 Method 
In this paper, we used a variety of sources to collect data: NZ legislation, 
information from professional and regulatory organizations, policy documents, 
information from education providers, and grey literature. The Ministry of Health 
NZ website was used to identify which health professions were regulated under 
the Health Practitioners Competence Assurance Act 2003, and who the responsible 
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authorities were for each health profession [136]. The Medicines Act 1981 and 
relevant Medicines Regulations were used to identify which of these health 
professionals were legally authorised to prescribe prescription medicines [43,137-
141]. The remaining responsible authorities for health professionals not initially 
identified as prescribers via the Medicines Act or Regulations were contacted by 
email to confirm whether those health professionals were allowed to prescribe 
prescription medicines e.g. New Zealand Chiropractic Board (chiropractors), 
Physiotherapy Board of New Zealand (physiotherapists), etc. After the initial step 
to identify who could prescribe prescription medicines, the remaining listed 
objectives were identified during the data collection phase as each data source was 
reviewed. Any conflicting data were resolved by emailing the regulatory 
organizations to seek clarification. 
The collected data were analysed under the themes identified as the objectives of 
the paper, that is, which health professions have prescribing rights, the prescribing 
model/s employed, practice settings, education requirements, and use of 
prescribing competency framework (if any) by each profession. Data were collated 
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3.4.5.1 Non-medical prescribing legislation in New Zealand 
There are at least five legislative documents that currently govern NMP in New 
Zealand [43,141,162-164]. The Medicines Act 1981 and its Regulations will be 
repealed in the foreseeable future and replaced with a new Therapeutic Products 
Bill which aims to provide an enabling legislative framework [165,166]. The new 
bill is still under development and is due for introduction to NZ parliament in 2017 
[165]. 
 
3.4.5.2 Non-medical prescribers in New Zealand 
Currently, there are seven non-medical health professionals with various 
prescribing rights in NZ (Table 3). Table 3 also lists the legal prescribing 
categories, the year that the prescribing rights were first gained, prescribing 
models used, predominant practice setting, educational requirements and use of 
prescribing competencies. 
Medicines in NZ are legally classified as prescription medicines, restricted 
medicines, pharmacy only, and general sales [141]. Parts 1 to 3 of Schedule 1 in the 
Medicines Regulations, 1984, list medicines that are classified as prescription, 
restricted (pharmacist only) and pharmacy only, respectively [141]. The Medicine 
Act, 1981, lists three legislative categories of prescribers: authorised prescriber, 
designated prescriber and delegated prescriber [43]. Authorised prescribers 
(dentists, midwives, nurse practitioners and optometrist prescribers) are allowed 
to prescribe any prescription medicine that is listed in Part 1 of Schedule 1 in the 
Medicines Regulations. Designated prescribers (pharmacist prescribers, dietitian 
prescribers and registered nurse prescribers practising in primary health and 
specialty teams) are only allowed to prescribe specified prescription medicines. 
The list of prescription medicines that each profession can prescribe from varies 
for pharmacist prescribers, dietitian prescribers and registered nurse prescribers 
[138,151,167]. Although not the focus of this review, it is noted that the list of 
specified medicines for these non-medical prescribers also includes medicines that 
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are legally classified as restricted medicines, pharmacy only, and general sales. 
Delegated prescribers are health professionals who may only prescribe medicines 
as detailed in a delegated prescribing order that has been issued by an authorised 
prescriber [43]. Currently, there are no delegated prescribers in NZ. 
 
3.4.5.3 Amendments to legislation since prescribing rights first gained 
The prescribing parameters for several health professionals have been modified 
over time, for example, dentists, midwives, nurse practitioners and optometrist 
prescribers [168]. With the introduction of registered nurse prescribing and the 
Medicines (designated prescriber: registered nurses) Regulations 2016, the initial 
cohort of diabetes nurse prescribers now falls under the registered nurse 
prescribers category, and the Medicines (designated prescriber: registered nurses 
practising in diabetes health) Regulations 2011, were revoked on 30 November 
2016. 
 
3.4.5.4 Numbers of non-medical prescribers in each health profession 
Table 4 collates workforce data for all the non-medical prescribers in NZ. There are 
no overall data for nurse prescribers, however, there are data on the initial cohort 
of diabetes nurse prescribers who fall within this category (0.09%). Currently, 
nurse practitioners combined with diabetes nurse prescribers make up 0.41% of 
the registered nurse workforce that can prescribe. This is similar to the proportion 
of pharmacist prescribers in the registered pharmacist workforce (0.42%). 
However, the absolute number of prescribers in the nursing workforce (i.e. nurse 
practitioners + diabetes nurse prescribers) is 209, and is significantly higher than 






Table 4 Number of non-medical prescribers in New Zealand and proportion of workforce that can 
prescribe (as at 31 March 2016 unless stated). 
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3.4.5.5 Prescribing models and prescribing settings of non-medical prescribers in New 
Zealand 
Prescribing models 
The two current prescribing models identified for authorised and designated 
prescribers in NZ are the independent prescribing model and the collaborative 
prescribing model (Table 3). 
 
Prescribing settings 
Table 3 indicates the predominant practice setting for the various non-medical 
prescribers. The Nursing Council of NZ Workforce Statistics 2015 publication 
reported that the largest proportion of the nurse practitioner workforce was 
working in primary healthcare (39%), however many nurse practitioners (25%) 
did not state a practice area [150]. A Ministry of Health NZ 2010 workforce survey 
indicated that 94–96% of optometrists are working in private practice [146]. The 
Pharmacy Council of NZ reported that of the 15 pharmacist prescribers registered 
in 2017, 40% of pharmacist prescribers work in primary care, 33% work in 
secondary care (hospitals), and 13.3% are working in a primary/secondary mixed 
care setting [147]. There are 45 diabetes nurse prescribers in total, working in GP 
practices or in specialist multidisciplinary teams within primary care. No data 
were available to determine the predominant practice setting for dietitian 
prescribers in NZ. 
 
3.4.5.6 Educational requirements and use of prescribing competencies for non-medical 
prescribers in New Zealand 
Non-medical prescribing educational requirements 
The regulatory organizations for the various NMP health professionals are 
responsible for determining and accrediting the educational and competency 
requirements for that health professionals’ scope of practice. Dentists, midwives, 
and optometrists (who graduated from 2007 onwards) are not required to 
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undertake extra educational training to prescribe medicines in NZ, as the 
prescribing qualification is included in their undergraduate degree (Table 3). From 
2014 onwards, nurse practitioner training in NZ, which is a Master’s-level 
programme and has a prerequisite of a minimum 4 years of experience in a 
specified area of practice, includes the prescribing qualification. A new training 
model for nurse practitioners that intends to reduce the overall training time, was 
trialled over a 12-month period in 2016 with the support of the Ministry of Health 
NZ [173]. From 2014 onwards, dietitians who complete the required postgraduate 
Master’s Degree in Dietetics or equivalent, will also qualify as dietitian prescribers 
[151]. Pharmacist prescribers and registered nurse prescribers are all required to 
complete further postgraduate prescribing programmes to enable prescribing. 
These applicants require a minimum of 2 years and 3 years, respectively, of recent 
appropriate post-registration experience [152,174]. 
Optometry graduates prior to 2007, dietitian graduates prior to 2014, and nurse 
practitioners who registered without prescribing status prior to 2014, are all 
required to complete additional approved postgraduate prescribing training to 
enable prescribing. 
 
Use of prescribing competencies 
A specific prescribing competency framework is a common set of competencies 
that is specific to prescribing regardless of the background of the health 
professional [27]. A single prescribing competency framework for all prescribers 
exists in the UK and Australia [27,23]. Table 3 collates information related to use of 
prescribing competencies by the various non-medical prescribers. Currently, only 
pharmacist prescribers and registered nurse prescribers use a specific prescribing 
competency framework in practice in NZ. No documentation could be sourced 
regarding any type of prescribing competency framework or prescribing 
competencies within dentists’ educational requirements. The scope of practice 
competencies for dentists did not identify any competencies that specifically 





3.4.6.1 Non-medical prescribing legislation in New Zealand 
This paper focused on the prescribing of prescription medicines in NZ by non-
medical prescribers. The lack of clarity around who can prescribe prescription 
medicines and what they can prescribe could compromise patient safety in NZ. 
Information on NMP in NZ included a large amount of material from a variety of 
different sources, as comprehensive, up to date information is not currently 
available from one source. 
The new Therapeutic Products Bill is still under development, with a draft version 
due in 2017 [165]. Only limited information is currently available and until it is 
passed, it is not known exactly how the bill will affect the regulations for NMP in 
NZ. One of its intentions is to control prescribing authority using the Health 
Practitioners Competence Assurance Act 2003. Thus, the regulatory authority for 
each health profession with prescribing rights (e.g. Nursing Council NZ for nurse 
prescribers and nurse practitioners, etc.) would govern the parameters of 
prescribing authority within the stated scope of practice for that health profession. 
Initial consultation on the new legislation noted concerns, including the risk that 
some responsible authorities may seek to advance their own profession [176]. 
 
3.4.6.2 Non-medical prescribers in New Zealand 
The most recent non-medical health professionals to gain prescribing rights in NZ 
are registered nurse prescribers practising in primary health and specialty teams 
(September 2016). Personal communication with the Physiotherapy Board of New 
Zealand indicated they have had discussions about the possibility of 
physiotherapists prescribing, but with no progress on this yet [177]. When seeking 
prescribing rights, an application by the responsible authority for a health 
profession is required under the Medicines Act, 1981. This is a rigorous and time-
consuming process, which involves discussions with the Ministry of Health NZ 
[178]. However, this approach could involve inconsistencies, and has the potential 
to be influenced by lobbying from the responsible authority for a health profession. 
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3.4.6.3 Amendments to legislation since prescribing rights first gained 
Nurse practitioners and optometrist prescribers, have been reclassified from 
designated prescribers to authorised prescribers as recognition by the Ministry of 
Health of the safe and appropriate prescribing practice over a period of time, 
although no evidence for the change appeared to be provided [168]. This 
progression of legislative rights possibly could be applied to other non-medical 
prescribers in NZ over time. 
 
3.4.6.4 Numbers of non-medical prescribers in each health profession 
The percentages of the nursing workforce and pharmacist workforce that 
prescribe (i.e. 0.41% and 0.42%, respectively) is much lower in NZ than in the UK 
(2% and 3%, respectively) [37,179]. In the UK, there is evidence to show that 
extending prescribing rights to non-medical health professionals provides benefits 
such as faster access to medicines, more flexible patient-orientated care, time 
savings, and improved service efficiency; and NMP has been found as safe, and 
acceptable to patients and other clinicians [37,8]. The Royal New Zealand College 
of General Practitioners’ 2016 Workforce Survey Report indicates that 44% of GPs 
intend to retire from general practice in the next 10 years and 49% of GPs work 
part time, both of which could influence the overall decline in the availability of GP 
services [180,181]. To address this issue and see the benefits found in the UK, the 
NMP workforce in NZ could be increased. 
It is important to ensure that sufficient health professionals with the appropriate 
skill set and knowledge are being educated and trained to be part of the 
prescribing workforce in NZ. Dentists and midwives contribute a significant 
proportion of the NMP workforce, as their entire workforces have prescribing 
authority. Although dietitian prescribers have the third highest percentage of a 
workforce (64%) that can prescribe medicines, they can only currently prescribe 
three medicines that are legally classified as prescription medicines and may 
therefore only have minimal impact on access to prescription medicines and NMP 
practice. The registered nurse workforce is the largest workforce of all the non-
medical prescribers, and introduction of the new registered nurse prescriber 
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legislation has the potential to increase the proportion of nurse prescribers within 
the NMP workforce, as well as the overall NMP workforce in NZ. The nursing 
prescribing workforce is already increasing as the Nursing Council 2016 annual 
report indicated that 21 new nurse practitioners were added to the register in 
2016, and there was also a 22% increase in the diabetes nurse prescriber 
workforce [169]. Implementation of pharmacist prescribers in NZ is small, as there 
are only 15 in practice, and there is potential to further utilise the skill set of this 
health profession within NMP in NZ. 
 
3.4.6.5 Prescribing models and prescribing settings of non-medical prescribers in New 
Zealand 
Prescribing models 
Non-medical prescribers in NZ, other than optometrist prescribers, utilise either 
an independent or a collaborative prescribing model only, depending on 
legislation. However, there is no information available as to whether the current 
prescribing models used by the various non-medical prescribers in NZ enable an 
effective service. 
Establishing clinical governance is seen as an important aspect of implementing 
prescribing models for NMP [16]. In the UK, clinical commissioning groups (CCGs) 
are clinically led statutory National Health Service (NHS) bodies responsible for 
the planning and commissioning of healthcare services for their local area [182]. 
Many of the CCGs in the UK have an NMP policy to enable the safe and robust 
implementation of the NMP service in their area [183,184]. Australia has 
developed a governance policy for non-medical prescribers in Australia, that is, the 
Health Workforce Australia (HWA) Health Professionals Prescribing Pathway 
(HPPP) Project; however implementation of this policy is still under consultation 
[185,186]. NZ does not have any systems in place yet to enable the development of 
an NMP implementation policy. A viable solution for NZ would involve the 
development and implementation of a national policy for NMP in NZ. The District 
Health Board (DHB) or Primary Health Organization (PHO) structures could be 
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used as the appropriate governance structures to implement the national NMP 
policy at a local level in NZ. 
 
Prescribing settings 
Non-medical prescribers in NZ work in a variety of practice settings and some 
qualitative feedback has been documented regarding these health professionals 
including: 
1). A dietitian prescriber working in an adult cystic fibrosis service: “The new 
regulations will enable me to now prescribe three prescription medicines: high-
dose vitamin D, high-dose zinc and high-dose pancreatic enzymes. Prior to the 
regulations, I would advise the specialist doctors, within my assessment and 
recommendations, on the dosing required by my patients for these particular 
medicines. I am now able to prescribe the whole package of cystic fibrosis 
nutrition therapies for the patient in clinic, or in their home.” [187] 
2). A pharmacist prescriber involved with hypertension clinics in primary care 
stated, “Prescribing is a natural extension to my established role as a clinical 
pharmacist working within a collaborative health care team.” [188] 
3). Feedback from patients interacting with diabetes nurse prescribers in the 2012 
Managed National Roll Out project included comments such as “…easier, more time 
to focus on my needs, more discussion and monitoring…” and “…more convenient 
and easier to see nurse rather than specialist in hospital setting…” [189] 
Current trends indicate that primary care in NZ will require more assistance to 
cope with the increased demand for patient services [180]. UK data for nurse and 
pharmacist prescribers indicate that their predominant practice setting is primary 
care and therefore attempting to address this increased demand in the primary 
care sector [37]. Available NZ data (Table 1) indicates that only the nursing 
workforce prescribers (i.e. nurse practitioners and diabetes nurse prescribers) 
confirm that primary care is their predominant practice area, so there may be a 
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need for increasing implementation of other non-medical prescribers within 
primary care. 
Current data indicate that six pharmacist prescribers (40%) work in primary care, 
and five (33%) in secondary care, hence similar numbers in the two sectors and no 
significant predominant practice setting. As NMP aims to improve access to 
medicines in primary care, this would be the expected predominant practice 
setting for pharmacist prescribers. However, the lower-than-expected number of 
primary care pharmacist prescribers could be due to fewer prospective 
employment opportunities, and the training programme pre-requisites of ‘already 
working in a collaborative team.’ Whilst hospital pharmacists usually work in 
multidisciplinary teams, community pharmacists traditionally have not been 
included in GP practices and primary care clinics, and current opportunities 
remain limited in NZ. Pharmacist prescribers are well established in NMP service 
delivery in the UK, as they are part of primary care organizations, including GP 
practices and primary care clinics in community pharmacy. 
 
3.4.6.6 Educational requirements and use of prescribing competencies for non-medical 
prescribers in New Zealand 
Non-medical prescribing educational requirements 
This paper highlights the variation in the educational requirements for NMP for 
different health professionals in NZ. The qualifications vary in level (i.e. 
undergraduate or postgraduate level), length, content and structure. The focus of 
undergraduate training of the different health professionals who can prescribe 
may account for some of differences noted in the training requirements to become 
a non-medical prescriber in NZ, for example, diagnostic skills (physiotherapists, 
optometrists) versus therapeutic skills (pharmacists, nurses). However, even with 
this concession, the UK has enabled some consistency in the educational 
requirements for the various health professionals who are non-medical 
prescribers [190,191]. The UK independent and supplementary prescriber 
programme for most non-medical prescribers typically comprises: 26 days of full-
time university education and a minimum of 12 days learning in practice 
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(practicum) under a designated medical practitioner (DMP) [17]. The postgraduate 
certificate for NZ pharmacist prescribers (i.e. 60 days of university education and 
20 days practicum under a DMP) is similar in structure to the UK [192]. NZ 
registered nurse prescribers require completion of a postgraduate diploma which 
includes the prescribing practicum of 20 days under a DMP [152]. NZ pharmacist 
prescribers have considerably more educational requirements than NZ registered 
nurse prescribers, as pharmacist prescribers must also complete a postgraduate 
diploma in clinical pharmacy as well as a postgraduate certificate in prescribing, 
which makes it a long and expensive training pathway [192]. A possible reason for 
the lack of consistency in educational requirements for the different health 
professional groups in NZ could be that the application processes for prescribing 
have occurred independently by the various regulatory authorities at different 
times with no underlying national NMP policy. 
Postgraduate NMP training programmes in NZ can also be lengthy and expensive, 
and access to funding might influence the numbers of non-medical prescribers in 
different health professional groups. Health Workforce New Zealand funds some 
postgraduate clinical training for dental, medical, nursing, and midwifery health 
professionals but currently none for pharmacists [193]. Access to equitable 
funding for pharmacists to undertake NMP training could improve the low number 
of pharmacist prescribers. 
 
Use of prescribing competencies 
The use of prescribing competencies is influential in ensuring responsible 
prescribing in practice, thereby increasing patient safety, and should be a 
requirement for all prescribers. However, only a few NMP groups in NZ use 
competencies in practice, and variation exists among them. For example, the 
prescribing competency framework used by NZ pharmacist prescribers is based on 
an earlier version of the UK single prescribing competency framework, while the 
prescribing competencies used by NZ registered nurse prescribers are based on 
the Australian NPS prescribing competency framework [157,194]. This difference 
could be due to the current lack of NZ NMP policy. 
72 
 
A specific prescribing competency framework is also a useful tool for evaluating 
whether the current educational requirements for the different non-medical 
prescribers provide adequate preparation for prescribing. If such a tool was 
available for NZ, it could be applied to ensure a systematic, consistent approach to 
the required training for all non-medical prescribers. The availability of a single 
prescribing competency framework in the UK could be a reason for the consistent 
structure noted in the educational requirements for most non-medical prescribers 
in the UK. 
 
3.4.6.7 Areas for further research 
Research is an important mechanism for evaluating the benefits of healthcare 
services, and can help inform policy and workforce development. In the UK, much 
of the research on NMP has been initiated and funded by Government 
departments, and includes evaluation of the NMP service, as well as patient and 
physician responses to NMP, education of, and continuing education for, non-
medical prescribers [195]. There has also been research into NMP in Australia, 
Canada, and the USA [186,29,6]. There is a considerable lack of research on NMP in 
NZ compared with other countries [195]. The establishment of a collaborative 
research network in NZ could address this issue. 
 
3.4.7 Conclusion 
Legislation pertaining to prescribing in NZ is difficult to interpret and continues to 
evolve as the country enables more non-medical health professionals to prescribe 
prescription medicines. There is variation in NZ in the educational requirements, 
training programmes, and the use of prescribing competencies between the 
different non-medical health professionals that prescribe medicines. 
Implementation of NMP by the different groups of health professions in NZ is also 
highly variable, with some groups well represented (i.e. dentists, midwives, and 
nurses) while others have the potential to be utilised further (i.e. pharmacists). 
The UK has successfully applied a standardised prescribing competency 
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framework to enable more consistency in the governance and implementation of 
NMP in the UK [27]. The development or application of a single prescribing 
competency framework in NZ could be beneficial for NMP in NZ. 
This paper provides policy makers with a current overview of prescribing rights, 
service delivery models, training, and competencies used for NMP in NZ. As NMP in 
NZ continues to expand and evolve, this paper will form a baseline for future NMP 
research in NZ. Although NZ is extending NMP rights, it does not currently have 
any policies to enable a consistent NMP strategy. A formalised strategy for NMP 
would help NZ acquire the benefits of NMP seen in other countries, as well as 
facilitating a sustainable service that would promote patient safety. 
 
3.5 Update since NZ NMP publication 
In the three years since the article in section 3.4 was published, the following 
points outline the progress/lack of progress of NMP aspects highlighted in the 
publication: 
• The new Therapeutic Products Bill, which was due for introduction to NZ 
parliament in 2017, is still in progress and has not been passed. 
• As a result, pharmacist prescriber education programmes at the University of 
Otago and University of Auckland are on hold as this new legislation can impact 
on how these programmes are developed and implemented. 
• No new health professions have been granted prescribing rights during this 
time. 





Chapter 4: Non-medical prescribing trends in New Zealand 
4.1 Context 
Chapter 3 provided a current overview of prescribing rights, and demonstrated the 
variability in service delivery models, training requirements, and prescribing 
competencies for the different health professions involved NMP in NZ. It confirmed 
that NZ non-medical prescribers include dentists, midwives, nurse prescribers 
(nurse practitioners and registered nurse prescribers), pharmacist prescribers, 
optometrists and dietitian prescribers [83]. 
The narrative literature review (Chapter 2) for this thesis highlights that very little 
research has investigated overall NMP practice in NZ. It identified three 
publications that investigated NMP practice, however these publications only 
focused on nurse practitioners’ prescribing practice in NZ [68,82,81]. One 
published conference abstract provided some information on the earlier NZ 
research involving overall NMP practice in NZ.   
This chapter examines NMP practice trends in NZ, and focuses on all NMP 
providers involved in this service (i.e. nurses, pharmacists, dentists, etc.). 
 
4.2 Chapter aims 
Chapter 4 aims to provide a current overview of the scale, scope and trends of NMP 
practice in NZ with specific objectives to determine the: 
• contribution and trends of non-medical prescribers to overall prescribing from 
2016 to 2020; 
• contribution and trends of each NMP health professional group to all non-
medical prescribing from 2016 to 2020; 
• demographics of patients who receive prescriptions from non-medical 
prescribers; 




4.3 Non-medical prescribing trends in New Zealand manuscript 
The manuscript entitled “Non-medical prescribing trends in New Zealand: 2016–
2020” was submitted to the BMC Health Services Research journal in December 
2020 and is currently under review. 
The manuscript is presented as submitted for publishing. However, aspects such as 
the numbering of the pages, figures and tables, and spelling have been adjusted to 
fit the overall style of the thesis. All references from the manuscript are found in 
the section ‘List of references’ at the end of the thesis. Journal permissions allow 
for the inclusion of the submitted/published manuscript in the thesis. 
 
4.3.1 Submitted manuscript: Statement of contribution 
PhD candidate, Rakhee Raghunandan (RR) and supervisor Dr Alesha Smith (AS) 
conceived and designed project. AS retrieved and aggregated the data. RR 
performed the analyses and interpretation of these data with supervision from AS, 
Prof Carlo A Marra (CM), and Assoc Prof June Tordoff (JT). RR drafted the 
manuscript, with all authors subsequently contributing to the critical review and 
revision of the manuscript. The final version of the manuscript was read and 




4.4 Submitted manuscript: Non-medical prescribing trends in 
New Zealand: 2016–2020 
Rakhee Raghunandan1*, Prof Carlo A Marra1, Assoc Prof June Tordoff1, Dr Alesha 
Smith1 
1 School of Pharmacy, University of Otago 
* Corresponding author 
 
4.4.1 Abstract:  
Background: Given increasing patient populations and general practitioner 
workforce constraints, non-medical prescribing (NMP) is one strategy that has 
been introduced in many countries, including New Zealand (NZ), to help cope with 
the increasing demand for health services. Little is known about the NMP practice 
trends in NZ. The aim of this study was to provide a current overview of the scale, 
scope and trends of NMP practice in NZ. 
Method: All claims for community dispensed medicines prescribed by a non-
medical prescriber were extracted from the NZ Pharmaceutical Collection for the 
period 2016–2020. Patient demographics were retrieved from the PHO enrolment 
collection. These national databases contain prescription information for all 
subsidised community pharmacy medicines dispensed and healthcare enrolment 
data for 96% of New Zealanders. 
Results: The proportion of prescriptions written by all NMP providers and 
patients receiving NMP prescriptions increased each year from 1.8% (2016) to 
3.6% (2019) and 8.4% (2016) to 14.4% (2019) respectively. From 2016 to 2019, 
the proportion of NMP patients who had at least one NMP prescription increased 
from 26% to 39% for nurse prescribers, from 1% to 9% for pharmacist 
prescribers, from 2% to 3% for dietitian prescribers, and decreased from 47% to 
22% for dentists, and from 20% to 12% for midwives. The most commonly 
prescribed medicines were antibiotics (amoxicillin, amoxicillin with clavulanic 
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acid, and metronidazole), and analgesics (paracetamol, and codeine phosphate). 
While some NMP providers were prescribing for patients with greater health 
needs, all NMP providers could be better utilised to reach more of these patients.   
Conclusion: This study highlights that although the NMP service has been 
implemented in NZ, it has yet to become mainstream healthcare practice. This 
work provides a baseline to evaluate the NMP service moving forward and enable 
policy development. Improved implementation and integration of primary care 
NMP services can ensure continued access to prescribing services and medicines 
for our communities. 
 





As in other countries, non-medical prescribing (NMP) was introduced in New 
Zealand (NZ) to address the increased demand for healthcare services and 
diminishing access to prescribing services and medicines [4,115]. NMP is the 
legislative extension of prescribing rights to health professionals other than 
medical doctors, thereby enabling them to prescribe medicines classified as 
prescription medicines, and facilitate timely access to medicines [50]. This is 
particularly significant as 49% of general practitioners (GPs) in NZ work part time 
and 47% of GPs intend to retire from general practice in the next 10 years [196]. 
The inequity of access to medicines in primary care in NZ is well documented and 
includes issues such as physical and timely access to a prescriber/prescription, 
and the direct and indirect costs associated with consulting a prescriber [197]. 
NMP is still a relatively new practice in NZ and is changing significantly with the 
number of non-medical health professional groups gaining prescribing rights 
increasing. NZ non-medical prescribers include dentists, midwives, nurse 
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prescribers (nurse practitioners and registered nurse prescribers), pharmacist 
prescribers, optometrists and dietitian prescribers [83]. There is some NZ research 
examining the rates of NMP in NZ [126], and the prescribing practice of nurse 
practitioners [68,82,81] and dentists [55]. There is paucity of research that 
encompasses all NMP and current research is very profession-specific. Little is 
known about the current utilisation of NMP services and the prescribing practice 
of all non-medical prescribers in NZ. Eliciting this type of information will help 
describe the current impact/contribution of NMP in primary care NZ, and can 
contribute to workforce development to enable efficient and sustainable NMP 
services in NZ. 
This study aims to provide a current overview of non-medical prescribers’ 
prescribing trends in NZ with specific objectives to determine the: 
• contribution and trends of non-medical prescribers to overall prescribing from 
2016 to 2020; 
• contribution and trends of each NMP health professional group to all non-
medical prescribing from 2016 to 2020; 
• demographics of patients who receive prescriptions from non-medical 
prescribers; 




4.4.3.1 Study design 
This retrospective nationwide observational study used the NZ Ministry of Health 
Pharmaceutical Collection and the Primary Health Organisation (PHO) Enrolment 
databases [198,199]. These databases capture 96% of all New Zealanders, as 
approximately 4% of people are not enrolled at a primary care practice [200].   
Medicines and therapeutic products that are publicly funded in NZ are listed in the 
NZ Pharmaceutical Schedule (community and hospital schedules), which is 
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managed by the Pharmaceutical Management Agency, PHARMAC [201]. PHARMAC 
is an independent statutory organisation responsible directly to the NZ Minister of 
Health and works with the Ministry of Health [202]. PHARMAC determines which 
medicines and therapeutic products will be fully and/or partly subsidised by 
public funding in NZ [203]. The Pharmaceutical Collection, which is jointly owned 
by the Ministry of Health and PHARMAC, is a data warehouse that records the 
claims submitted by all pharmacies in NZ for the reimbursement of the subsidised 
medicines that have been dispensed to all patients [204]. The PHO Enrolment 
Collection is a national database that holds primary care patient enrolment data 
[205].   
The Pharmaceutical Collection was searched between 1 January 2016 to 30 June 
2020 (4.5 years) using the distinct provider type codes to identify dispensed 
medicines prescribed by: dentists, nurse prescribers (which includes nurse 
practitioners and registered nurse prescribers), optometrists, midwives, 
pharmacist prescribers, and dietitian prescribers. The number of distinct enrolled 
patients who were dispensed a medicine from a NMP and the number of original 
prescriptions dispensed were also determined. The distinct original prescription 
dispensing refers to each single item prescribed by a prescriber on a prescription 
form to a patient, and does not include any repeat dispensing that occurred from a 
prescription. The distinct patients were identified using the encrypted National 
Health Index (NHI) number, which is unique for each patient and remains the same 
in each health-related database across a patient’s lifetime and allows the linking of 
collections. The following patient sociodemographic details were also retrieved 
from the PHO Enrolment Collection: age, gender, ethnicity, NZ Deprivation Index 
(NZDep2013 score), and District Health Board (DHB) provider. Data for the 100 
most dispensed medicines by therapeutic group and medicine chemical name (as 
listed in the community Pharmaceutical Schedule) [201] for overall NMP and each 






4.4.3.2 Analysis:  
Descriptive statistical analyses, using Excel 2016®, were conducted on the 
aggregated data set, to determine NMP contribution to overall community 
dispensed medicines in NZ, NMP by non-medical prescriber provider type (e.g. 
nurse prescriber, dentist, etc.), the demographics of the patients who received 
prescriptions from non-medical prescribers, and summarise the types of medicines 
prescribed by non-medical prescribers in NZ.  
The study analysed patients’ DHB, deprivation and self-reported ethnicity data. 
The following Statistics New Zealand reporting standards for ethnicity were used: 
Asian, Māori, MELAA (defined as Middle Eastern, Latin American, and African), NZ 
European/European, Other, and Pacific Peoples. The NZDep2013 score combines 
census data relating to income, home ownership, employment, qualifications, 
family structure, housing, access to transport and communications [206]. The 
NZDep2013 index groups deprivation scores into deciles, where 1 represents the 
areas with the least deprived scores and 10 the areas with the most deprived 
scores [206]. DHB rural populations were identified from a Ministry of Health 
commissioned report [207]. DHBs were categorised as ‘rural’ if they had a greater 
than 20% rural population.  
 
4.4.4 Results 
This study was approved by the University of Otago Human Ethics Committee 
(reference HD20/029)—see Appendix 2.  
 
4.4.4.1 NMP and non-medical prescriber providers 
The number of dispensed prescriptions written by all healthcare prescribers 
(medical and non-medical) increased by 10.8% from 2016 to 2019 (78,056,369 
prescriptions vs 86,514,345). The number of patients who had a prescription 
issued by all healthcare prescribers (medical and non-medical) increased by 4.7% 
from 2016 to 2019 (3,356,850 vs 3,514,106) (Table 5).  
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2016 1,407,028 78,056,369 1.8% 282,841 3,356,850 8.4% 
2017 1,851,714 83,023,775 2.2% 347,441 3,477,274 10.0% 
2018 2,610,400 87,075,543 3.0% 445,528 3,538,311 12.6% 
2019 3,101,161 86,514,345 3.6% 506,945 3,514,106 14.4% 
2020 




1,304,021 34,535,777 3.8% 239,478 2,641,302 9.1% 
2016–
2020 
10,274,324 369,205,809 2.8% 1,822,233 16,527,843 11.0% 
 
The annual proportion of NMP prescriptions to all prescriptions dispensed and NMP 
patients to all patients dispensed to, has increased over the past 4 years (i.e. 1.8% in 2016 
to 3.6% in 2019 for NMP prescriptions and 8.4% in 2016 to 14.4% in 2019 for NMP 
patients respectively) (Table 5), but not at the same rates for all prescribing (i.e. increases 
of 10.8% for prescriptions and 4.7% for patients).  
Nurse prescribers were the largest NMP contributors (1.40%) to all prescriptions 
(medical and non-medical) dispensed between 2016 and 2020, followed by 
dentists (0.64%), midwives (0.39%), and pharmacist prescribers (0.25%). 
Optometrists and dietitian prescribers were the smallest contributors equally 
(0.06%). Nurse prescribers increased their proportion of all NMP prescriptions 
from 35% (2016) to 56% (2019), and they contributed 50% of all NMP 
prescriptions for the four-and-a-half-year period (2016–2020) (Fig 2). Dentists 
had the largest proportion of NMP prescriptions in 2016 (36%) and the second 
largest (although decreasing) in 2019 (18%), and by mid-2020 this was 14%. 
Pharmacist prescribers’ contributions increased from 2% in 2016 to 11% in 2019, 
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Nurse and pharmacist prescribers were prescribing for an increasing proportion of 
NMP patients from 2016 to 2019 (Fig 3). Nurse prescribers prescribed for 36% of 
all NMP patients and pharmacist prescribers prescribed for 10% of all NMP 
patients for the four-and-a-half-year period (2016–2020). From 2016 to 2020, 47–
22% of NMP patients had prescriptions from dentists; 20-12% from midwives; 4-









Figure 3 Contribution by each NMP provider type towards NMP patients each year and overall from 1 January 2016–30 June2020 
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Table 6 presents the sociodemographic characteristics of the patients who had a 
NMP prescription dispensed between 1 January 2016–30 June 2020, and 
summarises these findings in terms of each specific non-medical provider type and 
NMP providers overall. Individual patients may have received a prescription from 
multiple NMP and medical providers (e.g. dentist, midwife, and GP). Hence, the 
number of original prescriptions and/or number of patients differs for many 
categories in the analyses. 
While the majority of patients seen by NMP providers were female (60.9%), 
dentists and dietitian prescribers prescribed for almost equal proportions of 
female and male patients (Table 6). During the period 2016–2020, the median age 
for the NMP patients was 39 years (IQR 25–61 years). The youngest patients were 
seen by midwives (median=29, IQR 24–33), followed by nurse prescribers 
(median=36, IQR 19–40), and dentists (median=48, IQR 30–62). The patients’ 
median age was 57-60 years for optometrists (median=57, IQR 38–71), pharmacist 
prescribers (median=59, IQR 31–72), and dietitian prescribers (median=60, IQR 
20–76). 
The NZDep2013 score was recorded for 1,017132 NMP patients with a median 
score of 6 (IQR 3–8). In total, 466,393 NMP patients (42.8%) were living in the 
more deprived areas (i.e. NZDep2013 decile 7–8 and above). During 2016–2020, 
optometrists saw patients living in the less deprived areas (NZDep2013 median 
score=5, IQR 2–7) and nurse prescribers saw patients living in more deprived 
areas (NZDep2013 median score=7, IQR 4–9). 
For all NMP providers overall, 171,882 (15.8%) patients self-identified as Māori 
and 54,011 (5.0%) as Pacific peoples. Nurse prescribers prescribed for the highest 
proportion of Māori patients (83,756 (21.6%)) and optometrists for the lowest 
proportion of Māori patients (2,676 (5.8%)). Midwives prescribed for the highest 
proportion of Pacific patients (11,309 (6.6%)) and optometrist prescribers 
prescribed for the lowest proportion of Pacific patients (1,284 (2.8%)). Twelve 




The five DHBs with the most patients receiving a prescription from a NMP 
provider were: Counties Manukau (117,157 patients (10.3%)), Waitematā 
(116,849 (10.3%)), Canterbury (115,353 (10.1%)), Waikato DHB (113,218 
(10.0%)), and Auckland (103,098 (9.1%)). Most rural DHBs had lower numbers of 
NMP patients (e.g. Wairarapa 17,246 (1.5%) and South Canterbury 12,500 
(1.1%)), and included the two DHBs with the least NMP patients which were West 




Table 6 Summary of sociodemographic characteristics of patients seen by all NMP providers and each specific NMP provider type for period 1 January 2016–30 June 
2020 
Variable: Dentist Nurse 
prescriber 







































































































































































































































































































































































































































































Hawke’s Bay  





West Coast*  
Canterbury  


















































































































* = rural DHBs (with a greater than 20% rural population) [207]  
SD = standard deviation 
IQR = Inter-quartile range 








Based on the 100 most frequently prescribed therapeutic groups by NMP 
providers, we ascertained the top five therapeutic products that were most 
prescribed by NMP providers during the period from 1 January 2016–30 June 
2020. For all NMP providers, the two most frequently prescribed therapeutic 
groups were antibacterials with 1,802,812 dispensings (23.4%), followed by 
analgesics (1,096,706 (14.3%)). Antibacterials were also the most prescribed 
therapeutic group by dentists (1,263,218 (53.8%)), and the second most 
prescribed therapeutic group by nurse prescribers (432,657 (8.4%)) and 
optometrists (5,320 (2.5%)). Analgesics were the most prescribed therapeutic 
group by nurse prescribers (534,387 (10.4%)), and the second most prescribed 
therapeutic group by dentists (418,768 (17.8%)) and midwives (115,852 (7.7%)). 
The analgesic therapeutic group included medicines such as paracetamol, codeine 
phosphate, and tramadol, but excluded ibuprofen and diclofenac, which are 
categorised as non-steroidal anti-inflammatory agents in the Pharmaceutical 
Collection data. 
The top five most prescribed therapeutic groups by pharmacist prescribers were 
contraceptives-hormonal with 159,013 dispensings (17.9%), followed by 
vaccinations (128,332 (14.4%)), treatments for substance dependence (113,378 
(12.7%)), lipid-modifying agents (38,199, (4.3%)), and agents affecting the renin-
angiotensin system (37,353 (4.2%)). Unsurprisingly, the eye preparation 
therapeutic group was most prescribed by optometrists (95.6%), and all the top 
five therapeutic groups prescribed by dietitian prescribers related to nutrition. 
Based on the 100 most frequently prescribed medicines by NMP providers, Table 7 
presents the top ten medicines prescribed during the study period. For all NMP 
providers, the most frequently prescribed medicine was amoxicillin (902,786 
dispensings, 17.5%), followed by paracetamol (617,500 (12.0%)), and amoxicillin 
with clavulanic acid (458,519 (8.9%)). Amoxicillin was most prescribed medicine 
by dentists (737,840 dispensings, 32.6%), and the third most prescribed medicine 
by nurse prescribers (140,754 (6.2%)). Paracetamol was the most prescribed 
medicine by nurse prescribers (362,511 (15.8%)), and featured in the top ten 
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medicines prescribed by dentists, midwives and pharmacist prescribers. 
Compared with the top ten medicines prescribed by dentists and nurses, 
pharmacist prescribers were prescribing more medicines associated with long 
term conditions (i.e. atorvastatin, metoprolol succinate, omeprazole, aspirin, 
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clavulanic acid  
458,519 (8.9%) 
 























Oral feed with fibre 





















Fat supplement  
6,212 (3.6%) 
 
Potassium iodate  
377,905 (7.3%) 
 

















































































Paediatric oral feed 
with fibre 1.5kcal/ml  
5,688 (3.3%) 
 




































[Hyaluronic acid]  
6,035 (3.0%) 


















4.4.5.1 Summary of findings 
This study reported the first data describing all NMP in New Zealand providing an 
important baseline for future comparisons. The increasing contribution trend of 
nurse prescribers towards NZ NMP could be due to their new ‘registered nurse 
prescriber’ scopes of practice [105], a supportive regulatory authority, and 
streamlined education programmes, allowing increasing numbers of nurses 
prescribers (nurse practitioners and registered nurse prescribers) to prescribe in 
practice in NZ [208].  
Only nurse prescribers and midwives prescribed for a higher proportion of Māori 
patients (21.6% and 17.6% respectively) than in the general New Zealand 
population (16.5%) [209]. However, overall it would appear that NMP providers 
were not providing healthcare to all communities with greater health needs, for 
example NMP providers prescribed for a lower proportion of patients of Pacific 
ethnicity than found in the general New Zealand population (8.1%) [209]. 
Midwives and nurse prescribers prescribed for a younger cohort of patients in NZ, 
with patient median ages (29 and 36 years respectively), slightly below the NZ 
national median age of 37.4 years [210]. 
Antibacterials and analgesics (including non-steroidal anti-inflammatory agents) 
were, on average, the most prescribed therapeutic groups by NMP providers. 
These two therapeutic groups were also in the top five groups prescribed by NZ 
GPs in the most recent statistics (2018) [211]. There is a lot of similarity in the top 
ten most prescribed medicines by NMP providers in this study and by GPs [211]. 
For example, amoxicillin and amoxicillin with clavulanic acid, which ranked highly 
in NMP, also featured in the top twenty most prescribed medicines by GPs [211]. 
The analgesics (including paracetamol, paracetamol with codeine, codeine, 
ibuprofen, diclofenac, and tramadol hydrochloride) featured in the top ten 
medicines prescribed by all NZ NMP providers overall, and all prescribers except 
dietitian prescribers. In contrast, paracetamol and ibuprofen were the only 
analgesics in the top twenty most prescribed medicines by GPs [211]. However, 
opioids may be lower on the list of most prescribed by GPs as they have a wider 
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range of patients/conditions to treat. NZ data indicates that codeine and tramadol 
were the two most prescribed opioids between 2013–2017, with tramadol use 
increasing by 13% [212].  
 
4.4.5.2 Comparison with existing literature 
It is difficult to compare the prescribing practice of the NZ NMP providers in this 
study as there a scarcity of published work about NMP providers’ practice in NZ 
and internationally. The number of original prescriptions written by non-medical 
prescribers in NZ is increasing and has surpassed the 1 million NMP prescriptions 
reported in earlier NZ research [126], with this study reporting 1,407,028 NMP 
prescriptions in 2016 and more than doubling to 3,101,161 NMP prescriptions by 
2019. 
Similar to NZ, UK research reported that nurse prescribers are the biggest 
contributor to NMP prescriptions in the UK, however UK nurse prescribers 
accounted for a much higher proportion (94.4%) of NMP prescriptions dispensed 
in primary care (93,102,682 out of 98,577,980 NMP prescriptions) for the 5 year 
period January 2011–December 2015 [213]. It is noted that in the UK, midwives 
are regulated by the Nursing and Midwifery Council UK and their prescribing is 
captured within nurse prescribing [214].  
While pharmacist prescribers contributed modestly (0.25%) to all NZ prescribing, 
they were the fourth largest contributors to NMP prescriptions (9.0%) from 2016–
2020 (Fig 2), with a high of 12% in 2018. In contrast, pharmacist prescribers in the 
UK are the second largest contributor to NMP prescriptions in primary care 
producing 5.5% of all NMP prescriptions dispensed during January 2011–
December 2015 [213]. While the UK percentage is smaller than that of pharmacist 
prescribers in NZ, the number of NMP prescriptions written by pharmacist 
prescribers is much higher in the UK (i.e. 5,454,942 out of 98,577,980 NMP 
prescriptions from 2011-2015) [213], than in NZ (i.e. 890,444 out of 10,274,324 
NMP prescriptions from 2016-2020). Pharmacist prescribers in both countries 




There is only one existing NZ study about NMP practice with which this present 
study can be compared (Poot et al), however, that study only focused on nurse 
practitioner prescribing practice [82]. This present study’s nurse prescribers’ 
patient cohort is younger than seen in Poot et al’s study (median age=40 years) 
[82]. One reason could be the broad practice scope of nurse practitioners 
compared to the primary care focus of the registered nurse prescribers. Poot et al 
found that nurse practitioners were prescribing for patients living in areas of more 
deprivation, to a higher proportion of Māori patients, and a lower proportion of 
Pacific people [82], which was similar to patient cohort findings for the nurse 
prescribers in the present study.   
NZ research found three antibiotics (amoxicillin, amoxicillin with clavulanic acid, 
and flucloxacillin) in the top ten most prescribed medicines by nurse practitioners 
in 2013–2015 [82]. UK research also confirms that penicillins, which include 
amoxicillin and amoxicillin with clavulanic acid, are the most prescribed 
antibacterial class for all non-medical prescribers overall, and nurse and 
pharmacist prescribers [213]. Given the increasing issue of antimicrobial 
resistance, further examination around the appropriateness of this prescribing is 
warranted as this is largely unknown. Earlier NZ research evaluating antibiotic 
prescribing found that generally NZ dentists followed clinical guidelines [55], 
however recent Australian research concluded the overuse of antibiotics by 
Australian dentists for both therapeutic and non-therapeutic reasons [215]. This 
Australian research also found that a small proportion of general dentists 
prescribed diclofenac, codeine, and tramadol, which were considered 
inappropriate analgesics according to their Australian oral and dental therapeutic 
guidelines [215]. While there are no specific dentist guidelines in NZ for 
prescribing analgesics, this present NMP study found that NZ dentists were 
prescribing diclofenac, codeine, and tramadol which were considered 






4.4.5.3 Implications for policy and practice in NZ 
The larger urban DHBs account for 48.3% of NZ NMP patients as they have bigger 
population bases. Based on current prescribing practice of the overall NMP service, 
there is a great opportunity for NZ NMP providers, including pharmacist 
prescribers, to contribute to communities with greater health needs, including 
Māori and Pacific communities [216,217]. Rural NZ struggles with adequate 
workforce and inequity of access to healthcare [218], and rural DHBs often have 
higher proportions of patients who experience an unmet need for primary 
healthcare (e.g. a higher proportion of Māori and Pacific patients) [219]. While it is 
acknowledged that the rural DHBs account for smaller proportions of all NMP 
patients in this study due to their smaller population bases, NMP services could be 
further utilised to reach communities who are experiencing unmet primary 
healthcare needs in rural NZ.  
The high prescribing of analgesics and antibiotics by non-medical prescribers 
suggest that they are dealing with a high number of acute conditions. These 
examples could signal that non-medical prescribers are prescribing within their 
scope such as dentists treating oral/dental infections and conditions that required 
pain relief. It also suggests that non-medical prescribers could be taking some of 
the burden from GPs and be helping to improve medicines access equity for acute 
conditions. UK research has indicated that NMP has made better use of health 
professionals’ skills (including nurse and pharmacist independent prescribers) to 
reduce workload pressures of GPs [220,221,37].  
NZ pharmacist prescribers prescribed more preventative agents (nicotine 
replacement therapy), and immunisations (influenza vaccine). UK pharmacists are 
also increasingly prescribing the influenza vaccine [222] and in 2018, pharmacists 
in Canada also delivered 34% of adult influenza doses [223]. The current uptake of 
NZ pharmacist prescribers for preventative agents demonstrates that they could 
be further utilised to prescribe preventative agents, including a wider range of 
funded immunisations in NZ. Older people (65 years and over) make up 15% of the 
NZ population, use 42% of health services, and over the last 10 years spending on 
services for older people is increasing faster than other expenses [224] Current NZ 
pharmacist prescriber practice indicates that they prescribe more medicines for 
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long term conditions and for a higher proportion of older patients. NZ pharmacist 
prescribing services could be improved in primary care to help manage the 
increasing prescribing burden associated with long term conditions and an aging 
population. Canadian research has demonstrated the value of pharmacist 
prescribing services to manage long term conditions such as hypertension and 
cardiovascular risk [39,38], which increase in prevalence as people age. 
Understanding NMP practice in NZ identifies areas that require sufficient initial 
and continuing education. NZ is a relatively high user of antibiotics [225,226], and 
overuse of antibiotics is a key factor [227,228] in the global health problem of 
antibiotic resistance [229,230]. Identifying that antibiotics are commonly 
prescribed by non-medical prescribers suggests that further research is required 
to evaluate the appropriateness of this prescribing. It also highlights the need for 
adequate education about antimicrobial stewardship to ensure that non-medical 
prescribers are not contributing to antibiotic resistance [231]. Appropriate 
analgesic prescribing is also important, especially with the concerns 
internationally about rising prescription opioid use and misuse [232]. Prescribers 
need to be fully aware of opioid-related risks and adverse effects [233,234] while 
optimising pain relief for patients.  
 
4.4.5.4 Strengths and limitations 
A strength of this study is the large data set available for analysis, with dispensing, 
prescriber, patient, and medicines details. The data set contained comprehensive 
sociodemographic details for each patient and captures >96% of the New Zealand 
population. It is acknowledged that dispensing may not fully reflect prescribing, as 
patients who had a prescription issued but did not take it to a pharmacy for 
dispensing, are not captured in this study. The Pharmaceutical Collection data did 
not differentiate between pharmacists prescribing funded medicines as registered 
pharmacist prescribers and via the pharmacist only medicines classification. This 
study captured both nurse practitioner and registered nurse prescribing within the 





All the NMP professions in NZ appear to be prescribing medicines within their 
usual practice. While there is modest growth in this service, NZ NMP still makes 
very small contributions to overall prescribing in primary care. Nurse prescribers 
are the largest contributor to NMP, and other NMP providers including pharmacist 
prescribers have the potential to contribute more to this service.  
There is some indication that NMP providers could be alleviating the prescribing 
burden on GPs and improving access by prescribing for acute conditions that 
require pain relief or antibiotics. However, overall all NMP providers could be 
better utilised to provide prescribing services to our communities with greater 
health needs and improve access to these healthcare services. NMP providers have 
the potential to improve healthcare service delivery to cope with unmet health 
needs in rural NZ, a sector that struggles to meet health needs due to workforce 
constraints and inequity of access. The variation of NMP service provision across 
the different DHBs in NZ indicates that the NMP service has been well integrated in 
certain geographic areas, and this variation could be due to better support and 
funding in some DHBs compared to others. This study highlights the importance of 
identifying what medicines NMP providers are prescribing, to ensure adequate 
education and continuing professional development to support best practice and 
appropriate prescribing decisions. Further research is needed to determine the 
impact of NMP on patient outcomes and access to healthcare. 
As NZ seeks to cope with the increasing demand for health services, factors such as 
workforce constraints have the potential to affect the availability of the usual GP 
prescriber in primary care. NZ has to make better use of the skills of other health 
professionals, and must consider new models of care and service delivery to meet 
these increasing healthcare needs. This study highlights that NMP has been 
implemented in NZ, but it has not yet become mainstream healthcare practice. This 
work provides a baseline to evaluate the NMP service moving forward and 
contribute to policy development. Improved implementation and integration of 
primary care NMP services can enable continued access and reduce inequity to 
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Chapter 5: Identifying community pharmacist preferences 
for prescribing services in primary care in New Zealand—a 
discrete choice experiment  
5.1 Context 
 The narrative literature review for this thesis confirms and highlights that 
research into non-medical prescribing (NMP) in other countries such as the UK 
and Canada have contributed to workforce development. Research into non-
medical prescribers in the UK have utilised various methodologies, to evaluate the 
preferences of health professionals as well as the patients and/or public to 
prescribing services in primary care, including pharmacist prescriber services 
[101,120,102,132,100,133]. UK evaluation, which included health preference 
methodology, indicated that nurse and pharmacist prescribing was well-integrated 
in the health system, was safe and clinically appropriate, had high patient 
satisfaction, and that NMP was viewed positively by other health professionals 
[37] 
Canadian research has also used various methodologies, including health 
preference research, to explore aspects of pharmacist services in primary care, 
including prescribing [38,97,134,39]. Canadian health preference research 
demonstrated that pharmacists were more willing to provide additional 
pharmacist services, compared with traditional dispensing services [134], and that 
patients preferred a collaborative pharmacist prescribing service that included a 
doctor, compared with an independent pharmacist prescribing model when 
treating a chronic health condition [41].  
Pharmacists have been identified as having an increasingly important role in the 
primary care team in NZ [135]. The types of research discussed above, help to 
address health workforce needs, including workforce development and allocation 
in areas such as primary care [9]. However, these research methodologies have yet 
to be utilised in NZ to explore the place of pharmacist prescribers within NMP in 
primary care. It would be beneficial to determine pharmacists’ preferences for 
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providing pharmacist prescribing services in primary care, as it can help clarify the 
circumstances within which they were willing to provide this service. 
Understanding these health provider preferences would be useful when 
developing future pharmacist prescribing services in NZ. 
 
5.2 Chapter aims 
Having determined in Chapters 3 and 4 that there are low numbers of pharmacist 
prescribers and pharmacist prescribing is inconsistently implemented and poorly 
utilised in NZ; we hypothesised that this could be due to factors that hinder the 
uptake and provision of this service by the pharmacist workforce.  
The objective of this chapter is to explore the place of pharmacist prescribers 
within NMP in primary care in NZ, from the perspective of the pharmacist 
workforce. The study aims to use a quantitative method (i.e. a discrete choice 
experiment) to identify preferences of community pharmacists for different types 
of prescribing models in primary care.  
 
5.3 Discrete choice experiment (DCE) methodology 
The discrete choice experiment (DCE) is a quantitative method that measures 
respondent preferences and is theoretically underpinned by Lancaster’s theory of 
demand and random utility theory. Lancaster’s theory states that goods/services 
can be described in terms of a number of attributes, each with multiple levels [235-
237]. In DCEs, individuals are asked to respond to a set of questions, which require 
them to choose one alternative from several options. Each option is characterised 
by the combination of the attributes and levels included in the DCE. Random utility 
theory indicates that when faced with two or more options, people will choose the 
option that gives them the highest overall utility value [238-241], and the choices 
people make reflect their preferences. The resulting choices are analysed to 




Random utility theory specifies the utility function as [242]: 
𝑈𝑗 = 𝑉(𝛽, 𝛸𝑗) +  𝑗  (1) 
where 
Uj is the utility for alternative j; 
V is a function defined by the attribute levels for alternative j (i.e. the observed 
component); 
Xj is a vector of attribute levels defining alternative j; 
β is a vector of estimated coefficients for the attribute levels; 
εj is a random error term (i.e. the unobserved component).  
DCEs can use either revealed preference (RP) data, or stated preference (SP) data, 
or both. Revealed preference data collects data on what a respondent actually did 
or chose when presented with a scenario that is based on existing goods or 
services [243,239]. Stated preference data collect data on what a respondent 
would do or choose when presented with a hypothetical scenario [243]. 
Stated preference choice experiments can include hypothetical alternatives, 
attributes or attribute levels in the choice tasks, thereby evaluating the desirability 
of goods and services that are not yet available in a market, which is especially 
useful in healthcare [239]. Discrete choice experiments can provide information on 
respondent preferences, as well as willingness to pay, willingness to accept or 
other value measures such as time (i.e. willingness to wait), or benefit harm trade-
offs for defined goods or services [239], thus allowing goods or services to be 
developed based on constructive evidence of preferences for product 
characteristics. DCE application in health research include eliciting preferences, 
quantifying trade-offs and predicting uptake to inform policy development and 
analysis; and measuring outcomes for inclusion in economic evaluation, 
respectively [243]. DCEs should be conducted according to good research practice 




5.3.1 Discrete choice design and analysis 
Experimental design refers to the process of generating the specific combinations 
of attributes and levels that respondents evaluate in choice questions [246]. We 
use the established practice of generating discrete choice experiment design to 
minimise the d-error i.e. a D-efficient design [245,246]. The main study design 
usually optimises on a multinomial logit (MNL) model. It is acceptable practice to 
use an MNL model to design for an mixed MNL model [248]. Our discrete choice 
experiments use a combination of fixed and Bayesian priors to generate the main 
study design. Bayesian priors can be more robust than fixed priors as they take 
into account the uncertainty associated with parameter priors [248,249]. 
However, using Bayesian priors for a discrete choice study design is time 
consuming and can be computationally intensive so the number of Bayesian priors 
are usually limited [250]. Our designs utilised an appropriate number of Gauss 
draws to enable better approximation of the design efficiency when using Bayesian 
priors [251]. 
For DCE analysis, we used a mixed multinomial logit (mixed MNL) model, which is 
also known as a random parameters logit (RPL) model [242]. This model accounts 
for the panel nature of the data (i.e. repeated choices completed by each 
respondent), and for preference heterogeneity [242,252,253].  
The utility that respondent n derives from choosing alternative j in choice task s 
using the mixed MNL model is given by [244,252]: 
𝑈𝑛𝑠𝑗 =  ∑ 𝛽𝑛𝑘𝑥𝑛𝑠𝑗𝑘
𝐾=1
𝑘
+ 𝑛𝑠𝑗     





n = respondent, 
k = attribute 
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s = choice task, 
j = alternative 
and there are N respondents (decision makers) choosing amongst J alternatives 
across S choice tasks. 
The observed or predictable component Vnsj (i.e. the attributes and relevant 
sociodemographic variables) is specified as [252]:  
𝑉𝑛𝑠𝑗 =  𝛼𝑗 + 𝐴𝑛𝑠𝑗𝑘
′ 𝛿 + 𝑍𝑛
′ 𝛾𝑗 (3) 
were Ansj is a vector of k attributes describing alternative j in choice task s, Zi is a 
vector of the characteristics of the individual respondent (decision maker) n, and αj 
(the alternative-specific constants), δ, γj are the parameters to be estimated. 
The error term εnsj includes the unobserved components of the mixed MNL model 
[244,242,243]. The mixed MNL model includes random coefficient specification to 
capture preference heterogeneity, where ηk represents the random variation 
around the parameter mean (see equation 4 below) [252]. This specification 
allows a more flexible substitution between choices (as it relaxes the 
independence of irrelevant alternatives (IIA) assumption); and also allows the 
ability to capture dependence due to the panel structure of the data, because ηk 
varies over the individual respondents but it is assumed to be fixed over the choice 
tasks [252,253]. The random parameters are estimated as the mean marginal 
utility in the sampled population and the deviation of the mean marginal utility 
held by the respondent under a determined distribution [242,254]. Based on this, 
the random parameters are represented as: 
𝛽𝑛𝑘 =  𝛽𝑘 + 𝜂𝑘𝑧𝑛𝑠𝑗𝑘 (4) 
where βk is the mean marginal utility in the sampled population and η is the 
deviation of the mean marginal utility held by respondent n for characteristic k 
belonging to alternative j in choice set s, and znsjk represents an underlying 
distribution, commonly (but not exclusively) a normal distribution such as 
znsjk~N(0,1) [254,242]. Both our DCEs usually specified a normal distribution for 
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most of the random parameters used in our mixed MNL model estimations. 
However, the NZ public preference DCE (see Chapter 6) specified the two cost by 
household income interaction terms as truncated triangular distributions to 
ensure that the estimated sign of the coefficients were logical (i.e. it constrained 
the cost coefficient to have a negative sign which would indicate that as cost 
increased, respondents had lower preferences for an alternative) [255]. 
The resulting choice probability of respondent n choosing alternative j using the 
mixed MNL model is [244]: 













The DCE analysis can also employ latent class (LC) analysis to understand which 
respondent characteristics may predict class membership and how preferences for 
attributes may vary across respondent classes (underlying latent classes) [256]. To 
account for this heterogeneity, the LC model assumes that there are a fixed number 
of (latent) classes within the sample such that each class has preference weights 
that are identical within the class and that are systematically different from 
preference weights in other classes in the sample [242,244]. The researcher 
usually defines the number of classes a priori [244,242]. The latent class model can 
allow some understanding of the composition of various class segments as the 
probability of class membership can be linked to respondent characteristics (e.g., 
age, gender, education, etc.) [256]. 
The latent class model allows respondent characteristics to enter the class 
assignment model as follows [256]: 






where Vnc is the observable utility of respondent n in class segment c, and h are the 
sociodemographic characteristics of respondent n in class segment c. 
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The resulting probability of respondent n belonging to latent class segment c is 
[244]: 







The utility that respondent n belonging to class segment c has for alternative j in 
choice task s using the latent class model is represented as [244]: 







n = respondent, 
s = choice task, 
j = alternative 
c = class segment. 
The observed component Vnsj|c (i.e. the observable utility) that respondent n 
belonging to class segment c has for alternative j in choice set s is [244]:  






The error term εnsj|c includes the unobserved components of the latent class model, 
and assumes an extreme value type 1 distribution [244,242,243]. The latent class 
model can incorporate fixed and/or random parameters [244], which are specified 
as described earlier in this chapter for the mixed MNL model.  
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Using the latent class model, the resulting choice probability of respondent n 
choosing alternative j in choice situation s, given membership of class segment c is 
[242,244]: 






where Vnsj|c represents the observed component of utility. 
Both the community pharmacist and NZ public DCEs explored latent class models 
during analyses. However, neither DCE reported on the results of the latent class 
analyses, as they did not add any explanatory value over the final mixed MNL 
analyses. 
We evaluated all the estimated models for goodness of fit using accepted criteria 
such as the log-likelihood ratio test, the McFadden’s pseudo R–squared value, and 
the normalised Akaike’s information criterion (AIC) value (i.e. AIC/N) [242]. The 
McFadden’s pseudo R-squared provides a measure of relative (rather than 
absolute) model fit, a measure from 0.2 to 0.4 can be considered a good model fit 
[242]. The final model for the DCE is selected based on the normalised AIC value as 
well as the model’s explanatory power, and model parsimony. 
DCEs allow estimation of trade-offs that respondents make between attributes—
also known as marginal rates of substitution [243].  The trade-offs between one 
attribute and other attributes allows estimation of the relative importance of 
attributes using a common metric [256]. These trade-offs can be calculated using a 
common metrics such as cost to calculate willingness to pay, risk factors attributes 
to calculate willingness to accept, or other value measures such as time to calculate 
willingness to wait for defined goods or services [239]. 
The trade-off (or marginal rate of substitution) is calculated as the ratio of the 
change in marginal utility of one attribute to the change in marginal utility for 
another attribute [244]. The trade-offs are calculated using the estimated model 
outputs for the attributes [238]. For example, in the NZ public preference DCE (see 
Chapter 6) willingness to pay (WTP) is calculated as the ratio of the change in 
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marginal utility of estimated attribute k to the change in marginal utility for the 
estimated cost attribute (per $1 increase) as follows: 







The use of DCEs by researchers, policy makers and practitioners in the health 
sector continues to increase [239,252]. DCEs can provide insight into preferences 
to inform clinical and policy decisions for health programmes, or understand the 
behaviour of stakeholders in the health sector (such as members of the health 
workforce, patients/consumers, policy makers, etc.) [243]. DCEs also provide 
quantification of the trade-offs individuals are prepared to make between different 
aspects of healthcare (e.g. benefit–risk trade-offs), monetary and non-monetary 
valuation (e.g. valuing healthcare and/or health outcomes for use in both cost 
benefit and cost-utility analysis) [243]. Many steps are involved in the design, 
conduct and analysis of discrete choice experiments to ensure they follow accepted 
DCE practice guidelines [242-246]. The community pharmacist preference project 
in this chapter and thesis demonstrates how to apply a DCE to pharmacy practice 
research. 
 
5.4 Identifying community pharmacist preferences for prescribing 
services in primary care in New Zealand publication 
This chapter contains a published original manuscript titled “Identifying 
community pharmacist preferences for prescribing services in primary care in 
New Zealand—a discrete choice experiment”. The manuscript was published in 
Health Economics and Health Policy on 19 October 2020—see Appendix 3.  
Citation: Raghunandan, R., Howard, K., Marra, C.A. et al. Identifying Community 
Pharmacist Preferences For Prescribing Services in Primary Care in New Zealand: 
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A Discrete Choice Experiment. Appl Health Econ Health Policy (2020). 
https://doi.org/10.1007/s40258-020-00615-3.  
The manuscript is presented as published. However, aspects such as the 
numbering of the pages, figures and tables, and spelling have been adjusted to fit 
the overall style of the thesis. All references from the manuscript are found in the 
section ‘List of references’ at the end of the thesis. Journal permissions allow for 
the inclusion of the submitted/published manuscript in the thesis. 
 
5.4.1 Published manuscript: Statement of contribution 
PhD candidate, Rakhee Raghunandan (RR) with supervision from supervisor Dr 
Alesha Smith (AS) conceived the project. RR designed the DCE (with advice from 
Prof Michiel Bliemer), created the DCE questionnaire, and carried out data 
collection. RR conducted the analyses and interpretation of these data with 
supervision from advisor Prof Kirsten Howard (KH). Supervisors AS, Prof Carlo A 
Marra (CM), and Assoc Prof June Tordoff (JT) supervised the project, providing 
overall direction and planning. RR drafted the manuscript, with all authors 
subsequently contributing to the critical review and revision of the manuscript. 




5.5 Published manuscript: “Identifying community pharmacist 
preferences for prescribing services in primary care in New 
Zealand—a discrete choice experiment” 
Rakhee Raghunandan*1, Kirsten Howard2, Carlo A. Marra1, June Tordof1, Alesha 
Smith1 
1 School of Pharmacy, University of Otago, PO Box 56, Dunedin 9054, Otago, New 
Zealand 
2 School of Public Health, University of Sydney, Sydney, NSW, Australia 
* Corresponding author 
 
5.5.1 Abstract 
Objective: Given increasing patient populations, general practitioner (GP) 
workforce constraints, and increasing demand for health services in New Zealand 
(NZ), the development and provision of pharmacist prescribing services may need 
to increase to improve people’s access to medicines. A discrete choice experiment 
(DCE) was utilised to determine community pharmacist preferences for 
prescribing services in primary care in NZ, and to understand how these factors 
could improve the provision of pharmacist prescribing services. 
Method: A D-efficient design generated 30 labelled choice questions in three 
blocks of ten, and three alternatives per choice question. The online DCE was 
emailed to practising community pharmacists in NZ. The DCE included two 
attributes with five levels (prescribing model, educational requirements) and three 
attributes with three levels (location, professional fee, change in income). A mixed 
multinomial logit model was used to estimate preferences. 
Results: A total of 264 respondents completed the survey with 2640 observations 
for analyses. This DCE found pharmacists preferred pharmacy services with the 
following characteristics: ability to prescribe using minor ailments and 
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independent prescribing models relative to the pharmacist only medicines 
prescribing model; prescribing education by accredited learning modules relative 
to PGDipClinPharm+PGCertPharmPres; remuneration via a professional fee; and 
pharmacist prescribing services located in community pharmacies rather than in 
GP practices. 
Conclusion: Prescribing policy could incorporate these pharmacist preferences to 
help develop accessible and effective pharmacist prescribing services that not only 
improve access to medicines, but also address inequity of access to medicines in 
NZ. These DCE results are encouraging as they signal that the community 
pharmacists also see themselves and their pharmacies as part of the prescribing 
team in primary care in NZ. 
 
Key points for decision makers: 
Community pharmacists considered themselves as part of the prescribing team in 
primary care, and favoured the minor ailments and independent prescribing 
models. 
Other attributes preferred by pharmacists were utilising accredited learning 
modules to provide prescribing education; remuneration via a professional fee; 
and locating pharmacist prescribing services in community pharmacies. 
Policy makers can utilise these preferences to develop prescriber training 
requirements and prescribing services that community pharmacists are more 
willing to engage in, thereby enabling greater provision of pharmacist prescribing 
services in primary care. 
 
5.5.2 Introduction 
Given increasing demand for health services, New Zealand (NZ) and other 
countries have introduced non-medical prescribing (NMP) to facilitate timely 
access to medicines [115,9]. NMP is the legislative extension of prescribing rights 
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to health professionals other than medical doctors, thereby enabling them to 
prescribe prescription medicines. This shift in roles utilises the skills of health 
professionals, such as nurses and pharmacists, more appropriately in the care of 
patients, and improves access to prescribers for patients [9]. The inequity of access 
to medicines in primary care in NZ is in part related to factors such as physical and 
timely access to a prescriber/prescription, as well as costs (direct and indirect) 
associated with consulting a prescriber [197]. 
Non-medical prescribers in NZ include dentists, midwives, nurse practitioners and 
registered nurse prescribers, pharmacist prescribers, optometrists, and dietitian 
prescribers. Compared to the other countries who utilise NMP, including the USA, 
Canada and the UK [115,9,36,37], NMP in NZ is underutilised and therefore not 
making the same health impact [83].  
The current model of pharmacist prescribing within NMP in NZ is the collaborative 
prescribing model. Within this model, the pharmacist prescriber works as part of a 
collaborative team and does not provide diagnoses. The pharmacist prescriber can 
write a prescription to initiate, modify or discontinue medicines (including 
medicines initiated by another prescriber). Pharmacist prescribers currently make 
up a very small part of the NMP workforce. This is in stark contrast to registered 
nurse prescribers whose prescribing scope is the closest to current pharmacist 
prescribers. The most recent statistics (March 2018) reported that there were only 
19 registered practising pharmacist prescribers, compared with 300 nurse 
practitioners and 187 registered nurse prescribers with various scopes of 
prescribing practice [257,258]. The Nursing Council of NZ Annual Report indicates 
that nurse prescriber numbers are increasing, while the Pharmacy Council of NZ 
workforce report indicates no significant growth in the number of pharmacist 
prescribers. Possible barriers for community pharmacists to become pharmacist 
prescribers could include the current pharmacist prescriber training requirements 
and lack of prescribing roles in primary care.   
Pharmacist prescribing services will need to increase, including among community 
pharmacists, to accommodate the increasing need for access, as well as addressing 
the inequity of access to medicines [259] in primary care in NZ. Although 
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community pharmacists in NZ do not currently utilise the collaborative prescribing 
model in their scope of practice, they do provide medicines that are classified as 
restricted medicines (i.e. pharmacist only medicines), and prescription medicines 
under the Standing Order legislation such as warfarin within the Community 
Pharmacy Anti-Coagulation Management Service (CPAMS). Community 
pharmacists make up the largest sector of the pharmacist workforce—
approximately 78% [258]. They are a key part of future pharmacy models of 
service provision, especially as the profession tries to incorporate a greater patient 
focus in primary care. Eliciting the preferences of community pharmacists is 
important as it can assist decision makers in the development and provision of a 
more comprehensive prescribing service in primary care.  
This study aims to use a quantitative method (i.e. a discrete choice experiment 
[DCE]) to: 
• Determine community pharmacists’ preferences for relevant attribute levels 
defining prescribing models in primary care in NZ. 
• Understand how these attributes and others factors could influence community 
pharmacist preferences for providing a pharmacist prescribing service. 
 
5.5.3 Method 
This study utilised a DCE that was designed and conducted in accordance with 
practice guidelines for DCEs [243-246,242]. 
5.5.3.1 Respondents 
Respondents were practising NZ community pharmacists. The electronic discrete 
choice questionnaire utilised the Qualtrics survey platform (version May 2018), 
and was disseminated online via the Pharmaceutical Society of NZ and Pharmacy 
Council of NZ member databases. Data collection occurred during June 2018 to 
November 2018. This study was approved by the University of Otago Human 




5.5.3.2 Discrete choice experiment attributes and attribute levels 
 Table 8 summarises the five attributes included in this DCE, which were derived 
through reviewing literature [100,260,134,261-263], individual feedback from 
local community pharmacists (n=3), and a focus group of community pharmacists 
(n=3) — see Supplementary material 1 in the Pharmacist DCE Online 
Supplementary Material 1 (OSM1) section at the end of this chapter.   
 
Table 8 Discrete choice experiment attributes and attribute levels 



















2). Location of 
prescribing 
























fee charge    
$0/he $50/h $100/h - - 
5). Change in 
pharmacist 
prescriber's 
personal income     







a Within BPharm = included within the undergraduate Bachelor of Pharmacy programme 
b PGCertPres = hypothetical postgraduate certificate in prescribing 
c PGDipPres = hypothetical postgraduate diploma in prescribing 
d PGCertPharmPres and PGDipClinPharm = postgraduate certificate in pharmacist 
prescribing plus postgraduate diploma in clinical pharmacy 




Hypothetical options in this stated preference DCE were the independent, 
delegated, and minor ailments prescribing models, and the postgraduate certificate 
in prescribing (PGCertPres) and postgraduate diploma in prescribing (PGDipPres) 
education attribute levels (Table 8), as these options do not currently exist in NZ.  
The first three attributes and levels in Table 8 were included as the researchers 
hypothesised that the current pharmacist prescriber service, which must operate 
from a GP practice, using the collaborative prescriber model, and requires the 
PGCertPharmPres and PGDipClinPharm education requirement, impeded 
pharmacists from becoming a pharmacist prescriber in a community pharmacy. 
Charging a professional service fee and a change in the pharmacist’s personal 
income were included to explore the influence of remuneration on preferences for 
providing a pharmacist prescribing service.  
The prescribing models were included in the DCE as labelled alternatives. The 
independent prescribing model enables the pharmacist prescriber to 
independently diagnose and prescribe prescription medicines within their area of 
competence. Within the collaborative prescribing model, the GP/authorised 
prescriber makes the initial diagnosis, and the pharmacist prescriber 
independently prescribes from a list of specified medicines for that condition only. 
With delegated prescribing, the GP/authorised prescriber makes the initial 
diagnosis and establishes the patient treatment plan, and the pharmacist 
prescriber only prescribes specified medicines within an agreed patient treatment 
plan. With the minor ailments prescribing model, the pharmacist prescriber 
independently diagnoses, prescribes, and dispenses from a specified list of 
medicines for specified minor ailments seen in primary health. The pharmacist 
only medicine prescribing model enables a pharmacist, who has completed the 
required training, to prescribe (via a specified algorithm) and dispense 







5.5.3.3 Study design  
The DCE was piloted on randomly selected local practising community 
pharmacists (n = 9) to assess interpretation and ability to complete the choice 
questions. The results of the pilot study were also used to generate the priors for 
the main study design.  
A partial choice set design was required to show three out of the five labelled 
alternatives (i.e. the prescribing models) in each choice question [264]. This 
method used Ngene v.1.1.2 software [265] and Excel 2016 to generate a D-efficient 
design of 30 choice questions in three blocks of 10 choice questions each, and 
three labelled alternatives per choice question. This approach was used for the 
pilot and main study designs. The DCE was a forced choice design—there was no 
opt out alternative as the current scope of pharmacist practice in NZ includes 
pharmacist only medicine ‘prescribing’. The design included one constraint; the 
“appointment at GP practice” attribute level was not displayed for the pharmacist 
only medicine prescribing alternative as this was an implausible combination. The 
main study design included eight normally distributed Bayesian priors. Bayesian 
priors can be more robust than fixed priors as they take into account the 
uncertainty associated with parameter priors [248,250]. The main study Bayesian 
mean d-error = 0.107.  
Qualtrics algorithms randomly assigned one of the three blocks of choice questions 
to each respondent. The DCE main study questionnaire (see Appendix 5 of the 
thesis) included background information, explanation of the choice questions, 
definitions of attributes and levels, ten choice questions, choice- and attribute-
related questions and sociodemographic questions. A dominance choice task test 
was not included as some of the attribute levels were very subjective, and made it 
difficult to identify and include an alternative that would be interpreted as 
dominant by all possible respondents. 





Figure 4 Example of discrete choice experiment (DCE) choice question 
 
5.5.3.4 Analyses 
R software was used to generate descriptive statistics for the pharmacist DCE data 
set and NLOGIT Version 6 software was used for the DCE analyses [266,267].  
All categorical data (i.e. attributes and sociodemographic variables) were effects 
coded. The professional service fee charge and change in pharmacist’s income 
attributes were included as continuous variables and all other attributes were 
categorical. Analyses included alternative-specific attributes (i.e. location of the 
119 
 
prescribing service and the education requirement to prescribe) and generic 
attributes (i.e. professional service fee charge and change in pharmacist’s income). 
The pharmacist’s sociodemographic variables in the analyses included alternative-
specific variables (i.e. the number of practice years and pharmacy location 
variables were interacted with each prescribing model alternative, relative to the 
reference alternative) as previous testing showed statistically significant 
differences between the alternatives. Previous iterations of model testing indicated 
no statistically significant differences between the alternatives so pharmacist 
ethnicity, total number of staff working with the pharmacist during a shift, 
pharmacist owners, and pharmacists with postgraduate pharmacy education were 
collapsed to generic sociodemographic variables. Based on other pharmacist 
preference research [261,268-270], we expected respondent characteristics such 
as the number of practice years and pharmacy location would affect respondents’ 
preferences for the different prescribing models, and pharmacist owners would be 
averse to a pharmacist prescriber service in primary care. 
The DCE data set was analysed using a mixed multinomial logit (mixed MNL) 
model. This model accounts for the panel nature of the data (i.e. repeated choices 
completed by each respondent), and preference heterogeneity [242]. Model results 
are presented as the estimated beta values of the variables in the DCE, odds ratios 
(OR), 95% confidence intervals of odds ratios, and the standard deviations of the 
variables that were specified as random parameters.  
 A statistically significant estimated beta coefficient (i.e. p value < 0.05) indicates 
respondents consider this an important variable when determining their 
preferences for an attribute level, and the sign of the coefficient indicates whether 
it positively or negatively contributes to their preferences, relative to the reference 
level for the attribute [271]. The random parameters with statistically insignificant 
standard deviations (i.e. p value > 0.05) were included as fixed parameters and the 
model was re-estimated and evaluated until the final mixed MNL model was 
achieved. Eighteen normally distributed random parameters were included in the 
final mixed MNL model, and 1000 Halton draws were used for model estimations. 
Statistically insignificant sociodemographic variables (p value > 0.05) were 
dropped if they did not improve the model fit evaluations.  
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Models were evaluated for goodness of fit using the log-likelihood ratio test, the 
McFadden’s pseudo R–squared value, and the normalised Akaike’s information 
criterion (AIC) value (i.e. AIC/N). The final model was selected based on the 
normalised AIC value as well as the model’s explanatory power. 
The utility functions for our DCE analyses to best explain pharmacist choices were 
specified as follows: 
𝑉𝐼𝑛𝑑𝑒𝑝𝑒𝑛𝑑𝑒𝑛𝑡 𝑃𝑟𝑒𝑠𝑐𝑟𝑖𝑏𝑖𝑛𝑔 (𝐼𝑃)
=  𝛽𝐼𝑃 +  𝛽1𝐼𝑃 𝑃𝑟𝑒𝑠𝑐𝑟𝑖𝑏𝑖𝑛𝑔 𝐿𝑜𝑐𝑎𝑡𝑖𝑜𝑛
+  𝛽2𝐼𝑃 𝑃𝑟𝑒𝑠𝑐𝑟𝑖𝑏𝑖𝑛𝑔 𝐸𝑑𝑢𝑐𝑎𝑡𝑖𝑜𝑛 𝑅𝑒𝑞𝑢𝑖𝑟𝑒𝑚𝑒𝑛𝑡 + 𝛽3𝑃𝑓𝑒𝑒 + 𝛽4𝑃𝑖𝑛𝑐
+  𝛽5𝐼𝑃 𝑃𝑟𝑎𝑐𝑡𝑖𝑐𝑒 𝑌𝑒𝑎𝑟𝑠 + 𝛽6𝐼𝑃 𝑃ℎ𝑎𝑟𝑚𝑎𝑐𝑦 𝐿𝑜𝑐𝑎𝑡𝑖𝑜𝑛 +  𝛽7𝐸𝑡ℎ𝑛𝑖𝑐𝑖𝑡𝑦
+  𝛽8𝑇𝑜𝑡𝑎𝑙 𝑆𝑡𝑎𝑓𝑓 +  𝛽9𝑃𝑜𝑠𝑡𝑔𝑟𝑎𝑑𝑢𝑎𝑡𝑒 𝑃ℎ𝑎𝑟𝑚𝑎𝑐𝑦 𝐸𝑑𝑢𝑐𝑎𝑡𝑖𝑜𝑛
+  𝛽10𝑃ℎ𝑎𝑟𝑚𝑎𝑐𝑖𝑠𝑡 𝑂𝑤𝑛𝑒𝑟 
 
𝑉𝐶𝑜𝑙𝑙𝑎𝑏𝑜𝑟𝑎𝑡𝑖𝑣𝑒 𝑃𝑟𝑒𝑠𝑐𝑟𝑖𝑏𝑖𝑛𝑔 (𝐶𝑃)
=  𝛽𝐶𝑃 + 𝛽11𝐶𝑃 𝑃𝑟𝑒𝑠𝑐𝑟𝑖𝑏𝑖𝑛𝑔 𝐿𝑜𝑐𝑎𝑡𝑖𝑜𝑛
+  𝛽12𝐶𝑃 𝑃𝑟𝑒𝑠𝑐𝑟𝑖𝑏𝑖𝑛𝑔 𝐸𝑑𝑢𝑐𝑎𝑡𝑖𝑜𝑛 𝑅𝑒𝑞𝑢𝑖𝑟𝑒𝑚𝑒𝑛𝑡 +  𝛽3𝑃𝑓𝑒𝑒 +  𝛽4𝑃𝑖𝑛𝑐
+  𝛽13𝐶𝑃 𝑃𝑟𝑎𝑐𝑡𝑖𝑐𝑒 𝑌𝑒𝑎𝑟𝑠 +  𝛽14𝐶𝑃 𝑃ℎ𝑎𝑟𝑚𝑎𝑐𝑦 𝐿𝑜𝑐𝑎𝑡𝑖𝑜𝑛
+  𝛽7𝐸𝑡ℎ𝑛𝑖𝑐𝑖𝑡𝑦 +  𝛽8𝑇𝑜𝑡𝑎𝑙 𝑆𝑡𝑎𝑓𝑓 
+  𝛽9𝑃𝑜𝑠𝑡𝑔𝑟𝑎𝑑𝑢𝑎𝑡𝑒 𝑃ℎ𝑎𝑟𝑚𝑎𝑐𝑦 𝐸𝑑𝑢𝑐𝑎𝑡𝑖𝑜𝑛 +  𝛽10𝑃ℎ𝑎𝑟𝑚𝑎𝑐𝑖𝑠𝑡 𝑂𝑤𝑛𝑒𝑟 
 
𝑉𝐷𝑒𝑙𝑒𝑔𝑎𝑡𝑒𝑑 𝑃𝑟𝑒𝑠𝑐𝑟𝑖𝑏𝑖𝑛𝑔 (𝐷𝑃)
=  𝛽𝐷𝑃 +  𝛽15𝐷𝑃 𝑃𝑟𝑒𝑠𝑐𝑟𝑖𝑏𝑖𝑛𝑔 𝐿𝑜𝑐𝑎𝑡𝑖𝑜𝑛
+  𝛽16𝐷𝑃 𝑃𝑟𝑒𝑠𝑐𝑟𝑖𝑏𝑖𝑛𝑔 𝐸𝑑𝑢𝑐𝑎𝑡𝑖𝑜𝑛 𝑅𝑒𝑞𝑢𝑖𝑟𝑒𝑚𝑒𝑛𝑡 +  𝛽3𝑃𝑓𝑒𝑒 +  𝛽4𝑃𝑖𝑛𝑐
+  𝛽17𝐷𝑃 𝑃𝑟𝑎𝑐𝑡𝑖𝑐𝑒 𝑌𝑒𝑎𝑟𝑠 +  𝛽18𝐷𝑃 𝑃ℎ𝑎𝑟𝑚𝑎𝑐𝑦 𝐿𝑜𝑐𝑎𝑡𝑖𝑜𝑛
+  𝛽7𝐸𝑡ℎ𝑛𝑖𝑐𝑖𝑡𝑦 +  𝛽8𝑇𝑜𝑡𝑎𝑙 𝑆𝑡𝑎𝑓𝑓 




𝑉𝑀𝑖𝑛𝑜𝑟 𝐴𝑖𝑙𝑚𝑒𝑛𝑡𝑠 𝑃𝑟𝑒𝑠𝑐𝑟𝑖𝑏𝑖𝑛𝑔 (𝑀𝐴𝑃)
=  𝛽𝑀𝐴𝑃 +  𝛽19𝑀𝐴𝑃 𝑃𝑟𝑒𝑠𝑐𝑟𝑖𝑏𝑖𝑛𝑔 𝐿𝑜𝑐𝑎𝑡𝑖𝑜𝑛
+  𝛽20𝑀𝐴𝑃 𝑃𝑟𝑒𝑠𝑐𝑟𝑖𝑏𝑖𝑛𝑔 𝐸𝑑𝑢𝑐𝑎𝑡𝑖𝑜𝑛 𝑅𝑒𝑞𝑢𝑖𝑟𝑒𝑚𝑒𝑛𝑡 +  𝛽3𝑃𝑓𝑒𝑒
+  𝛽4𝑃𝑖𝑛𝑐 +  𝛽21𝑀𝐴𝑃 𝑃𝑟𝑎𝑐𝑡𝑖𝑐𝑒 𝑌𝑒𝑎𝑟𝑠
+  𝛽22𝑀𝐴𝑃 𝑃ℎ𝑎𝑟𝑚𝑎𝑐𝑦 𝐿𝑜𝑐𝑎𝑡𝑖𝑜𝑛 +  𝛽7𝐸𝑡ℎ𝑛𝑖𝑐𝑖𝑡𝑦 +  𝛽8𝑇𝑜𝑡𝑎𝑙 𝑆𝑡𝑎𝑓𝑓 
+  𝛽9𝑃𝑜𝑠𝑡𝑔𝑟𝑎𝑑𝑢𝑎𝑡𝑒 𝑃ℎ𝑎𝑟𝑚𝑎𝑐𝑦 𝐸𝑑𝑢𝑐𝑎𝑡𝑖𝑜𝑛 +  𝛽10𝑃ℎ𝑎𝑟𝑚𝑎𝑐𝑖𝑠𝑡 𝑂𝑤𝑛𝑒𝑟 
𝑉𝑃ℎ𝑎𝑟𝑚𝑎𝑐𝑖𝑠𝑡 𝑂𝑛𝑙𝑦 𝑀𝑒𝑑𝑖𝑐𝑖𝑛𝑒 𝑃𝑟𝑒𝑠𝑐𝑟𝑖𝑏𝑖𝑛𝑔 (𝑃𝑂𝑃)
= 𝛽23𝑃𝑂𝑃 𝑃𝑟𝑒𝑠𝑐𝑟𝑖𝑏𝑖𝑛𝑔 𝐿𝑜𝑐𝑎𝑡𝑖𝑜𝑛
+  𝛽24𝑃𝑂𝑃 𝑃𝑟𝑒𝑠𝑐𝑟𝑖𝑏𝑖𝑛𝑔 𝐸𝑑𝑢𝑐𝑎𝑡𝑖𝑜𝑛 𝑅𝑒𝑞𝑢𝑖𝑟𝑒𝑚𝑒𝑛𝑡 +  𝛽3𝑃𝑓𝑒𝑒
+  𝛽4𝑃𝑖𝑛𝑐 
 
The alternative-specific constants (βIP, βCP, βDP, βMAP), relative to a reference 
alternative (i.e. pharmacist only medicine prescribing), captures the average effect 
on utility from all factors associated with that specific alternative that are not 
included in the model. 
The overall value of the pharmacist prescribing model alternatives were 
calculated, using the utility functions, the estimated parameters from the mixed 
MNL model (Table 11), the scenario that maximised the pharmacist preferences 
from the mixed MNL model, and the representative pharmacist characteristics 
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Pharmacist characteristics used (from Table 10): 
Mean practice years for pharmacist  = 17.6 years 
Pharmacy location = 52% major city (reference level); 21% provincial city; 27% provincial town/rural  
Pharmacist ethnicity = 65% European (reference level); 23% Asian/Indian; 12% Māori/Pacific 
peoples/Middle Eastern/Latin American/African/Other ethnicity  
Mean number of total staff working shift with pharmacist = 7.7 
16% of pharmacists have postgraduate pharmacy education 
33% are pharmacist owners 
 
Multinomial (MNL) and random parameter (RPL) latent class analyses were 
conducted to explore any observed preference heterogeneity. However, these 
latent class analyses are not presented, as they did not add any explanatory value 




The PCNZ 2018 Workforce report indicated there were 2958 practising 
community pharmacists in NZ [258]. Although the DCE invitation had the potential 
to reach this number of community pharmacists, we were unable to confirm this 
final potential sample size (i.e. email address lists may be inaccurate and so forth). 
In total 264 respondents completed the survey (approximately 8.9% of the 
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potential sample size of 2958) and the resultant data set included 2640 
observations for analyses. 
The DCE community pharmacist characteristics are summarised in Table 10. The 
data set was representative by gender and age [258]. Most (66%) of the workforce 
was in full time employment and 16% had a postgraduate pharmacy qualification. 
Approximately one third (33%) of participants were pharmacist owners. 
 
Table 10 DCE community pharmacist sociodemographic characteristics 
Variable Variable sub-level/s N (total = 264) % 
Age Mean age (SD) 41.2 years (12.3) Range 22-70 
Gender Female 170 64.4% 
Male 94 35.6% 
Employment Full time employment         





Part time employment         













Practice years Mean years of practice (SD) 17.6 (12.8) Range 0.5-50 
Pharmacy owner status Pharmacist owner  86 33% 
Pharmacist employee 178 67% 
Additional number of 
pharmacists working with 
pharmacist during shift 
Mean (SD) 2.2 (1.7) Range 0-15 
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Total number of pharmacy 
staff working with 
pharmacist during shift  
Mean (SD) 7.7 (5.8) Range 0-54 
Current job satisfaction Satisfied 216 81.8% 
Unsatisfied 48 18.2% 
Pharmacy location 
(location of pharmacist’s 
primary work pharmacy)  
Major city 138 52.3% 
Provincial city 56 21.2% 
Provincial town or rural 70 26.5% 




<100 23 8.7% 
100-200 68 25.8% 
201-300 73 27.7% 
301-400 38 14.4% 
401-500 23 8.7% 
>500 39 14.8% 
Ethnicity 
 
European 171 65% 
Asian/Indian 61 23% 




Māori 3 1% 
Pacific peoples 2 1% 
Extra pharmacy services 
qualifications 
 
No extra service qualifications 5 1.9% 
Pharmacist only medicines 
accreditations 
79 29.9% 
Pharmacist only medicines 




Pharmacist only medicines 
accreditations + vaccinator + 
CPAMS 
35 13.3% 
Pharmacist only medicines 
accreditations + CPAMS 
23 8.7% 
Pharmacist only medicines 
accreditations + MUR 
20 7.6% 
Pharmacist only medicines 
accreditations + vaccinator + 
CPAMS + MUR 
14 5.3% 
Pharmacist only medicines 
accreditations + vaccinator + 
MUR 
10 3.8% 
DCE survey distribution 
 
Personal e-mail link 197 74.6% 
Anonymous link 67 25.4% 
Difficulty of DCE questions 
 
Extremely easy 15 5.7% 
Moderately easy 111 42.0% 
Moderately difficult 118 44.7% 
Extremely difficult 20 7.6% 
Duration of DCE 
questionnaire 
 
Median duration  24 minutes - 
CPAMS = Community Pharmacy Anti-Coagulation Management Service 
MUR = Medicines Use Review Service. 







5.5.4.2 Mixed multinomial logit (mixed MNL) results 
Not all attribute and sociodemographic variables were statistically significant 
contributors to the mixed MNL model (i.e. p value < 0.05) (Table 11). 
Table 11 Community pharmacist preferences for prescribing models relative to pharmacist only 
medicine prescribing using mixed MNL model 
Variable: Estimated 
beta value 
OR† OR 95% CI  SD  
(if random 
parameter) 
Alternative-specific attributes:     
Alternative-specific constant ( ASC)       
(Reference utility = Pharmacist only 
medicines prescribing(POP))                                                                                                                                                      
    
IP  -0.180 0.835 (0.484-1.441) 0.457* 










MAP  -0.301 0.740 (0.420-1.305) 0.703* 
     
Appointment at community pharmacy 
(Prescribing location)                                                     
(Reference level = Walk in consultation at 
community pharmacy) 
    
IP 0.564* 1.758 (1.280-2.414)  
CP -0.037 0.963 (0.681-1.364)  
DP 0.395* 1.485 (1.037 -2.125)  
MAP 0.428* 1.534 (1.162-2.025)  
POP# 0.026 1.026 (0.807-1.305) 0.623* 
Appointment at GP practice  
(Prescribing location) 
    
IP -1.050* 0.350 (0.225-0.546) 1.016* 
CP -0.265 0.767 (0.563-1.045)  
DP -0.079 0.924 (0.665-1.284) 1.348* 
MAP -1.781* 0.169 (0.113-0.252) 1.201* 
Within BPharm   
(Prescribing education requirement)  
(Reference level = 
PGDipClinPharm+PGCertPharmPres) 
    
IP 0.367 1.443 (0.866-2.404) 1.936* 




DP 0.487* 1.628 (1.079-2.457)  
MAP 1.105* 3.019 (1.868-4.879)  
POP# 0.059 1.061 (0.666-1.690) 1.150* 
Accredited learning modules  
(Prescribing education requirement) 
    
IP 0.642* 1.900 (1.248-2.892)  
CP 1.134* 3.109 (1.921-5.033) 0.724* 
DP 0.228 1.256 (0.770-2.051) 1.058* 
MAP 0.808* 2.243 (1.382-3.640) 1.764* 
POP# 0.782* 2.185 (1.468-3.253) 0.669* 
PGCertPres  
(Prescribing education requirement) 
    
IP 0.029 1.030 (0.703-1.509) 0.504 
CP -0.140 0.869 (0.482-1.567)  
DP 0.302 1.352 (0.924-1.979)  
MAP -0.167 0.846 (0.543-1.319)  
POP# -0.378 0.685 (0.417-1.126)  
PGDipPres  
(Prescribing education requirement)  
    
IP -0.556* 0.574 (0.355-0.928)  
CP -0.254 0.776 (0.488-1.234)  
DP -0.172 0.842 (0.567-1.251)  
MAP -0.346 0.707 (0.450-1.111)  
POP# 0.213 1.237 (0.837-1.828)  
 
Generic attributes: Estimated 
beta value 
OR† OR 95% CI  SD  
(if random 
parameter) 
Professional service fee charge (Pfee)  0.003* 1.003 (1.001-1.005) 0.010* 
     
Change in pharmacist prescriber's income 
(Pinc)  






OR† OR 95% CI  SD  
(if random 
parameter) 
Practice years      
IP -0.022* 0.979 (0.961-0.997)  
CP -0.023* 0.977 (0.958-0.996)  
DP -0.024* 0.977 (0.957-0.997)  
MAP 0.005 1.005 (0.985-1.025)  
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Provincial city  
(Pharmacy location)  
(Reference level = Major city) 
    
IP -0.216 0.806 (0.568-1.143)  
CP -0.068 0.934 (0.637-1.369)  
DP -0.285 0.752 (0.510-1.108)  
MAP -0.352 0.703 (0.477-1.037)  
Provincial town/rural  
(Pharmacy location) 
    
IP 0.501* 1.651 (1.179-2.310)  
CP 0.281 1.324 (0.913-1.920)  
DP 0.395* 1.484 (1.020-2.160)  
MAP 0.429* 1.536 (1.077-2.191)  
 
Generic pharmacist characteristics: Estimated 
beta value 




(Reference level = European ethnicity) 
0.647* 1.910 (1.355-2.693)  
Māori/Pacific peoples/Middle Eastern/Latin 
American/African/Other ethnicity  
-0.623* 0.536 (0.372-0.773)  
     
Pharmacist's total staff during shift 
(TotalStaff)   
0.033* 1.034 (1.003-1.066)  
     
Postgraduate pharmacy education (Reference 
level = undergraduate pharmacy education)  
0.099 1.104 (0.877-1.388)  
     
Pharmacist owner (POwner)  
(Reference level = pharmacist employee) 
-0.150 0.861 (0.705-1.051)  
Goodness of fit measures of mixed MNL model: 
Log likelihood function = -2415.50692 
McFadden’s Pseudo R-squared = 0.4315 
Normalised AIC (i.e. AIC/N) = 1.883 
CI confidence interval, CP Collaborative prescribing, DP Delegated prescribing,  
IP Independent prescribing, MAP Minor ailments prescribing, POP pharmacist only 
medicine prescribing 
MNL multinomial logit, OR odds ratio, SD standard deviation. 
* p value < 0.05 
† Odds of preferring a scenario given a 1 unit/level change in the attribute. 




The DCE outputs are presented relative to the reference level for each attribute 
and the reference alternative of pharmacist only medicine prescribing. The outputs 
of the alternative-specific variables are presented in terms of each of the 
prescribing alternatives followed by the generic variables.  
For the independent prescribing (IP) alternative, the pharmacists were 
significantly more likely to prefer the appointment at the community pharmacy 
(OR 1.758, 95% CI 1.280-2.414; p < 0.05) for the prescribing location, and the 
accredited learning modules (OR 1.900, 95% CI 1.248-2.892; p < 0.05) for the 
prescribing education requirement, respectively. They were significantly less likely 
to prefer the appointment at the GP practice (OR 0.350, 95% CI 0.225-0.546; p < 
0.05) for the prescribing location, and the PGDipPres level (OR 0.574, 95% CI 
0.355-0.928; p < 0.05) for the prescribing education requirement, respectively. The 
following levels for the alternative-specific prescribing education requirements 
attribute did not significantly affect preferences for independent prescribing: 
within BPharm, and PGCertPres. Alternative-specific sociodemographic 
characteristics of the community pharmacists did influence prescribing model 
preferences. Pharmacists who worked in pharmacies in provincial towns or rural 
areas were significantly more likely to prefer independent prescribing (OR 1.651, 
95% CI 1.179-2.310; p < 0.05). Pharmacists with more practice years were 
significantly less likely to prefer independent prescribing (OR 0.979, 95% CI 0.961-
0.997; p < 0.05). Working in a pharmacy in a provincial city did not significantly 
affect preferences for independent prescribing. 
For collaborative prescribing (CP), pharmacists were significantly more likely to 
prefer the accredited learning modules level (OR 3.109, 95% CI 1.921-5.033; p < 
0.05) for the prescribing education requirement. None of the other alternative-
specific attribute levels significantly affected preferences for collaborative 
prescribing. Pharmacists with more practice years were significantly less likely to 
prefer collaborative prescribing (OR 0.977, 95% CI 0.958-0.996; p < 0.05).  
For delegated prescribing (DP), pharmacists were significantly more likely to 
prefer the appointment at the community pharmacy (OR 1.485, 95% CI 1.037-
2.125; p < 0.05) for the prescribing location, and the within BPharm level (OR 
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1.628, 95% CI 1.079-2.457; p < 0.05) for the prescribing education requirement, 
respectively. None of the other alternative-specific attribute levels significantly 
affected preferences for delegated prescribing. Pharmacists who worked in 
pharmacies in provincial towns/rural areas were significantly more likely to prefer 
delegated prescribing (OR 1.484, 95% CI 1.020-2.160; p < 0.05) than their urban 
counterparts. Pharmacists with more practice years were significantly less likely to 
prefer delegated prescribing (OR 0.977, 95% CI 0.957-0.997; p < 0.05).  
For minor ailments prescribing (MAP), pharmacists were significantly more likely 
to prefer the appointment at the community pharmacy (OR 1.534, 95% CI 1.162-
2.025; p < 0.05) for the prescribing location. They were also more likely to prefer 
the within BPharm (OR 3.019, 95% CI 1.868-4.879; p < 0.05) and accredited 
learning modules (OR 2.243, 95% CI 1.382-3.640; p < 0.05) levels for the 
prescribing education requirement, with a higher preference for the within 
BPharm. The pharmacists were significantly less likely to prefer the appointment 
at the GP practice (OR 0.169, 95% CI 0.113-0.252; p < 0.05) for the prescribing 
location. Pharmacists who worked in pharmacies in provincial towns/rural areas 
were significantly more likely to prefer minor ailments prescribing (OR 1.536, 95% 
CI 1.077-2.191; p < 0.05).  
For pharmacist only medicine prescribing (POP), pharmacists were significantly 
more likely to prefer the accredited learning modules level (OR 2.185, 95% CI 
1.468-3.253; p < 0.05) for the prescribing education requirement. None of the 
remaining alternative-specific attribute levels significantly affected preferences for 
pharmacist only medicine prescribing.  
The generic attributes of charging a professional service fee (per $1 increase) (OR 
1.003, 95% CI 1.001-1.005; p < 0.05), and a change in the pharmacist’s income (per 
1% increase) (OR 1.040, 95% CI 1.031-1.050; p < 0.05) were both significantly 
positive for all prescribing models. Pharmacists who worked with more staff 
during a shift (OR 1.034, 95% CI 1.003-1.066; p < 0.05) and pharmacists of Asian 
or Indian ethnicity (OR 1.910, 95% CI 1.355-2.693; p < 0.05) were significantly 
more likely to prefer all the prescribing model alternatives, compared with the 
reference alternative. The pharmacists of the remaining ethnicity groups were 
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significantly less likely to prefer all the prescribing model alternatives (OR 0.536, 
95% CI 0.372-0.773; p < 0.05). Having postgraduate pharmacy education and 
being a pharmacist owner did not significantly influence preferences for the 
prescribing model alternatives. None of the alternative-specific constants were 
significant. 
 
5.5.4.3 Overall value of prescribing models 
Utilising a scenario illustrates the part-worth nature of the utility function [239]. 
Rather than just interpreting the estimated parameters relative to a reference 
level, the scenario illustrates how the estimated parameters (i.e. the choice 
attributes and sociodemographic characteristics of respondents) collectively 
contribute positively and negatively to the prescribing model alternatives, so we 
can directly compare respondent’s preferences for the different prescribing 
models. The relative overall values of the pharmacist prescribing models are listed 
in Table 12. Minor ailments prescribing had the highest relative overall value and 
was the most preferred prescribing model, followed by the independent 
prescribing model. Delegated prescribing had the lowest relative overall value and 
was the least preferred prescribing model. 
Table 12 Relative overall value of pharmacist prescribing models 
Preference (in 
descending order i.e. 
most preferred to 
least preferred) 
Pharmacist prescribing model Relative 
overall 
utility value 
1 Minor ailments prescribing (MAP) 2.005 
2 Independent prescribing (IP) 1.318 
3 Pharmacist only medicine prescribing (POP) 1.138 
4 Collaborative prescribing (CP) 1.080 






Non-medical prescribing (NMP) has been introduced in many countries due to 
increasing health demands on primary care and GP workforce constraints, and 
pharmacist and nurse prescribers have been shown to be effective in this scope of 
practice [9]. 
The use of DCEs in pharmacy is increasing [263,262]. To our knowledge, this is the 
first DCE used in pharmacy practice in NZ, and the first DCE to explore the 
parameters of a pharmacist prescribing service in primary care. This DCE is 
intended to be explanatory, with the aim to quantify community pharmacists’ 
preferences for providing a pharmacist prescribing service in primary care and 
discuss how these preferences could be incorporated into the future development 
of pharmacist prescribing services.  
 
5.5.5.1 Mixed MNL interpretation 
Keeping it in community pharmacy 
Locating the prescribing service at a GP practice either had a significant negative 
contribution or had no significant contribution to any of the prescribing 
alternatives. In terms of the prescribing service location, community pharmacists 
overwhelmingly prefer to provide the prescribing service, no matter what 
prescribing model is utilised, from the community pharmacy rather than the GP 
practice. This makes sense as community pharmacies can be more accessible with 
longer operating hours including weekend hours. Locating the prescribing service 
at the community pharmacy could be considered more convenient and efficient as 
patients can access a prescribing service and their medicines from one location. 
Pharmacists preferred the walk in and wait consultation for pharmacist only 
medicine prescribing and collaborative prescribing, and the appointment option at 
the community pharmacy for all the other prescribing alternatives. This indicates 
the pharmacists may prefer a more structured approach to their workday when 





The overwhelming preference for the prescribing education requirement for the 
prescribing alternatives is the accredited learning modules. Potential reasons for 
this outcome could be that community pharmacists are time poor and may feel 
reluctant to engage in education programmes that are longer [270,272], follow a 
more traditional structure, and hence are expensive. Based on the DCE 
preferences, progressing pharmacist prescribing services within the community 
pharmacist sector would require a more innovative approach to setting up the 
prescribing education requirement. Micro-credentials could be a possibility, as 
they are similar to the accredited learning modules included in this DCE. Micro-
credentials focus on smaller learning modules, include competency-based 
assessment, and often allow learners to complete the requisite work in a shorter 
timeframe than conventional academic programmes [273]. Many professions use 
micro-credentialing, and it’s application in the health sector is also emerging [274]. 
Utilising stackable micro-credentials within education programmes could be 
considered when developing innovative solutions to enable flexible yet robust 
pharmacist prescribing education programmes in NZ.  
 
Increased funding for services and skills 
The positive preference for charging a professional service fee indicates that 
community pharmacists prefer to be paid for their clinical skills via a consultation 
fee. Currently, remuneration for pharmacist only medicine prescribing in NZ is 
bundled within the selling price of a pharmacist only medicine. Having funded 
pharmacist prescribing services in primary care is also important to ensure that 
patients can easily access these services and their medicines. The current 
pharmacist only medicine prescribing model in NZ is unfunded and contributes to 
the inequity of access to medicines for patients [197], as only patients who can 
afford to pay can access these medicines. 
Pharmacists showed a positive preference for a change in the pharmacist’s income. 
This is consistent with other DCEs that investigated preferences for extended 
pharmacist services [269,134]. It reflects that pharmacists would like to be 
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The preference for all prescribing alternatives, except minor ailments prescribing 
and pharmacist only medicine prescribing, decreases with increasing number of 
practice years. This may be due to experienced pharmacists not being familiar with 
these other prescribing models and/or not wanting the increased responsibility of 
these prescribing services [275]. It could also be indicative of how high the current 
threshold is set for the collaborative pharmacist prescriber model in NZ, which 
could be deterring the more experienced pharmacists from perceiving newer 
models of pharmacist prescribing services as a viable option for their practice. 
The preference for all prescribing alternatives increased with pharmacists who 
worked in bigger teams (i.e. more staff working during the pharmacist’s usual 
shift). This could be due to the increased capacity for providing new services 
among pharmacies with bigger teams. Other research also found pharmacists 
preferred working with extended teams, and having adequate pharmacy staff 
seems to be an important facilitator of providing a pharmacist prescribing service 
[269,275].  
Being a pharmacist owner did not negatively contribute to any of the prescribing 
alternatives. This was unexpected, as a priori assumptions were that pharmacist 
owners might be averse to new pharmacy services such as pharmacist prescribing 
services. These assumptions could be associated with the lack of support to set up 
funded pharmacist services in primary care [272].  
 
5.5.5.2 Overall value of prescribing models  
Flexible models of prescribing 
We also determined community pharmacists’ preferences for prescribing models 
in primary care in NZ. The relative overall value of the prescribing models 
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indicates a strong preference for the minor ailments prescribing model, which is 
consistent with other DCE research [269]. Community pharmacists would be 
familiar with the minor ailments prescribing model being used in primary care in 
other countries. They recognise the potential benefits to their communities if this 
prescribing model was available in NZ. The minor ailments prescribing model has 
been successfully implemented in primary care in many countries including 
England, Scotland and Canada [276,277]. UK evaluation indicates the main benefits 
of their minor ailment schemes include costs avoided elsewhere in the NHS system 
(including avoided GP appointments), and avoided costs to patients, which result 
from delayed recoveries and lost time from attending less accessible points of 
delivery in the health system [278]. The pharmacist minor ailment services were 
associated with a high level of patient satisfaction in the UK and Canada [277,279]. 
The second most preferred prescribing model was independent prescribing. This 
is in contrast to a priori perceptions that community pharmacists tend to be risk 
averse [280], and would be more inclined towards the restrictive prescribing 
models. Pharmacists in smaller towns and rural areas positively preferred minor 
ailments and independent prescribing models. These pharmacists may be located 
in areas with limited numbers of GP prescribers, and see benefit for their patient 
communities from being able to offer more autonomous prescribing services 
through the community pharmacy.  
The preference for more than one prescribing model also indicates that multiple 
prescribing models could be utilised to provide pharmacist prescribing services in 
primary care. Many countries with pharmacist-led minor ailments prescribing 
services also have other models of pharmacist prescribing available including 
independent, collaborative and delegated prescribing models [276]. Developing 
prescribing models that exist along a prescribing continuum for pharmacists to 
utilise in primary care can ensure that patients have continued access to their 
medicines. Evaluations of pharmacist prescribing in the UK and Canada have been 
positive. UK evaluation found pharmacist prescribing was safe, clinically 
appropriate, and viewed positively by patients [37]. Two Canadian studies found 
pharmacist prescribing led to effective clinical outcomes, was safe, cost effective, 
and associated with a high level of patient satisfaction [38,97].   
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5.5.5.3 Study strengths and limitations 
This is the first DCE to investigate community pharmacist preferences for 
prescribing models in primary care in NZ. This type of evidence is required by the 
pharmacy profession, policy makers, and funders to inform the future direction of 
the profession in NZ. 
Information from this DCE could be used to inform decisions on service provision, 
education requirements, and resource/workforce allocation priorities, and it 
enables these decisions to be based on evidence that is more constructive. DCEs 
are a robust quantitative method to elicit preferences, and this DCE was conducted 
in accordance with good research practice for DCEs. The community pharmacist 
DCE data set was diverse and representative by gender and age [258].  
Although the DCE method is robust, its results indicate preferences for attributes 
and attribute levels as defined in this DCE. Some of the preferences may have been 
affected by how our study defined these factors. For example, some of the negative 
preferences for the PGCertPres and PGDipPres prescribing education 
requirements may have been due to how we defined these programmes rather 
than the pharmacists being averse to these levels of education programmes. If 
these hypothetical education programmes were set up differently in the DCE, it 
may have possibly changed the preferences seen here. The pre-requisite 
PGDipClinPharm was also removed for the pharmacist prescriber programme in 
July 2019 [281]. 
 
5.5.6 Conclusion 
This DCE study, although exploratory in intent, provides useful insights into the 
preferences of NZ community pharmacists for providing a pharmacist prescribing 
service in primary care. Knowing what services community pharmacists are 
willing to engage in is invaluable as these preferences could be utilised to develop 
accessible and effective pharmacist prescribing services. We want policy makers 
and funders to see beyond the traditional roles of community pharmacists. We 
would like to see them extend the use of a pharmacist’s knowledge and skills by 
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incorporating them into the primary care prescribing team. These DCE results are 
encouraging as they signal that the community pharmacists also see themselves 
and their pharmacies as part of the prescribing team. This is especially relevant as 
increasing patient populations and GP workforce constraints lead to increasing 
demand for health services in NZ.  
Developing a continuum of prescribing models provides more options for 
community pharmacists to engage in prescribing services. Their prescribing 
education requirement preferences highlight that new, innovative approaches 
need to be considered when developing prescribing education programmes, and 
could include micro-credentials. Developing prescribing education programmes 
that are both robust and attractive to community pharmacists would encourage 
them to engage in prescribing services, thereby increasing the number of 
pharmacist prescribers in primary care. Although it is considered a challenge, 
funding pharmacist prescribing services in primary care is an important 
requirement to make these services truly viable options for patients to utilise, and 
can help to address inequity of access to prescribing services.  
Improving and extending pharmacist prescribing models and services would allow 
pharmacists to share the ever-increasing prescribing workload in primary care. 
This enables pharmacists to be part of a primary care prescribing team that 
addresses inequity of access to prescribing services and ensures timely access to 
medicines for patients. 
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Supplementary material 1: 
Process of deriving attributes and attribute levels: 
The selection of relevant choice attributes and their levels was based on a brief 
review of the literature [15-20]. Reasons for the selection of levels within each 
attribute included ensuring that the attributes levels presented were plausible. 
This led to the one constraint imposed on the choice task design i.e. the 
“appointment at GP practice” attribute level was not displayed for the pharmacist 
only medicine prescribing alternative as this was an implausible combination. We 
also selected attribute levels that would allow respondents to trade-off between 
them.  
The attributes and attribute levels were further refined following feedback from 
our target sample population. Using semi-structured questionnaires, we obtained 
feedback from individual community pharmacists (n=3) and a focus group of 
different community pharmacists (n=3). The community pharmacists were 
recruited using a convenience sample to cover a range of community pharmacist 
profiles including different ages, practice experience, pharmacist services they 
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could provide, and employee pharmacists versus pharmacists who owned a 
pharmacy.  
The semi-structured questionnaire presented the list of possible attributes and 
levels to the community pharmacists, who were then asked to provide information 
about whether these attributes and levels were reasonable, how they should be 
described to be clear for respondents, and whether there were any missing 
attributes or levels that might be included. The project team discussed the 
feedback obtained from community pharmacists. 
From this process the final set of attributes and attribute levels were selected and 
are presented in Table 1. 
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Chapter 6: Identifying New Zealand public preferences for 
pharmacist prescribers in primary care—a discrete choice 
experiment 
6.1 Context 
Consumer and/or patient preferences play an important role in the development 
of any new/different healthcare service. The narrative literature review in Chapter 
2 identifies that UK and Canadian research have utilised various methodologies, 
including health preference research, to evaluate the preferences of patients 
and/or public to NMP services in primary care, including pharmacist prescriber 
services [38,97,100,101,120,102,132-134,39]. This type of research is lacking in 
NZ. When expanding or enabling improved pharmacist services, it useful to know 
how patients/consumers would ‘react’ to the implementation of the new or 
evolved service in terms of potential utilisation.  
 
6.2 Chapter aims 
It was unknown if the current poor utilisation of pharmacist prescribing services 
identified in Chapter 4 is due to a lack of demand/need from patients and/or the 
general population. The objective of this chapter is to explore the place of 
pharmacist prescribers within NMP in primary care in NZ, from the perspective of 
the public in NZ. The study aims to use a quantitative method (i.e. a discrete choice 
experiment) to identify preferences of NZ public for pharmacist prescribing 






6.3 Identifying New Zealand public preferences for pharmacist 
prescribers in primary care manuscript 
This chapter contains the manuscript entitled “Identifying New Zealand public 
preferences for pharmacist prescribers in primary care—a discrete choice 
experiment”. This manuscript was submitted to The Patient– Patient Centered 
Outcomes Research journal in October 2020 and is currently under review. 
The manuscript is presented as submitted for publishing. However, aspects such as 
the numbering of the pages, figures and tables, and spelling have been adjusted to 
fit the overall style of the thesis. All references from the manuscript are found in 
the section ‘List of references’ at the end of the thesis. Journal permissions allow 
for the inclusion of the submitted/published manuscript in the thesis. 
 
6.3.1 Submitted manuscript: Statement of contribution 
PhD candidate, Rakhee Raghunandan (RR) with supervision from supervisor Dr 
Alesha Smith (AS) conceived the project. RR designed the DCE (with advice from 
Prof Michiel Bliemer and Prof John Rose) and created the DCE questionnaire. RR 
conducted the analyses and interpretation of these data with supervision from 
advisor Prof Kirsten Howard (KH). Supervisors AS, Prof Carlo A Marra (CM), and 
Assoc Prof June Tordoff (JT) supervised the project, providing overall direction and 
planning. RR drafted the manuscript, with all authors subsequently contributing to 
the critical review and revision of the manuscript. The final version of the 





6.4 Submitted manuscript under review: “Identifying New 
Zealand public preferences for pharmacist prescribers in primary 
care—a discrete choice experiment” 
Rakhee Raghunandan*1, Kirsten Howard2, Carlo A. Marra1, June Tordof1, Alesha 
Smith1 
1 School of Pharmacy, University of Otago, PO Box 56, Dunedin 9054, Otago, New 
Zealand 
2 School of Public Health, Faculty of Medicine and Health, University of Sydney, 
Sydney, NSW, Australia 
* Corresponding author 
 
6.4.1 Abstract 
Objective: Given increasing patient populations, general practitioner workforce 
constraints, and growing demand for health services in New Zealand (NZ), the 
development and provision of pharmacist prescribing services could be used to 
improve people’s access to medicines. A discrete choice experiment (DCE) was 
utilised to determine NZ public preferences for pharmacist prescribing services in 
primary care in NZ. 
Method: A D-efficient DCE design generated 20 choice questions in four blocks of 
five questions with three labelled alternatives per choice question. The online DCE 
used a NZ general public online research panel administered by an external 
organisation (SurveyEngine). The DCE included six attributes with two attributes 
each with two levels (location of consultation and consultation type), three levels 
(type of service and operating hours), and four levels (waiting time and cost). 
Results: 924 respondents completed the survey with 4620 observations available 
for analyses. Respondents preferred pharmacist prescribing services with the 
following characteristics: optimisation of medicines and changes to only current 
145 
 
medicines service type (relative to repeat prescribing); lower consultation costs, 
shorter waiting times, longer operating hours, and consultation by appointment 
(relative to walk-in and wait clinic).  
Conclusion: Prescribing policy could incorporate these public preferences to help 
develop accessible and effective primary care prescribing services utilising the 
skills of pharmacist prescribers to improve and reduce inequities in access to 
medicines in NZ. These results suggest the NZ public see pharmacists as part of the 
primary care prescribing team and are willing to utilise them if these services are 
implemented. 
 
Key points for decision makers: 
This NZ public sample consider pharmacists as part of the prescribing team in 
primary care, and favoured the minor optimisation of medicines and changes to 
only current medicines service types from pharmacist prescribers. 
Other attributes preferred by the DCE sample were lower consultation costs, 
shorter waiting times, longer operating hours, and consultation by appointment. 
Policy makers can utilise these preferences to develop pharmacist prescribing 
services that suit the NZ public, thereby enabling improved and equitable access to 




Similar to other countries, primary care in New Zealand (NZ) will require more 
assistance to cope with the increased demand for patient services. This is 
particularly important as 49% of GPs in NZ work part time and 47% of GPs intend 
to retire from general practice in the next 10 years [196]. These factors could lead 
to a decline in the availability of GP services, and reduce patients’ access to 
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essential primary care services, including prescribing of medicines. In response to 
increasing demand for health services, NZ and other countries, have introduced 
non-medical prescribing (NMP) to facilitate timely access to medicines [115,9]. 
NMP is the legislative extension of prescribing rights to health professionals other 
than medical doctors, thereby enabling them to prescribe prescription medicines. 
This shift in roles utilises the skills of health professionals such as nurses and 
pharmacists to improve patients’ access to prescribers [9]. The inequity of access 
to medicines in primary care in NZ is well documented and is related to factors 
such as physical and timely access to a prescriber/prescription, and the direct and 
indirect costs associated with consulting a prescriber [197]. Compared to the other 
countries who utilise NMP, including the USA, UK, and Canada [115], NMP in NZ is 
inconsistently implemented and an underutilised service [83]. 
Non-medical prescribers in NZ include pharmacist prescribers [83] and 
pharmacist prescribing within NMP is currently based on a collaborative 
prescribing model. The pharmacist prescriber works as part of a team and does 
not provide diagnoses—they can write prescriptions to initiate, modify or 
discontinue medicines (including medicines initiated by other prescribers) [282].  
Pharmacist prescribers currently make up a very small part of the NMP workforce 
in NZ (n=20, Mar 2019) [283]. This is in stark contrast to registered nurse 
prescribers (n=264) whose prescribing scope is the closest to pharmacist 
prescribers [208]. In the UK, where NMP has been successfully implemented, there 
were approximately 3,944 pharmacist prescribers (8% of registered pharmacists) 
in 2015 [36,284]. In 2013, 13% of UK pharmacist prescribers were working in a 
community pharmacy setting and 30% were working in a primary care setting 
other than community pharmacy [285]. 
As acknowledged elsewhere [9], pharmacist prescribing services will need to 
increase in primary care in NZ, particularly among community pharmacists, to help 
improve equitable access to medicines [259]. Pharmacists have the knowledge and 
accessibility to enable timely access to primary care services, however little is 
known about consumers’ preferences for such services. Eliciting consumer 
preferences are important as they can assist decision makers to develop and 
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provide more comprehensive pharmacist prescribing services in primary care. 
Understanding consumer preferences can be useful to inform policy, service 
provision, and decision making including resource/workforce allocation priorities. 
This study aims to use a quantitative method (discrete choice experiment) to: 
• Determine NZ public preferences for a pharmacist prescriber service in 
primary care in NZ. 
• Understand what factors could influence the public’s utilisation of such a 
service. 





Respondents for the online discrete choice experiment (DCE) survey were 
recruited using a NZ general public online research panel administered by an 
external organisation (SurveyEngine) [286] for the pilot and main study phases. 
Respondents were NZ adults aged 18 years and older, and the sample frames were 
stratified according to age, gender, and ethnicity to broadly represent the NZ adult 
general population (see Supplementary Appendix S1). Data collection occurred 
during June—July 2019 (pilot and main studies). The University of Otago Human 
Ethics Committee approved this study (reference D19/019)—see Appendix 6. 
 
6.4.3.2 Discrete choice experiments 
The DCE is based on Lancaster’s theory where goods/services can be described in 
terms of a number of attributes, each with multiple levels [235]. In DCEs, 
individuals respond to a set of questions, which require them to choose one 
alternative from several options presented. Each option is characterised by the 
combination of the attributes and levels included in the DCE. Random utility theory 
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indicates that when faced with two or more options, people will choose the option 
that gives them the highest overall utility value [238,239] and the choices people 
make reflect their preferences. The resulting choices are analysed to estimate the 
relative contribution of the attributes and attribute levels to overall utility.  
DCEs are useful in health research as they provide information on respondent 
preferences, as well as willingness to pay or other trade-offs [239], thus allowing 
goods/services to be developed based on constructive evidence. This approach 
aligns with the patient-centred care focus for the NZ health system and lends itself 
to a co-design approach to new services.  

















6.4.3.3 Attributes and attribute levels 
Table 13 describes the six attributes and their levels included in this DCE.  
Table 13 Discrete choice experiment attributes and attribute levels 
Attributes Level 1 Level 2 Level 3 Level 4 





At GP practice# - - 





Within 1 day 
from now 
3 days from now 5 days from now 7 days from now 








usual GP cost 
Respondent’s 
usual GP cost 
plus 20% 





























dose changes as 



























5). Type of 
consultation 
(CT) 







Open 8 hours a 
day (e.g. 9am-
5pm) 
Open 16 hours a 
day (e.g. 7am-
11pm) 
Open 24 hours a 
day 
- 
# = Reference level 
† = For the purposes of this DCE, optimisation of medicines is defined as the prescriber being able 
to make any changes to the patient’s medicine regimen including changing doses of current 




Attributes included: location of consultation, waiting time, cost, prescribing service 
type, type of consultation and service operating hours, which were derived 
through reviewing the literature [100-102,260,262,263,287], and refined following 
qualitative feedback using a semi-structured questionnaire from two focus groups 
with primary care patients (n=9)—see Supplementary Appendix S1 in NZ Public 
DCE Online Supplementary Material 1 section at the end of this chapter.  The cost 
attribute levels were calculated by varying the respondent’s usual reported GP cost 
by +/- 20%.  
The three prescribers were included as labelled alternatives. The GP prescriber 
was included because they are the usual (status quo) primary care prescriber, 
while the registered nurse prescriber was included as they have the closest scope 
of practice to the pharmacist prescriber.  
 
6.4.3.4 Study design  
The DCE was piloted (n = 100) to assess interpretation and ability to complete the 
choice questions, and to generate the priors for the main study design. 
Ngene v.1.2.1 [288] was used to generate a Bayesian D-efficient design [248,249] 
with 20 choice tasks in four blocks of five choice tasks each with three labelled 
alternatives per choice task (d-error = 0.09953). The DCE used was a forced choice 
design—there was no opt out alternative. The design included one constraint—the 
“location at community pharmacy” attribute level was not displayed for the GP 
prescriber alternative, as this was an implausible combination (see Supplementary 
Appendix S1 in NZ Public DCE Online Supplementary Material 1 section at the end 
of this chapter). 
Respondents were randomly assigned to one of the four blocks of choice questions; 
the order of the three labelled alternatives was also randomised. The DCE 
questionnaire included: background information and choice context framing, 
explanation of the choice questions, definitions of attributes and levels, practice 
choice task, five choice questions, choice- and attribute-related questions, and 
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sociodemographic questions (see Appendix 7 of this thesis). The practice choice 
task also served as a test for within-set monotonicity to assess whether the 
respondent chose the dominant alternative [239,289]. Choosing the non-dominant 
alternative may indicate that the respondent misunderstood the choice task 
attributes and levels, therefore only respondents who selected the dominant 
alternative were included in the analyses [289]. 
The DCE health scenario and an example choice question are shown in Fig.5 and 













R software was used to generate descriptive statistics and NLOGIT Version 6 was 
used for the DCE analyses [266,267]. 
All categorical data (attributes and sociodemographic variables) were effects 
coded. The consultation waiting time, cost of consultation, and prescribing service 
operating hours attributes were included as continuous variables and all other 
attributes were categorical. Analyses included alternative-specific attributes 
(prescribing service location, consultation waiting time, type of prescribing 
service, type of consultation, and prescribing service operating hours), and one 
generic attribute (cost of consultation). The generic cost attribute was interacted 
with the respondent’s household income (≤ $50,000/year and >$50,000/year). 
Other attribute and sociodemographic interactions were explored but not included 
due to lack of statistical significance and explanatory power. 
Most sociodemographic variables (age, most preferred prescriber, employment 
type, residential location, number of medicines taken per day, number of 
diagnosed chronic conditions, and type of community pharmacy usually visited) 
were included as alternative-specific variables. These variables were interacted 
with each prescribing model alternative, relative to the reference alternative (GP 
prescriber). GP visit frequency was included as a generic variable as testing found 
no significant difference between alternatives.  
A mixed multinomial logit (mixed MNL) model was used to estimate the 
parameters and choice probabilities [242,244]. This model accounts for the panel 
nature of the data, and preference heterogeneity [242]. Model results are 
presented as the estimated beta parameters, their 95% confidence intervals and p 
values, and the standard deviations of variables that were specified as random 
parameters.  
Nineteen random parameters (of which seventeen were estimated as normally 
distributed) were included in the final mixed MNL model and 1000 Halton draws 
were used for model estimations. The two costs by household income interaction 
terms were specified as truncated triangular distributions. Random parameters 
with statistically insignificant standard deviations were subsequently included as 
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fixed parameters and statistically insignificant sociodemographic variables were 
dropped if they did not improve model fit.  
The final model was selected based on the normalised Akaike information criterion 
value (AIC/N), as well as the model’s explanatory power (see Supplementary 
Appendix S1 in NZ Public DCE Online Supplementary Material 1 section at the end 
of this chapter). 
The utility functions for our DCE analyses were specified as follows: 
𝑉𝑃ℎ𝑎𝑟𝑚𝑎𝑐𝑖𝑠𝑡 𝑃𝑟𝑒𝑠𝑐𝑟𝑖𝑏𝑒𝑟 (𝑃𝑃)
=  𝛽𝑃𝑃 +  𝛽1𝑃𝑃 𝑃𝑟𝑒𝑠𝑐𝑟𝑖𝑏𝑖𝑛𝑔 𝐿𝑜𝑐𝑎𝑡𝑖𝑜𝑛
+  𝛽2𝑃𝑃 𝑊𝑎𝑖𝑡𝑖𝑛𝑔 𝑡𝑖𝑚𝑒 𝑓𝑜𝑟 𝑛𝑒𝑥𝑡 𝑎𝑣𝑎𝑖𝑙𝑎𝑏𝑙𝑒 𝑐𝑜𝑛𝑠𝑢𝑙𝑡𝑎𝑡𝑖𝑜𝑛 +  𝛽3𝐶𝑜𝑠𝑡
∗ ℎ𝑜𝑢𝑠𝑒ℎ𝑜𝑙𝑑 𝑖𝑛𝑐𝑜𝑚𝑒 𝑝𝑒𝑟 𝑦𝑒𝑎𝑟 +  𝛽4𝑃𝑃 𝑆𝑒𝑟𝑣𝑖𝑐𝑒 𝑡𝑦𝑝𝑒
+  𝛽5𝑃𝑃 𝐶𝑜𝑛𝑠𝑢𝑙𝑡𝑎𝑡𝑖𝑜𝑛 𝑡𝑦𝑝𝑒 + 𝛽6𝑃𝑃 𝑂𝑝𝑒𝑟𝑎𝑡𝑖𝑛𝑔 ℎ𝑜𝑢𝑟𝑠 +  𝛽7𝑃𝑃 𝐴𝑔𝑒
+  𝛽8𝑃𝑃 𝑀𝑜𝑠𝑡 𝑝𝑟𝑒𝑓𝑒𝑟𝑟𝑒𝑑 𝑝𝑟𝑒𝑠𝑐𝑟𝑖𝑏𝑒𝑟 +  𝛽9𝑃𝑃 𝑈𝑛𝑒𝑚𝑝𝑙𝑜𝑦𝑒𝑑
+  𝛽10𝑃𝑃 𝑇𝑜𝑤𝑛 𝑜𝑟 𝑟𝑢𝑟𝑎𝑙 𝑙𝑜𝑐𝑎𝑡𝑖𝑜𝑛
+  𝛽11𝑃𝑃 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑚𝑒𝑑𝑖𝑐𝑖𝑛𝑒𝑠 𝑡𝑎𝑘𝑒𝑛 𝑝𝑒𝑟 𝑑𝑎𝑦
+ 𝛽12𝑃𝑃 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑒𝑑 𝑙𝑜𝑛𝑔 𝑡𝑒𝑟𝑚 𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛𝑠
+  𝛽13𝑃𝑃 𝑆𝑎𝑚𝑒 𝑐𝑜𝑚𝑚𝑢𝑛𝑖𝑡𝑦 𝑝ℎ𝑎𝑟𝑚𝑎𝑐𝑦 𝑢𝑠𝑒𝑑 𝑚𝑜𝑠𝑡 𝑜𝑓 𝑡ℎ𝑒 𝑡𝑖𝑚𝑒
+  𝛽14𝐺𝑃 𝑣𝑖𝑠𝑖𝑡 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 
 
𝑉𝑅𝑒𝑔𝑖𝑠𝑡𝑒𝑟𝑒𝑑 𝑁𝑢𝑟𝑠𝑒 𝑃𝑟𝑒𝑠𝑐𝑟𝑖𝑏𝑒𝑟 (𝑅𝑁𝑃)
=  𝛽𝑅𝑁𝑃 +  𝛽15𝑅𝑁𝑃 𝑃𝑟𝑒𝑠𝑐𝑟𝑖𝑏𝑖𝑛𝑔 𝐿𝑜𝑐𝑎𝑡𝑖𝑜𝑛
+  𝛽16𝑅𝑁𝑃 𝑊𝑎𝑖𝑡𝑖𝑛𝑔 𝑡𝑖𝑚𝑒 𝑓𝑜𝑟 𝑛𝑒𝑥𝑡 𝑎𝑣𝑎𝑖𝑙𝑎𝑏𝑙𝑒 𝑐𝑜𝑛𝑠𝑢𝑙𝑡𝑎𝑡𝑖𝑜𝑛
+  𝛽3𝐶𝑜𝑠𝑡 ∗ ℎ𝑜𝑢𝑠𝑒ℎ𝑜𝑙𝑑 𝑖𝑛𝑐𝑜𝑚𝑒 𝑝𝑒𝑟 𝑦𝑒𝑎𝑟 + 𝛽17𝑅𝑁𝑃 𝑆𝑒𝑟𝑣𝑖𝑐𝑒 𝑡𝑦𝑝𝑒
+  𝛽18𝑅𝑁𝑃 𝐶𝑜𝑛𝑠𝑢𝑙𝑡𝑎𝑡𝑖𝑜𝑛 𝑡𝑦𝑝𝑒 + 𝛽19𝑅𝑁𝑃 𝑂𝑝𝑒𝑟𝑎𝑡𝑖𝑛𝑔 ℎ𝑜𝑢𝑟𝑠
+  𝛽20𝑅𝑁𝑃 𝐴𝑔𝑒 +  𝛽21𝑅𝑁𝑃 𝑀𝑜𝑠𝑡 𝑝𝑟𝑒𝑓𝑒𝑟𝑟𝑒𝑑 𝑝𝑟𝑒𝑠𝑐𝑟𝑖𝑏𝑒𝑟
+  𝛽22𝑅𝑁𝑃 𝑈𝑛𝑒𝑚𝑝𝑙𝑜𝑦𝑒𝑑 +  𝛽23𝑅𝑁𝑃 𝑇𝑜𝑤𝑛 𝑜𝑟 𝑟𝑢𝑟𝑎𝑙 𝑙𝑜𝑐𝑎𝑡𝑖𝑜𝑛
+  𝛽24𝑅𝑁𝑃 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑚𝑒𝑑𝑖𝑐𝑖𝑛𝑒𝑠 𝑡𝑎𝑘𝑒𝑛 𝑝𝑒𝑟 𝑑𝑎𝑦
+ 𝛽25𝑅𝑁𝑃 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑒𝑑 𝑙𝑜𝑛𝑔 𝑡𝑒𝑟𝑚 𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛𝑠




𝑉 𝐺𝑃 𝑃𝑟𝑒𝑠𝑐𝑟𝑖𝑏𝑒𝑟 (𝐺𝑃)
=  𝛽𝐺𝑃 +  𝛽26𝐺𝑃 𝑃𝑟𝑒𝑠𝑐𝑟𝑖𝑏𝑖𝑛𝑔 𝐿𝑜𝑐𝑎𝑡𝑖𝑜𝑛
+ 𝛽27𝐺𝑃 𝑊𝑎𝑖𝑡𝑖𝑛𝑔 𝑡𝑖𝑚𝑒 𝑓𝑜𝑟 𝑛𝑒𝑥𝑡 𝑎𝑣𝑎𝑖𝑙𝑎𝑏𝑙𝑒 𝑐𝑜𝑛𝑠𝑢𝑙𝑡𝑎𝑡𝑖𝑜𝑛 +  𝛽3𝐶𝑜𝑠𝑡
∗ ℎ𝑜𝑢𝑠𝑒ℎ𝑜𝑙𝑑 𝑖𝑛𝑐𝑜𝑚𝑒 𝑝𝑒𝑟 𝑦𝑒𝑎𝑟 +  𝛽28𝐺𝑃 𝑆𝑒𝑟𝑣𝑖𝑐𝑒 𝑡𝑦𝑝𝑒
+ 𝛽29𝐺𝑃 𝐶𝑜𝑛𝑠𝑢𝑙𝑡𝑎𝑡𝑖𝑜𝑛 𝑡𝑦𝑝𝑒 +  𝛽30𝐺𝑃 𝑂𝑝𝑒𝑟𝑎𝑡𝑖𝑛𝑔 ℎ𝑜𝑢𝑟𝑠 
 
The utility and choice probability values for the three prescriber alternatives were 
calculated. Marginal rates of substitution (trade-offs) between waiting time (in 
days) and service type attribute were examined (willingness to wait). Willingness 
to pay was calculated for service type and waiting time for the next available 
consultation.  
Respondents were asked to rank one of the three prescribers as their most 
preferred prescriber and provide a reason for their ranking. The choice task 
section included an additional question, which asked respondents to list their 
reasons for their preference in choice task five. A thematic descriptive analysis 





Of the 1978 eligible respondents who correctly selected the dominant alternative 
in the practice question, 924 completed the online DCE questionnaire (47% 
completion rate). The data set included 4620 observations for analyses. 
The respondent characteristics are summarised in Table 14. The self-reported 
average GP consultation cost for this sample was $32.43, and is within proximity of 
the average GP consultation cost of $34.79 for NZ adults reported elsewhere [291]. 
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Table 14 Summary of DCE respondent characteristics 
Variable Variable sub-level/s N (total = 924) % 
Age 
(in years) 





Age groups 18-34 years old 310 34% 
35-49 years old 221 24% 
50-64 years old 217 23% 
65+ years old 176 19% 
Gender Female 470 51% 








Māori 104 11% 
Pacific peoples 41 4% 
Asian/Indian 144 16% 
Highest education level High school or less 302 33% 
Post high school 
qualification 
622 67% 
Employment status Full time employment         
(≥ 30 hours per week) 
391 42% 
Part time employment        
(< 30 hour per week) 
199 22% 
Unemployed 334 36% 
Household 
income/year (in NZ 
dollars before tax) 
< $25 000/year 146 16% 
$25 000-$50 000/year 259 28% 
> $50 000-$80 000/year 216 23% 
> $80 000-$100 000/year 118 13% 
> $100 000/year 185 20% 
Type of residential 
location 
Major city = urban area with 




Provincial city = urban area 
with population > 30 000 
people  
157 17% 
Provincial town = urban 
area with a population 
between 1 000 and 30 000 
people. 
158 17% 
Rural = non-urban areas 
such as rural centres with 
population under 1 000 
people 
83 9% 
Residential Region Northland            33 3% 
Auckland             314 34% 
Waikato       90 10% 
Bay of Plenty 53 6% 




Wellington              117 13% 
Tasman/Nelson/ 
Marlborough/ West Coast  
42 5% 
Canterbury               112 12% 
Otago/Southland 54 6% 
Most preferred 
prescriber 
GP prescriber 757 82% 
Pharmacist prescriber 88 9% 
Registered Nurse prescriber 79 9% 
Satisfaction with 
current access to your 
GP 
Extremely satisfied 320 35% 
Somewhat satisfied 457 49% 
Somewhat dissatisfied 114 12% 
Extremely dissatisfied 33 4% 
Knowledge of 
pharmacist prescribers 
prior to DCE study 
Yes 358 39% 
No 566 61% 
Knowledge of 
registered nurse 
Yes 461 50% 
No 463 50% 
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prescribers prior to 
DCE study 
GP usually seen  Same GP each time (i.e. your 
own GP) 
660 71% 
Any available GP 264 29% 
GP visit frequency  Less often than once/3 
months 
568 61% 




usually visited  
Same community pharmacy 
most of the time 
676 73% 
Different community 
pharmacies most of the time 
due to convenience 
248 27% 
Community pharmacy 




Never 89 10% 
Once/year 184 20% 
Once/6 months 157 17% 
Once/3 months 329 35% 
Once/month or more often 165 18% 
Number of regular 







Number of diagnosed 














Difficulty of DCE choice 
task questions 
 
Easy 838 91% 
Difficult 86 9% 
Duration of DCE 
questionnaire 
Median duration 12 minutes - 





6.4.4.2 Mixed multinomial logit (mixed MNL)  
Results of the final mixed MNL model are presented in Table 15. 
Table 15 NZ public preferences for a primary care prescriber relative to GP prescriber using mixed 
MNL model 
Preferences for primary care prescribers (mixed MNL model) – compared to reference 
utility level GP prescriber: 
Variable:    
Alternative-specific attributes:  Estimated 
mean & 
(Std Dev) 
95% CI p value 
1). Alternative-specific constant (ASC)       
(Reference level = GP prescriber) 
   
• Pharmacist prescriber (PP) -0.213 (-0.880 – 0.455) 0.5319 
• Nurse prescriber (RNP) -0.951* (-1.682 – -0.221) 0.0107 
2). Location of prescribing consultation     
(Reference level = At GP practice) 
   
• PP_ At community pharmacy -0.082 
(0.071) 
(-0.224 – 0.061) 









(-0.457 – -0.200) 
(0.142 – 0.643) 
<0.0001 
0.0021 
3). Waiting time for next available consultation 
(per 1 day increase) 
 
   
• PP_Waiting time -0.303** 
(0.149**) 
 
(-0.361 – -0.246) 
(0.099 – 0.199) 
<0.0001 
<0.0001 
• RNP_Waiting time -0.192** 
(0.097**) 
 
(-0.255 – -0.130) 
(0.034 – 0.159) 
<0.0001 
0.0024 
• GP_Waiting time -0.284** 
(0.237**) 
 
(-0.339 – -0.228) 
(0.191 – 0.284) 
<0.0001 
<0.0001 
4). Type of service your consultation covers 
(Reference level = Repeat prescription) 
   
• PP_Changes only to current medicines  0.211* 
(0.345) 
 
(0.042 – 0.380) 
(-0.082 – 0.772) 
0.0146 
0.1129 
• RNP_Changes only to current medicines -0.331** 
(0.122) 
 
(-0.496 – -0.167) 
(-0.339 – 0.583) 
0.0001 
0.6041 
• GP_Changes only to current medicines  0.010 
(0.014) 
(-0.143 – 0.163) 
(-0.221 – 0.249) 
0.9007 
0.9083 
• PP_Optimisation of medicines  0.288** 
(0.015) 
(0.122 – 0.454) 
(-0.502 – 0.531) 
0.0007 
0.9553 
• RNP_Optimisation of medicines  0.562** 
(0.441**) 
 
(0.394 – 0.730) 
(0.110 – 0.772) 
<0.0001 
0.0090 
• GP_Optimisation of medicines  0.178* 
(0.087) 
 
(0.018 – 0.337) 





5). Type of consultation 
(Reference level = By appointment) 
   
• PP_Walk-in and wait clinic -0.168** 
(0.621**) 
(-0.293 – -0.043) 




• RNP_Walk-in and wait clinic  0.143* 
(0.120) 
(0.031 – 0.255) 




• GP_Walk-in and wait clinic -0.102 
(0.350*) 
(-0.222 – 0.018) 




6). Prescribing service operating hours 
(per 1 hour increase) 
 
   
• PP_Operating hours  0.023* 
(0.014) 
(0.003 – 0.043) 




• RNP_Operating hours  0.050** 
(0.005) 
 
(0.032 – 0.068) 
(-0.019 – 0.028) 
<0.0001 
0.6978 
• GP_Operating hours -0.024** 
(0.025*) 
(-0.042 – -0.006) 




    





95% CI p value 
7). Cost of consultation_annual household income 
(per $1 increase) 
 
   
• Cost (income ≤$50, 000 /year) -0.062** 
(0.062**) 
 
(-0.070 – -0.054) 
(0.054 – 0.070) 
<0.0001 
<0.0001 
• Cost (income > $50, 000/year) -0.059** 
(0.059**) 
 
(-0.065 – -0.052) 
(0.052 – 0.065) 
<0.0001 
<0.0001 
    
Alternative-specific respondent characteristics: 




95% CI p value 
8). Age 
(per year increase) 
   
• PP_Age -0.021** (-0.029 – -0.013) <0.0001 
• RNP_Age -0.015** (-0.023 – -0.008) 0.0001 
9). Most preferred prescriber (MPRxer) 
(Reference level = MPRxer is GP prescriber) 
   
• PP_MPRxer is nurse prescriber -0.029 (-0.358 – 0.299) 0.8619 
• RNP_MPRxer is nurse prescriber  0.391* (0.096 – 0.686) 0.0094 
• PP_MPRxer is pharmacist prescriber  0.405** (0.098 – 0.712) 0.0096 
• RNP_MPRxer is pharmacist prescriber  0.132 (-0.161 – 0.424) 0.3782 
10). Employment type 
(Reference level = employed) 
   
• PP_Unemployed -0.176* (-0.316 – -0.036) 0.0139 
• RNP_Unemployed -0.137* (-0.270 – -0.003) 0.0448 
11). Residential location    
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(Reference level = major/provincial city) 
• PP_Town/rural  0.008 (-0.135 – 0.150) 0.9158 
• RNP_Town/rural -0.006 (-0.142 – 0.131) 0.9328 
12). Number regular medicines taken per day 
(Meds) 
   
• PP_Meds -0.042 (-0.092 – 0.008) 0.0967 
• RNP_Meds -0.081** (-0.130 – -0.032) 0.0013 
13). Number of diagnosed chronic/long term 
conditions (LTCS) 
   
• PP_LTCS  0.088** (0.027 – 0.149) 0.0049 
• RNP_LTCS  0.069* (0.009 – 0.129) 0.0250 
14). Type of community pharmacy usually visited 
(Reference level = Different community 
pharmacies most of the time) 
   
• PP_Same pharmacy most of the time  0.109 (-0.013 – 0.230) 0.0793 
    
Generic respondent characteristics: 




95% CI p value 
15). GP visit frequency 
(Reference level = Less often than once every 3 
months) 
   
• Once every 3 months or more often -0.127* (-0.247 – -0.007) 0.0385 
Model goodness of fit measures: 
Log likelihood function   -3837.51206 





PP = Pharmacist prescriber 
RNP = Registered nurse prescriber 
GP = GP prescriber 
Std Dev = standard deviation 
** = significance at 1% level 
* = significance at 5% level 
CI = confidence interval 
AIC = Akaike information criterion 
 
For the service type attribute, respondents were significantly more likely to prefer 
changes only to current medicines by a pharmacist prescriber (β=0.211, 95% 
CI=0.042 to 0.380, p=0.0146), relative to the repeat prescription service. They 
were significantly more likely to prefer optimisation of medicines by a nurse 
prescriber (β=0.562, 95% CI=0.394 to 0.730, p=<0.0001), followed by a 
pharmacist prescriber (β=0.288, 95% CI=0.122 to 0.454, p=0.0007), and GP 
prescriber (β=0.178, 95% CI=0.018 to 0.337, p=0.0291).  
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With the prescribing service operating hours attribute, respondents were 
significantly more likely to prefer longer operating hours for a pharmacist 
prescriber (β=0.023, 95% CI=0.003 to 0.043, p=0.0240). For the consultation type 
attribute, respondents were significantly less likely to prefer the walk-in and wait 
clinic option for a pharmacist prescriber (β=-0.168, 95% CI=-0.293 to -0.043, 
p=0.0083) relative to an appointment. With the consultation waiting time 
attribute, respondents were significantly less likely to prefer a longer waiting time 
for a pharmacist prescriber (β=-0.303, 95% CI=-0.361 to -0.246, p=<0.0001). 
Locating the pharmacist prescriber at the community pharmacy, relative to GP 
practice location, did not significantly affect preferences.  
Higher consultation costs were significantly less preferred. For those with an 
income ≤$50,000 the cost attribute was -0.062 per $1 increase; for those with an 
income >$50,000 per year the cost attribute was -0.059 per $1 increase in 
consultation cost. Unsurprisingly, respondents with lower income were more price 
sensitive.  
Respondents who ranked pharmacist prescribers as their most preferred 
prescriber or had a higher number of chronic conditions were significantly more 
likely to prefer a pharmacist prescriber, compared with GP and nurse prescribers. 
Respondents who were older, unemployed, or visited their GP at least once every 
three months were significantly less likely to prefer a pharmacist prescriber, 
compared with GP and nurse prescribers.  
The nurse prescriber alternative-specific constant (ASC) was the only statistically 
significant ASC. It contributes a significant negative impact on the nurse prescriber 
alternative, indicating that respondents do not prefer the nurse prescriber 







6.4.4.3 Willingness to pay and trade offs 
The willingness to pay (WTP) and willingness to wait (WTW) values are 
summarised in Supplementary Table S2 (see NZ Public DCE Online Supplementary 
Material 2 section at the end of this chapter). 
Respondents who had a household income ≤$50 000/year were willing to pay 
more to use the optimisation of medicines (WTP=$5.13, 95% CI=$4.97–$5.29) and 
changes only to current medicines (WTP=$3.76, 95% CI=$3.61–$3.91) service 
types provided by a pharmacist prescriber, compared to the optimisation of 
medicines service type provided by a GP prescriber (WTP=$3.16, 95% CI=$3.07–
$3.26). Respondents who had a household income ≤$50 000/year were willing to 
pay the most to avoid a one day increase in waiting time to see a pharmacist 
prescriber (WTP=$5.41, 95% CI=$5.22–$5.60). Similar, albeit slightly higher WTP 
values were estimated for respondents on a higher income.  
 
6.4.4.4 Utility value of prescribers 
Table 16 lists the relative overall utility and choice probabilities for the three 
primary care prescribers based on the two scenarios described. The pharmacist 
prescriber had the highest relative overall value and probability of being chosen by 
the respondent described in scenario one (utility value=-1.27; choice 
probability=0.39). In scenario two, the GP prescriber had the highest relative 
overall value and probability of being chosen by the respondent (utility 








Table 16 Scenarios and calculated utility values and choice probabilities for the three primary care 
prescriber alternatives 
Scenario 1 Scenario 2 
● The person has a side effect of a persistent 
dry cough from his current blood pressure 
medicine and he would like to see a 
prescriber who can assess and change the 
medicine. 
● He works Mon-Fri 8:30am-5:30pm so 
would like an appointment within 1 day at 
the local GP practice as it is close to his 
home and is open from 8:00am-8:00pm.  
● The cost of consultation is $30. 
● Respondent characteristics: 
⮚ 35 year old man, lives in a large city, and 
has a household income of $45 
000/year. 
⮚ He has two chronic conditions and is 
taking two medicines per day. 
⮚ He usually sees the GP once every 6 
months, and uses different community 
pharmacies due to convenience. 
● The person needs a review of all her 
medicines, including her blood pressure 
medicines, and the prescriber may need 
to change her medicines. 
● She is retired and would like an 
appointment within 1 day at the local GP 
practice which is open from 9:00am-
5:00pm. 
● The cost of consultation is $20. 
● Respondent characteristics: 
⮚ 68 year old retired woman, lives in a 
provincial town, and has a household 
income of $52 000/year. 
⮚ She has five chronic conditions and is 
taking seven medicines per day. 
⮚ She usually sees the GP once every 3 
months, and uses the same 
community pharmacy. 
Calculated utility value and probability using mixed MNL model outputs: 
 Scenario 1 Scenario 2 
Prescriber Utility value Probability 
of being 
selected 
Utility value Probability of being 
selected 
GP prescriber -1.49 0.32 0.39 0.84 
Pharmacist 
prescriber 




-1.56 0.29 -2.30 0.06 
 
 
6.4.4.5 Reasons for preferences 
Eighty two percent (82%) of respondents ranked the GP prescriber as most 
preferred (see Supplementary Table S3 in the NZ Public DCE Online 
Supplementary Material 2 section at the end of this chapter), while 9% each of the 
respondents ranked either nurse prescribers or pharmacist prescribers as most 
preferred. The ‘training & skills’ theme featured within the top two reasons for all 
the prescribers when respondents ranked their most preferred prescriber. 
Respondent reasons for their most preferred prescriber ranking were enlightening 
and a notable quote was: 
166 
 
“The GP is really busy so I like to let patients who need consultations first choice of 
their time. The pharmacist is not usually located in the same location as the GP or 
nurse and it is a lot easier to consult the Pharmacist and at the same time get the 
script filled.” 
The choice attributes featured frequently as the reason for respondents’ 
preferences for choice task five (see Supplementary Table S4 in the NZ Public DCE 
Online Supplementary Material 2 section at the end of this chapter), with lower 




NMP has been introduced in many countries due to increasing health demands on 
primary care and GP workforce constraints, and pharmacist and nurse prescribers 
have been shown to be effective in this scope of practice [9,36].  
6.4.5.1 Mixed MNL 
To our knowledge, this is the first DCE in NZ to explore preferences for a 
pharmacist prescribing service in primary care. A priori, we anticipated that 
respondents might only choose the GP prescriber (the status quo) for prescribing 
services in primary care. However, the results from this DCE indicate this NZ 
public sample is willing to utilise both the optimisation of medicines and changes 
only to current medicines service types provided by pharmacist prescribers. This 
suggests that respondents would prefer to have a range of pharmacist prescribing 
services that provides them with more options to see a prescriber depending on 
their needs. This is consistent with other studies that have also shown positive 
preferences for pharmacist prescribers from patients and/or the public 
[100,101,132].  
For all three prescribers, the respondents showed a higher preference for the more 
autonomous prescribing service type—the optimisation of medicines service type, 
which allowed the prescriber to make any type of medication change. UK research 
has also shown higher consumer and carer preferences for less restrictive 
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pharmacist prescribing services when compared to a doctor [260]. In contrast, 
Canadian research has shown higher patient preferences for pharmacist 
prescribing services that included a doctor [41]. Studies have shown positive 
experiences for respondents who have used pharmacist and nurse prescribers 
[100,99,85]. There is evidence of doctors’ positive perceptions of pharmacist 
prescribing, which suggests more acceptance of pharmacist prescribing by GPs and 
is an important facilitator for establishing these services [99,40,292,106].  
Respondents had no significant preference for the location of the pharmacist 
prescriber (community pharmacy or GP practice), which is contrary to current NZ 
policy where pharmacist prescribers cannot prescribe from community 
pharmacies. Other research indicated utilising a pharmacist prescribing service in 
a community pharmacy setting was more convenient for the patient [100,98]. 
Unsurprisingly, respondents preferred shorter waiting times, which is in line with 
our a priori expectations and other studies [293-296]. Respondents differed in 
their preferences for the appointment type for the different prescribers, and in 
contrast to other research [297], respondents in this DCE preferred an 
appointment to see the pharmacist prescriber. 
Consistent with a priori expectations [298], respondents preferred longer 
operating hours for pharmacist prescribing services. This would allow people in 
full time employment or who have other responsibilities during the working day 
easier access to a prescribing service and their medicines. However, respondents 
had a negative preference for longer operating hours by GP prescribers. This may 
be because out of hours or extended hours GP services in NZ are usually associated 
with higher consultation costs for the patient, and respondents may have 
correlated longer operating hours for GP prescribers with higher costs 
(respondents imputed other factors into the operating hours attribute for the GP 
prescriber alternative).  
Consistent with a priori expectations and other research [260,132,295], 
respondents preferred a lower consultation cost. This DCE also indicates that 
consultation cost increases would likely have a greater negative impact on service 
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preferences for respondents who earn below the NZ median annual income  of 
$52,832 [299]. 
Sociodemographic characteristics also influenced preferences. Unsurprisingly, 
respondents who ranked pharmacist prescribers as their most preferred 
prescriber were significantly more likely to prefer a pharmacist prescriber. 
Increasing age or being unemployed were negative contributors to the utility of a 
pharmacist prescriber service, relative to GP prescribers. Other research indicated 
younger respondents preferred a combined service, where a pharmacist both 
prescribed and dispensed [300], while in contrast other research found that age 
did not influence respondent’s preferences for pharmacist prescribers [101].  
 
6.4.5.2 Willingness to pay and trade-offs 
Respondents valued both pharmacist prescriber service types (relative to repeat 
prescribing service type) as they were willing to pay more to use the optimisation 
of medicines and changes only to current medicines service types provided by a 
pharmacist prescriber than from a GP prescriber (Supplementary Table S2). A 
higher, although not significant WTP to see the pharmacist prescriber, relative to 
the GP, was also seen in other DCE research [132].  
Respondents were willing to pay the most to see the pharmacist prescriber sooner, 
rather than waiting to see the GP prescriber. Although there is no direct 
comparison, other research has shown preferences for shorter waiting times for 
GP prescribers [293], and a willingness to pay more to avoid waiting longer [295].  
 
6.4.5.3 Utility value of prescribers  
The two scenarios describe two contrasting individuals who are seeking a 
prescribing service type to illustrate which prescriber they would choose and how 
this differs based on their relevant sociodemographic characteristics. In scenario 
two, the relative utility calculation based on the mixed MNL outputs indicated that 
all else being equal, the GP prescriber would be the preferred prescriber for an 
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older, retired person who has a few chronic conditions and is taking seven 
medicines per day. This is in line with the a priori expectation that the GP 
prescriber would be the usual/status quo prescriber for a person of this 
demographic. 
In scenario one, the pharmacist prescriber had the highest utility score and the 
highest probability of being selected by the respondent. This scenario described a 
younger person with an uncomplicated medical history, who is unable to access a 
prescriber during usual business hours. Thus, the DCE provides evidence that the 
NZ public with these characteristics would likely use a pharmacist prescriber in 
primary care if this alternative model were available.  
Other DCEs using scenarios and utility values, based on the estimated model 
outputs, have also shown positive preferences for pharmacist prescriber services 
when compared to a GP prescriber [101]. Other research indicates positive 
outcomes with pharmacist prescribing services including safety, clinical 
appropriateness, cost effectiveness, and patient satisfaction [37,38,97,122,123].  
 
6.4.5.4 Reasons for preferences 
This DCE found that when respondents ranked pharmacists as their most 
preferred prescriber (9% of DCE sample), this variable contributed positively to 
the pharmacist prescriber alternative. Respondent’s reasons for these rankings 
were useful to understand this facilitator for pharmacist prescribers.  
Unsurprisingly, when considered in isolation, 82% of the DCE sample ranked the 
GP as the most preferred prescriber, as this is the usual prescriber seen in primary 
care, perhaps reflecting a strong status quo bias. The respondent’s reasons for 
ranking their most preferred prescriber were mainly intrinsic themes—personal 
perception themes such as training & skills, trust/emotional attachment, access to 
medical history, and status quo. However, when respondents considered the three 
prescriber alternatives within the context of choice task five, only 44% of 
respondents selected the GP prescriber alternative. Within the context of their 
preference in choice task five, respondents’ reasons for the choice made were now 
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attributed more to the extrinsic factors (the choice attributes), rather than the 
intrinsic factors (their personal perception themes). Therefore, it could be 
interpreted that by selecting the pharmacist prescriber, respondents were also 
trading off their personal perceptions associated with a GP, for favourable levels of 
the DCE choice attributes (lower cost, shorter waiting times, and longer operating 
hours).  
The qualitative information from the DCE provides useful insight, notably barriers 
and facilitators for pharmacist prescribing services. Other studies have indicated 
that the benefits of pharmacist prescribing services include patient convenience, 
easier access to medicines, and reducing physician’s workload to enable them to 
focus on more complex patients [100,297,300,114,133]. These themes were 
evident in the DCE respondent’s reasons for their preferences, especially the 
convenience of accessing their prescription and medicine supply at one location—
the pharmacy. Concerns identified in this DCE and other research [297,133] 
included the lack of privacy in a pharmacy and the potential conflict of interest 
with a pharmacist prescriber also supplying the medicines. Prescribing behaviour 
concerns can be allayed, as prescribing is an auditable task for all prescribers in 
NZ, which can be reviewed when required.  
Although high satisfaction has been reported with pharmacist prescribing services 
[98,120,301], barriers such as the lack of awareness of these services and lack of 
understanding of pharmacist prescriber roles have been identified [119,302]. Only 
39% of respondents were aware of pharmacist prescribers prior to participating in 
this DCE. Ensuring that the public is educated and aware of factors like the 
availability of a pharmacist prescribing service, and the pharmacist prescriber’s 
capabilities, and their role within the primary care prescribing team seem to be 
important facilitators for developing a pharmacist prescriber service and ensuring 
confidence in the service.  
 
6.4.5.5 Strengths and limitations 
This is the first DCE to investigate public preferences for a pharmacist prescriber 
in primary care in NZ. Policy makers and funders can use this information to 
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inform the future direction of prescribing services in NZ, and influence the 
direction of the pharmacy profession. DCEs are a robust quantitative method to 
elicit consumer preferences, and this DCE was conducted in accordance with good 
research practice for DCEs. It was informed by qualitative work prior to the DCE 
and with robust sample sizes for the pilot and main study phases. The DCE data set 
was diverse and representative by age, gender, and ethnicity [303].  
Although the DCE method is robust, its results indicate preferences for attributes 
and attribute levels as defined in this DCE, so preferences may have been affected 
by how our study defined these factors.  
 
6.4.6 Conclusion 
This DCE study provides useful insights into the preferences of the NZ public, 
which can be utilised to develop accessible and effective pharmacist prescribing 
services within the NMP framework in NZ. This DCE has provided evidence that 
the NZ public are willing to trade off using their GP prescriber for favourable levels 
of significant attributes—they are willing to use various models of pharmacist 
prescriber services in primary care if they can utilise them when they need to, cost 
less than their GP, and are open longer hours. Other countries, including the UK 
and Canada, have seen the potential of pharmacist prescribers and utilised them 
within NMP primary care services. Developing pharmacist prescribing services 
that use a variety of models would provide more opportunities for people to find a 
prescribing service that suits their healthcare situation. A challenge is ensuring 
funded pharmacist prescribing services so that cost is not a barrier. Promoting and 
educating the public and other healthcare professionals, about the pharmacist’s 
evolving role and capabilities are important facilitators for the development and 
sustainability of pharmacist prescribing services. 
As demand for health services increase and resource constraints (both financial 
and workforce related) affect equitable access to prescribing services in primary 
care, new models of healthcare need to be explored to provide solutions. These 
DCE results signal that the NZ public are willing to utilise pharmacist prescribers if 
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these services are available. Policy makers and funders should take note of these 
consumer preferences and see beyond the traditional roles of pharmacists. 
Incorporating pharmacists as integral members of the primary care prescribing 
team in NZ would enable pharmacists to utilise their skills to share the increasing 
prescribing workload in primary care, thereby providing more options for our 
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1). Supplementary Appendix S1: 
Method: 
2.1). Respondents: 
The DCE respondents were NZ adults aged 18 years and older, and the sample 
frames were stratified according to age, and gender, and with a soft quota on 
ethnicity to broadly represent the NZ adult general population. The soft quota 
approach attempted to match the distribution of the ethnicity groups in NZ as 
closely as possible. 
 
2.3). Reasons for DCE attributes and levels: 
The waiting time, cost and operating hours attributes and levels were included as 
the researchers hypothesised that longer waiting time, higher cost and longer 
operating hours would influence respondents’ preferences for prescriber type. The 
prescribing service attribute and levels were included to explore the influence of 






2.4). DCE study design: 
The DCE did not include an opt out alternative as we wanted to maximise 
information obtained about respondents trade-offs [1], and including an opt out 
alternative could decrease the precision of the parameter estimates as 
respondents tend to select the opt out alternative when making difficult trade-offs 
on attribute levels [2,3]. 
The main study design optimised on a multinomial (MNL) model and evaluated for 
the mixed multinomial (mixed MNL) model. The design included six normally 
distributed Bayesian priors. Bayesian priors can be more robust than fixed priors 
as they take into account the uncertainty associated with parameter priors [4,5].    
 
2.5). Analyses 
The estimated DCE models were evaluated for goodness of fit using the log-
likelihood ratio test, the McFadden’s pseudo R–squared value, and the normalised 
Akaike’s information criterion (AIC) value (AIC/N). 
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2.1). Supplementary Table S2:  
Supplementary Table S 2  WTP and trade off calculations based on mixed MNL output 
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PP = Pharmacist prescriber 
RNP = Registered nurse prescriber 
GP = GP prescriber 
WTP = Willingness to pay 
WTW = Willingness to wait 




2.2). Supplementary Table S3: 





GP prescriber Pharmacist 
prescriber 
Nurse prescriber 
% of sample with 
this ranking: 
82% 9% 9% 
Top 4 reasons for 
ranking the 
prescriber as most 
preferred: 
Training & skills 
Trust/emotional 
attachment 















“Traditionally that is 
what everyone is used 
to.” 
“They have access to 
medical history.” 
 
“It means that I could 
get the prescription 
and medication in the 
same 
location/shop/visit.” 
“The GP is really busy 
so I like to let patients 
who need 
consultations first 
choice of their time. 
The pharmacist is not 
usually located in the 
same location as the 
GP or nurse and it is a 
lot easier to consult 
the Pharmacist and at 
the same time get the 
script filled.” 
“The condition being 
dealt with I felt can be 
safely dealt with by a 
nurse prescriber.” 
“The convenience of 
being able to quickly 
sort prescriptions 
without having to 
wait up to 7 days to 





2.3). Supplementary Table S4:  
Supplementary Table S 4  Summary of respondents' reasons for their preference in choice task 5 
Prescriber selected in 
choice task 5: 
GP prescriber Pharmacist 
prescriber 
Nurse prescriber 
% of sample with this 
selected prescriber: 
44% 22% 34% 
Top 5 reasons for 
respondent’s choice: 
Lower cost 
Training & skills 
Shorter waiting time 





Shorter waiting time 





Shorter waiting time 
for next consultation 





“The GP and the 
registered Nurse 
prices were the same, 
so I chose the GP over 
the Nurse as in my 
opinion they have 
more training, and are 
more qualified to 
assess and prescribe 
medication. I don't 
mind waiting extra 
days to see a GP (who 
I trust) over a Nurse.  
I've never heard of a 
Pharmacist being able 
to prescribe medicine, 
and until I heard 
more about that, I 
wouldn't feel 
comfortable getting 
checked out by them.” 
“Cheaper for my 
lower income.” 
“The cost was the 
largest factor and 
availability how soon 
I could see and how 
convenient the time 
they open.” 
 “It good and 
innovative.” 
“I usually leave my 
appointment making 
until I have almost 
run out of pills. I am a 
firm believer that I do 
not need to see a GP 
to get repeat pills and 
would be extremely 
happy to see a 
Pharmacist or a 
Registered Nurse. 
Often a pharmacist 
has a tendency to 
know more about side 
effects of medications 
and what are the 
effects of mixing 
certain pills.” 
“I would choose the 
cheapest option, on 
the least waiting time, 
that met my needs. 
For myself, Doctor's 
visits are a luxury and 
I only go when 
absolutely necessary.” 
“I choose that because 
it is reasonable quick 
time frame to health 
care professional, 









Chapter 7: Discussion and conclusion 
Non-medical prescribing (NMP) is evolving in New Zealand and there are several 
non-medical health professional groups that are engaged in these services. The 
literature review highlighted the paucity of NMP research in NZ and the lack of 
quantitative research. There is little NZ research that encompasses the overall 
NMP service, and current research is very profession-specific and mainly utilised 
qualitative methods. Although pharmacist prescribers exist in NZ, little is known 
about how they currently practice and fit into the NMP service in NZ. 
Based on the literature review, the PhD aimed to answer the following objectives: 
•  Understand the current non-medical prescribing environment in NZ. 
• Determine NZ non-medical prescribing trends in primary care. 
• Ascertain preferences for pharmacist prescribing services in primary care in 
NZ. 
These four research projects were undertaken to address the three objectives 
above: 
• Project 1: Non-medical prescribing in New Zealand—an overview of 
prescribing rights, service delivery models and training. 
• Project 2: Non-medical prescribing trends in New Zealand from 2016–2020. 
• Project 3: Identifying community pharmacist preferences for prescribing 
services in primary care in New Zealand—a discrete choice experiment. 
• Project 4: Identifying New Zealand public preferences for pharmacist 
prescribers in primary care—a discrete choice experiment. 
This chapter summarises the four projects included in this thesis and discusses the 
implications of the research interventions for practice and/or policy change for the 
overall NMP service and pharmacist prescribing services in NZ.  
7.1. Summary of research projects in this thesis 
Fig 7 provides a visual summary of the research projects undertaken for this thesis 




Figure 7 Summary of NZ NMP projects completed for this thesis and their outcomes 
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7.1.1 Project 1: Non-medical prescribing in New Zealand—an overview of 
prescribing rights, service delivery models and training 
Project one aimed to provide an updated source of information that described the 
current prescribing rights and educational requirements for non-medical 
prescribers in New Zealand. 
The specific objectives were to determine: 
• which health professions have prescribing rights; 
• the prescribing model/s employed; 
• practice settings; 
• the training or education required; 
• use of prescribing competency framework (if any) by each profession. 
Project one established that it is difficult to gauge the current state of non-medical 
prescribing in NZ as the available information is widespread and difficult to find. 
Information about NMP in NZ occurs in siloes i.e. information is available within 
the confines of each health profession that has prescribing rights. Unless one is 
aware of all the health professionals that have prescribing rights, it is impossible to 
find the relevant information to gain a comprehensive overview of NMP in NZ. This 
project collated all the relevant information relating to NMP in NZ into one 
consolidated document and provided an easily accessible information source for 
stakeholders such as health professionals, the NZ public and policy makers. 
The project highlighted the variations in the regulation, educational programmes 
and prescribing competencies used by the different prescribing health 
professionals involved in NMP in NZ. Considering pharmacists’ comprehensive 
knowledge gained during their undergraduate education, project one also 
demonstrated the difficulties pharmacists currently face to gain prescribing rights 
in NZ i.e. the time consuming and expensive postgraduate education requirements, 
as well as the restrictive prescribing models compared to other NMP providers, . 
The project also provided recommendations such as setting up a collaborative 
research network in NZ that can evaluate and improve the NMP service in NZ. It 
also recommended that NZ needs to develop overarching NMP policy to enable 
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consistency in the various aspects of NMP, thereby delivering a safe and 
sustainable NMP service in NZ. 
Google Scholar has indicated that the publication from project one has already 
been cited 15 times by other researchers [304]. This illustrates the need for this 
type of consolidated work to provide a current overview of NMP in NZ, and 
demonstrates its impact on current NMP and pharmacist prescribing research. 
 
7.1.2 Project 2: Non-medical prescribing trends in New Zealand from 2016–
2020 
Having determined a current overview of prescribing rights, and demonstrated the 
variability in service delivery models, training requirements, and prescribing 
competencies for the different health professions involved in NMP in NZ; the next 
task was to examine the scale and scope of NMP practice in NZ. 
Project two aimed to provide a current overview of non-medical prescribing 
trends in NZ with specific objectives to determine: 
• The contribution and trends of non-medical prescribers to overall prescribing 
from 2016 to 2020. 
• The contribution and trends of each NMP health professional group to all non-
medical prescribing from 2016 to 2020. 
• The demographics of patients who received prescriptions from non-medical 
prescribers. 
• The most frequently prescribed therapeutic groups and medicines by non-
medical prescribers. 
Project two confirmed that there was modest growth in the NZ NMP service in the 
4-year period, although it still makes a very small contributions to overall 
prescribing in primary care. Nurse prescribers were the largest contributor to 
NMP in NZ, and other NMP providers including pharmacist prescribers (who were 
one of the smallest contributors) have the potential to contribute more to this 
service. While all the NMP providers prescribed a broad range of medicines, there 
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was considerable similarity in the medicines prescribed. There is some indication 
that NMP providers could be alleviating the prescribing burden on GPs and 
improving access by prescribing for acute conditions that require pain relief or 
antibiotics. Nurse prescribers prescribed to higher proportion of Māori patients 
and patients living in higher deprivation, but overall, all NMP providers (including 
pharmacist prescribers) could be better utilised to provide prescribing services to 
our communities with greater health needs and improve access to healthcare 
services for our priority populations.  
The larger urban DHBs account for 48.3% of NZ NMP patients as they have bigger 
population bases. Based on current prescribing practice of the overall NMP service, 
there is great opportunity for NZ NMP providers, including pharmacist prescribers, 
to contribute to communities with greater health needs, including Māori and 
Pacific communities [216,217]. Rural NZ struggles with adequate workforce and 
inequity of access to healthcare [218], and rural DHBs often have higher 
proportions of patients who experience an unmet need for primary healthcare (e.g. 
a higher proportion of Māori and Pacific patients) [219]. While it is acknowledged 
that the rural DHBs account for a smaller proportion of all NMP patients in this 
study due to their smaller populations, NMP services could be further utilised to 
reach communities who are experiencing unmet primary healthcare needs in rural 
NZ. The variation of NMP service provision across the different DHBs in NZ 
suggests that while the service has been well integrated in specific regions, the 
variation could be due to more support and funding for NMP in some DHBs 
compared to others.  
The study highlights the importance of identifying what medicines NMP providers 
are prescribing, to ensure adequate education and continuing professional 
development that supports NMP providers to enable appropriate prescribing 
decisions. This study highlighted that while NMP has been implemented in NZ; it 
has not yet become mainstream healthcare practice.  
As identified earlier, there is the potential for pharmacy to contribute more to this 
service however, numbers of pharmacists with prescribing rights remains low. 
Project one highlighted the difficulties that pharmacist prescribers face to gain 
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prescribing authority, thereby hindering successful implementation of current 
pharmacist prescribing services in primary care in NZ.  The low numbers of 
pharmacist prescribers further demonstrate this issue and the meagre 
contribution of pharmacist prescribing services seen in project two. The 
development of improved and accessible pharmacist prescribing services 
delivered from community pharmacists has the potential to improve access to 
these healthcare services for our priority populations. 
 
7.1.3. Project 3: Identifying community pharmacist preferences for 
prescribing services in primary care in NZ—a discrete choice experiment 
Based on the findings demonstrated earlier in the thesis, we hypothesised that the 
lack of growth in the pharmacist prescriber workforce and the small contribution 
to overall prescribing by pharmacist prescribers might be due to the reservations 
of practising pharmacists to undertake and provide pharmacist prescribing 
services. Hence, project three aimed to use a quantitative method (a discrete 
choice experiment [DCE]) with specific objectives to: 
• Determine community pharmacists’ preferences for relevant attribute levels 
defining prescribing models in primary care in NZ. 
• Understand how these attributes and other factors could influence community 
pharmacist preferences for providing a pharmacist prescribing service. 
The community pharmacist DCE study (project three) provided useful insights into 
the preferences of NZ community pharmacists for providing a pharmacist 
prescribing service in primary care. Knowing what services community 
pharmacists are willing to engage in is invaluable as these preferences could be 
utilised to develop accessible and effective pharmacist prescribing services. These 
DCE results are encouraging as they signal that the community pharmacists see 
themselves and their pharmacies as part of the prescribing team. This is especially 
relevant as increasing patient populations and GP workforce constraints lead to 
increasing demand for health services in NZ.  
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This DCE concluded that developing a continuum of prescribing models provides 
more options for community pharmacists to engage in prescribing services in 
primary care. The prescribing education requirement preferences of the 
community pharmacist cohort highlighted that new, innovative approaches need 
to be considered when developing prescribing education programmes and could 
include micro-credentials. Developing prescribing education programmes that are 
both robust and attractive to community pharmacists would encourage them to 
engage in prescribing services, thereby increasing the number of pharmacist 
prescribers in primary care. Challenges included better information technology 
systems that enable seamless connectedness and communication, and funding 
pharmacist prescribing services.   
Improving and extending pharmacist prescribing models and services would allow 
pharmacists to share the ever-increasing prescribing workload in primary care. It 
would enable pharmacists to be part of a primary care prescribing team that 
addresses inequity of access to prescribing services and ensures timely access to 
these services for patients. 
 
7.1.4 Project 4: Identifying NZ public preferences for pharmacist 
prescribers in primary care—a discrete choice experiment 
Consumer and/or patient preferences play an important role in the development 
of any new/different healthcare service. It was unknown if the current poor uptake 
of pharmacist prescribing services is due to a lack of demand/need from patients 
and/or the general population. When expanding or enabling improved pharmacist 
services, it useful to know how patients/consumers would ‘react’ to the 
implementation of the new or evolved service in terms of potential utilisation. 
Therefore, project four aimed to use a quantitative method (DCE) to: 
• Determine NZ public preferences for a pharmacist prescriber service in 
primary care in NZ. 




• Determine public’s willingness to pay and trade-offs for access to pharmacist 
prescribing services. 
The public preference DCE study (project four) provided useful insights into the 
preferences of the NZ public for a pharmacist prescribing service in primary care. 
Knowing what services the public are willing to engage in is invaluable as these 
preferences could be utilised to develop accessible and effective pharmacist 
prescribing services within the NMP framework. These DCE results are 
illuminating as they signal that the NZ public see pharmacists as part of the 
prescribing team in primary care and are willing to utilise them if they are 
available. Again, this is especially relevant as increasing patient populations and GP 
workforce constraints lead to increasing demand for primary care health services 
in NZ.  
This DCE has provided evidence that cost, waiting times and operating hours are 
important factors to people, and that they are willing to trade off using the status 
quo primary care prescriber (i.e. a GP prescriber) for favourable levels of these 
attributes. Developing a sustainable pharmacist prescribing service that take these 
factors into account can help address the inequity of access to prescribers and 
medicines in NZ. Implementing a pharmacist prescribing service that uses more 
than one prescribing model in primary care not only provides more opportunities 
for our people and communities to find a prescribing service that is suitable for 
their situation; it also enables the pharmacist workforce to be utilised in a variety 
of ways to provide these prescribing services. 
Challenges include ensuring that pharmacist prescribing services are funded so 
that cost is not a barrier. Better information technology systems that enable 
efficient communication between health professionals is also required. Promoting 
and educating the public, as well as other healthcare professionals, about the 
pharmacist prescribing service and the pharmacist’s role and capabilities are 
important facilitators for the development and sustainability of the service.  
Improved pharmacist prescribing services would make better use of pharmacist’s 
skills and enable them to share the increasing prescribing workload in primary 
care. Efficacious pharmacist prescribing services could provide more options for 
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our people and communities, thereby addressing the inequity of access to 
prescribing services. 
 
7.2 Implications of research projects in this thesis 
This section explores potential implications of the research projects in this thesis, 
looking towards the overall intended outcome of developing better pharmacist 
prescribing services within primary care in NZ. Fig 8 summarises the potential 
over-arching outcomes from this thesis and possible implications for pharmacist 





Figure 8 Simplified logic model demonstrating possible implications of research outcomes from this thesis 
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7.2.1 Recommendation 1: A single NMP competency framework in NZ 
The research outcomes from this thesis provide evidence to show how non-
medical prescribing in NZ is fragmented, underutilised, and how pharmacists can 
be part of the solution to improve NMP implementation in primary care in NZ.  
Non-medical prescribing in NZ is governed by the many pieces of legislation that 
apply to the different health professionals in a variety of aspects, and regulation of 
these NMP providers is enforced by the specific health professional regulatory 
authorities e.g. the Pharmacy Council for pharmacists or the Nursing Council for 
nurses. The research outcomes from projects one and two provided evidence that 
implementation of non-medical prescribing in NZ is inconsistent and 
underutilised.  
A possible reason for the fragmentation and variation noted in the NMP service in 
NZ could be that the application processes for prescribing rights have occurred 
independently by the various regulatory authorities at different times with no 
underlying national NMP policy or framework [178,83]. There is variation in NZ in 
the educational requirements, training programmes, and the use of prescribing 
competencies between the different non-medical health professionals that are 
non-medical prescribers in NZ [83]. Currently, only pharmacist prescribers, nurse 
practitioners, and registered nurse prescribers use a specific prescribing 
competency framework in practice in NZ, while optometrists have some 
prescribing competencies embedded within their usual practice competencies 
[305,76,157,194]. There is also variation between the prescribing competency 
frameworks used; pharmacist prescribers use a framework that is based on an 
earlier version of the UK single prescribing competency framework, and nurse 
prescribers’ use one based on the Australian prescribing competency framework 
[83]. Optometrist clinical guidelines do not indicate where their prescribing 
competencies have been derived from.  
A single prescribing competency framework for all prescribers (medical and non-
medical) exists in the UK and Australia [27,23]. A prescribing competency 
framework is a common set of competencies that is specific to prescribing 
regardless of the background of the health professional [27,23]. The UK and 
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Australian prescribing competency frameworks provide a consistent structure that 
can be used by prescribers to evaluate their prescribing  proficiency, and by 
regulators, education providers, professional organisations and specialist groups 
to inform standards, develop education pathways, and inform guidance and advice 
[27,23]. The availability of a single prescribing competency framework has been a 
facilitator for the implementation of the NMP service in the UK, which 
encompasses various health professionals and has become acceptable healthcare 
practice [106,9,37]. 
NZ could benefit from the development of a single competency framework for all 
prescribers, or at least non-medical prescribers. This could entail selecting either 
the Australian or the UK prescribing competency frameworks and contextualising 
it for NZ practice. This approach has worked well for areas such as developing 
prescribing and medicines information resources in NZ, and the New Zealand 
Formulary contextualising the British National Formulary to develop an online 
resource in NZ is a successful example [306].  This single NMP competency 
framework in NZ could be used to enable better consistency in the 
implementation, regulation and education requirements for NMP services and 
providers in NZ.  
 
7.2.2 Recommendation 2: Utilise the potential of pharmacist prescribers in 
primary care 
The research projects in this thesis have highlighted that implementation of NMP 
by the different groups of health professionals in NZ is highly variable, with some 
groups well represented (i.e. nurse prescribers and dentists), while others have 
the potential to be utilised better (e.g. pharmacist prescribers). The NZ Pharmacy 
Action Plan 2016–2020 indicated that various levels of healthcare governance 
supported the development and delivery of pharmacist prescriber services in 
primary care [46]. However, this thesis has shown that pharmacist prescribing 
services are not currently well implemented in NZ and there is variation of 
provisions of this service across the different DHBs. While current pharmacist 
workforce data indicates urban areas have more access to a pharmacist, it also 
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shows that a sizable pharmacist workforce delivers healthcare services to rural 
areas in NZ [47]. Between 96.8%–98.7% of more deprived populations (i.e. decile 
5–10) in rural areas of NZ are located within a reasonably accepted distance of a 
community pharmacy (i.e. 25 kilometre radius) [49], and for many of these areas, a 
community pharmacy is the only option for healthcare services as there may be no 
GP service available. Pharmacist prescribers have the potential to be utilised in a 
variety of settings, including rural NZ, to help people with unmet and/or greater 
health needs access healthcare services. Our research has shown community 
pharmacists are willing to provide prescribing services in primary care and the NZ 
public are willing to utilise pharmacist prescribers if these services are available.  
Other countries, including the UK, Canada, and the USA, have seen the potential of 
pharmacist prescribers to contribute to the high levels of prescribing workload in 
primary care, and have implemented various models of pharmacist prescribing to 
utilise them within NMP services. International research indicated positive 
outcomes with pharmacist prescribing services including safety, clinical 
appropriateness, cost effectiveness, patient experience/satisfaction, and doctors’ 
perceptions of the services [85,37,40,38,97,99,100,106,122,123,292,307]. Scotland 
has recognised the community pharmacy infrastructure and has implemented a 
variety of prescribing options that people can easily access, including independent 
pharmacist prescriber clinics in community pharmacy settings, and minor ailment 
and chronic medication prescribing models [308]. 
Pharmacists can be part of the solution to improve NMP implementation and 
access to prescribing services in primary care in NZ. There is the potential for 
policy makers in NZ to develop a variety of prescribing models that exist along a 
prescribing continuum for pharmacists to utilise in primary care, from minor 
ailments through to fully independent prescribing [50]. Responsibility moves to 
the policy makers to use our research outcomes within the context of the NMP 
evidence base, to enable policy change for NMP and pharmacist prescribing in 
primary care in NZ. Policy makers and funders in NZ could utilise these research 
outcomes to see beyond the traditional roles of pharmacists working in primary 
care, and develop policies that extend the use of a pharmacist’s knowledge and 
skills by incorporating them into the primary care prescribing team. When policy 
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change occurs, systems can then move forward to develop and implement an 
improved pharmacist prescribing service in primary care within the domains of 
NMP. Policy and practice change and implementation at various levels of 
healthcare governance in the UK has been a facilitator of NMP implementation, 
including pharmacist prescribing services [220,221].   
The aims for system changes to further advance pharmacist practice models in 
primary care includes making better use of pharmacists’ knowledge and skills and 
alleviating prescribing burden on GPs. Our research has provided evidence that 
community pharmacists prefer to engage in prescribing services based in 
community pharmacies, and that the NZ public see benefit to these prescribing 
services including ease of access, convenience of acquiring a prescription and 
medicines in the same location, and leaving GP consultations for patients with 
more complex needs. Multiple examples of UK primary care policy implementation 
include utilising various health professions within NMP services to maximise the 
use of their skills to ease the prescribing burden on doctors and improve access to 
prescribing services and medicines [309-311].  UK research has indicated that 
NMP has made better use of health professionals’ skills (including nurse and 
pharmacist independent prescribers) to reduce workload pressures of GPs 
[220,221]. 
Funding pharmacist prescribing services in primary care is essential to enable the 
NZ public to access these services—our research has shown that cost is an 
important factor for accessing a prescriber and prescribing services. The current 
NZ pharmacist prescriber model is funded i.e. they can prescribe prescription 
medicines that are fully funded for patients. However, this pharmacist prescribing 
model potentially has little impact on the community as there are very low 
numbers of practising pharmacist prescribers in NZ. The pharmacist only medicine 
prescribing model in NZ is predominantly an unfunded prescribing model and 
contributes to inequity of access to healthcare services as only patients who can 
afford to, can pay to use this service. However, there are exceptions such as funded 
nicotine replacement and influenza immunisation for some sectors of the 
population via the pharmacist only medicine prescribing classification, both of 
which have had good uptake from the NZ public. 
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7.2.3 Recommendation 3: Flexible and streamlined education programmes 
for pharmacist prescribers 
Project three (the community pharmacist DCE) confirmed that the current 
education pathway was not preferred for the cohort of community pharmacists 
participating in the DCE. NZ pharmacists spend four years plus an additional intern 
year before they can register as practising pharmacists. This is a significant period 
of learning and equips pharmacists with a comprehensive knowledge base and 
skill set. This includes some basic training in prescribing skills as the current scope 
of practice for NZ pharmacists includes prescribing ‘pharmacist only’ medicines. 
Community pharmacists are time poor and may feel reluctant to engage in lengthy 
education programmes [270,272] that follow a more traditional structure. Micro-
credentials might be a possible option, as they are similar to the accredited 
learning modules preferred by the community pharmacists in the pharmacist DCE 
study and can be used to build on the comprehensive undergraduate education 
programme that pharmacists have already completed. Utilising stackable micro-
credentials within education programmes could be considered when developing 
innovative solutions to enable flexible yet robust pharmacist prescribing education 
programmes in NZ. Financial support is also required to encourage NZ pharmacists 
to engage in pharmacist prescribing education programmes. Health Workforce 
New Zealand funds postgraduate clinical training for dental, medical, nursing, and 
midwifery health professionals but currently provides none for practising 
pharmacists [193]. In contrast, UK healthcare governance organisations provide 
funding for their health professionals, including pharmacists, to undertake non-
medical prescribing training [309,312]. 
Flexible and streamlined education programmes for NZ pharmacist prescribers 
would encourage more pharmacists to become prescribers and increase the 
number of registered pharmacist prescribers. This would overturn the current 
state of no significant growth in the number of NZ pharmacist prescribers [283]. 
Increasing the number of pharmacist prescribers in NZ could mirror the 
progression of nurse prescribers seen in NZ. Nurse prescribers are the biggest 
contributor to non-medical prescribing in NZ and potential reasons for this include 
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the reported increased numbers of nurse prescribers and improved 
implementation of multiple scopes of nurse prescribing in NZ [208]. 
 
7.3 Strengths and limitations  
The strengths and limitations of the four projects undertaken for this thesis are 
covered in the individual chapters (i.e. Chapters 3–6). This section summarises the 
strengths and limitations of the four projects undertaken for this thesis, and 
overall.  
7.3.1 Overview of non-medical prescribing in NZ 
Project one, the overview of non-medical prescribing in NZ, utilised a qualitative 
method. The flexible approaches employed by this qualitative method enabled 
exhaustive information capture and collation from a wide range of data sources 
into one consolidated document. The project provided a comprehensive current 
overview of various aspects of NMP in NZ, including regulation, practising models, 
and educational requirements for all the health professions involved in NZ NMP. 
However, non-medical prescribing in NZ continues to evolve, and the main 
limitation of the research is that it provided a snapshot of NMP in NZ at that date. 
As NZ NMP evolves, ascertaining current information about NZ NMP and its 
providers may continue to be to be difficult as this information is widespread and 
fragmented. 
 
7.3.2 Non-medical prescribing practice trends in NZ 
A strength of this study is the large data set available for analysis, with dispensing, 
prescriber, patient, and medicines details. The dataset contained comprehensive 
sociodemographic details for each patient and captures >96% of the New Zealand 
population. This study reported the first data describing all NMP in New Zealand 
providing an important baseline for future comparison. This work can be used to 
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evaluate NMP over time, and to develop policies to improve implementation and 
integration of the different health professions involved in NZ NMP. 
Dispensing was used as a surrogate marker to ascertain prescribing levels in this 
study. It is acknowledged that dispensing may not fully reflect prescribing as 
patients who had a prescription issued but did not take it to a pharmacy for 
dispensing are not captured in this study. This study captured nurse practitioner 
and registered nurse prescribing within the ‘nurse prescribing’ umbrella term. The 
Pharmaceutical Collection data did not differentiate between pharmacists 
prescribing funded medicines as registered pharmacist prescribers and 
pharmacists prescribing medicines via the pharmacist only medicines 
classification. Another limitation was that the study did not capture inpatient 
prescribing within hospital and secondary care settings where a number of non-
medical prescribers work (including pharmacists, nurses and midwives,). As at 30 
June 2019, 9 out of the 20 practising pharmacist prescribers worked in hospitals 
and secondary care, 9 worked in primary care and 2 worked in a mixed practice 
[313]. This could be a topic for future research.  
 
7.3.3 Community pharmacist and NZ public discrete choice experiment 
(DCE) projects 
The two DCE projects in this thesis were the first to investigate community 
pharmacist preferences for prescribing models in primary care in NZ, and public 
preferences for pharmacist prescriber services in NZ, respectively. Primary care 
policy makers and funders can use this information to inform the future direction 
of prescribing services in NZ, and influence the direction of the pharmacy 
profession. Information from these DCEs could be used to inform decisions on 
service provision, education requirements, and resource/workforce allocation 
priorities, and it enables these decisions to be based on evidence that is more 
constructive. DCEs are a robust quantitative method to elicit preferences, and both 
DCEs were conducted in accordance with good research practice for DCEs [243-
246,242]. Both DCEs were informed by qualitative work prior to the DCE and with 
robust sample sizes for the pilot (NZ public preference DCE) and main study 
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phases (both community pharmacist preference and NZ public preference DCEs). 
The data sets used in both DCEs were diverse and representative of their target 
sample populations. The community pharmacist preference DCE was 
representative by gender and age [258], while the NZ public preference DCE was 
representative by gender, age, and ethnicity [303].  
Although the DCE method is robust, its results indicate preferences for attributes 
and attribute levels as defined in that specific DCE, so preferences may have been 
affected by how our DCE studies defined these factors. In addition, results from the 
DCE method indicate preferences at a single point in time, and all outputs should 
be interpreted within the context and constraints of the estimated model and the 
variables included in the final model. Both DCE studies in this thesis used a main 
effects design. While it is acknowledged that DCE guidelines recommend the 
inclusion of interactions where possible in experiment design [243,246], this is a 
complicated process which is not always feasible to implement. As a result, the 
majority of health-related DCEs use a main effects design, and this is considered 
acceptable practice [314]. 
The community pharmacist DCE reported a completion rate of approximately 8.9% 
(i.e. 264 fully completed choice task questionnaires out of a potential sample size 
of 2958), and the NZ public DCE reported a completion rate of 47% (i.e. 924 
completed choice task questionnaires out of 1978 eligible respondents). The low 
completion rate and resulting small sample size with the community pharmacist 
DCE must be acknowledged and discussed. Non‐response error is a type of 
selection bias that occurs when sampled individuals who respond to the survey 
differ from those who do not respond [315,316]. Health-related DCEs are prone to 
non-response errors resulting from low response rates [315,317]. So, the low 
response rate is a potential limitation of the community pharmacist DCE as it 
might limit the representativeness of the community pharmacist sample and 
generalisability of findings to the community pharmacist population in NZ. 
Selection bias could exist in the community pharmacist DCE cohort as those 
pharmacists who were most interested in pharmacist prescribing may have been 
more likely to respond. Furthermore, the smaller sample size of the community 
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pharmacist DCE could be a potential limitation, as it may have been too small to 
detect a significant effect for some attribute levels in the mixed MNL model [318]. 
 
7.3.4 Overall thesis  
The research projects undertaken for this thesis have each successfully answered 
the objectives of this thesis and have added to the non-medical prescribing in NZ 
evidence base. The types of research projects undertaken have been innovative 
and, in all cases, have provided specified outcomes to address current knowledge 
gaps and gain a better understanding of the NZ NMP landscape. Project one was 
the first to provide an overview of NMP in NZ, as well the regulation, practising 
models, and educational requirements for all the health professions involved in 
this service. Project two reported the first data describing all NMP in NZ, providing 
an important baseline for future comparisons. Projects three and four were the 
first to apply the DCE technique to pharmacy practice research in NZ to elicit 
pharmacist and public preferences respectively. 
Reflecting on the thesis overall highlights that further NMP research, including 
pharmacist prescribing services, would be beneficial. Future studies would add to 
the outcomes of the research projects from this thesis. Qualitative research has the 
potential to build on the quantitative outcomes of the thesis to provide a more 
detailed picture of current and/or future pharmacist prescribing services in NZ. 
 
7.4 Future research 
Potential future research regarding pharmacist prescribing and NMP services has 
been identified from this thesis. Further research to determine the impact of NMP 
on patient outcomes in NZ could be beneficial. Undertaking randomised studies 
comparing clinical outcomes in specific groups of patients would be useful but they 
can also be complicated. For example, outcomes in patients with cardiovascular 
disease seen regularly by a particular type of NMP (e.g. a pharmacist prescriber) 
could be compared to patients randomised to ‘usual care’. However, we 
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acknowledge there are many potential confounders in such studies (such as 
disease severity), and, in practice, most patients have multiple inputs from a 
variety of health professionals. 
In addition, studies are required to identify the extent to which the NMP providers, 
including pharmacist prescribers, are improving access to healthcare services for 
patients and/or communities with the greater health needs. This could include 
following patients who have seen non-medical prescribers and those who have not 
and determining whether utilising non-medical prescribers is improving access to 
prescribing services and medicines for patients. Determining patient 
experience/satisfaction in those who have utilised NZ pharmacist prescribing 
services and other NMP services would provide invaluable insight to help improve 
these prescribing services in NZ. 
Qualitative work to further determine the barriers and facilitators to NZ 
pharmacists engaging in pharmacist prescribing qualifications and services would 
be useful. This would build on the outcomes from the community pharmacist DCE 
in this thesis. An ethnographic study following pharmacist prescriber/s practising 
in very low cost access (VLCA) practices in primary care to identify how this 
service was operationalised would be beneficial. This type of study could identify 
barriers and facilitators to setting up and implementing a pharmacist prescribing 
service in primary care, evaluate if the service was improving access for our high 
priority patient populations, and gain perspectives from patients and colleagues 
involved in these services.  
Another example of future research could be to evaluate the implementation of 
new nurse prescriber guidelines in NZ that are due to be released in late 
2020/early 2021, and to determine if these guidelines could be rolled out across 
all non-medical prescribers in NZ. This type of research could help develop a single 






This chapter concludes that the research projects undertaken have each 
successfully contributed to the objectives of this thesis. The research outcomes 
have added to the available evidence base on non-medical prescribing in NZ. This 
includes providing an updated overview of overall NMP and NMP prescribing 
practice in NZ, and how pharmacists can be part of the solution to improve access 
to prescribing services in primary care. The potential exists to utilise the outcomes 
of these research interventions to make meaningful changes in the NMP service in 
primary care, with the overall intended outcome of developing better pharmacist 
prescribing services within the primary care in NZ. 
NMP aims to make the most impact in primary care by improving patient access to 
prescribers in this setting  [29]. Pharmacists are considered one of the most 
accessible health professionals globally and in NZ [46,319], and have the 
opportunity to provide accessible prescribing services to make a beneficial impact 
for patients in primary care. Other countries, including the UK and Canada, have 
seen the potential of the pharmacist workforce and utilise their skills within the 
NMP structure in primary care. NZ has the potential to make use of the largest 
proportion of the NZ pharmacist workforce (i.e. community pharmacists), which is 
based in primary care, to develop and implement an improved pharmacist 
prescribing services in primary care in NZ.  
Inequitable access to health services in primary care, including prescribing 
services and medicines, is an issue for many of our communities in NZ. The 
demand for health services continues to increase, due to an aging NZ population 
and GP workforce constraints. The usual prescribers in primary care in NZ (i.e. 
GPs) have ever-increasing workloads, including prescribing. The research 
interventions from this thesis provide the opportunity for the policy makers, 
health strategists and funders in NZ to think outside the traditional roles of 
pharmacists and make meaningful change for people in NZ by considering new and 
improved models of health service provision. The opportunity exists to make 
pharmacists part of the solution by implementing new services within the 
untapped potential of NMP in NZ. Improved pharmacist prescribing services 
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includes the better utilisation of the pharmacist workforce to help share the 
prescribing workload and alleviate prescribing burden in NZ primary care. Most 
importantly, improved development and implementation of pharmacist 
prescribing services in primary care would help enable equitable access to safe 







1. World Health Organization. The World Health Report 2006 - working together 
for health. Geneva. 2006. Available from: http://www.who.int/whr/2006/en/. 
Accessed September 2016. 
2. Nissen L. Pharmacist prescribing: What are the next steps? Am J Health Syst 
Pharm. 2011;68(24):2357-61. doi:10.2146/ajhp110216. 
3. Courtenay M, Carey N, Stenner K. An overiew of non medical prescribing across 
one strategic health authority: a questionnaire survey. BMC Health Serv Res. 
2012;12(1):1-13. doi:10.1186/1472-6963-12-138. 
4. Department of Health. Prescribing by Non-Medical Healthcare Professionals. 
United Kingdom. 2016. https://www.health-ni.gov.uk/articles/pharmaceutical-
non-medical-prescribing. Accessed 16 February 2016. 
5. Schindel TJ, Given LM. The pharmacist as prescriber: A discourse analysis of 
newspaper media in Canada. Res Social Adm Pharm. 2013;9(4):384-95.  
6. Kroezen M, van Dijk L, Groenewegen PP, Francke AL. Nurse prescribing of 
medicines in Western European and Anglo-Saxon countries: a systematic review of 
the literature. BMC Health Serv Res. 2011;11(1):1-17. doi:10.1186/1472-6963-11-
127. 
7. Department of Health. Review of prescribing, supply and administration of 
medicines: Final report (Crown II). London: Department of Health, England. 1999. 
8. Fittock A. Non-medical prescribing by nurses, optometrists, pharmacists, 
physiotherapists, podiatrists and radiographers: A quick guide for commissioners. 
National Prescribing Centre. Liverpool. 2010. 
https://static1.squarespace.com/static/515ab73de4b01cd3b024edd0/t/51eefaf8
e4b0de4b8d276d80/1374616312229/NMP_QuickGuide.pdf. Accessed 15 
February 2016. 
9. Weeks G, George J, Maclure K, Stewart D. Non-medical prescribing versus 
medical prescribing for acute and chronic disease management in primary and 
secondary care. Cochrane Database Syst Rev. 2016;11(11):CD011227-CD. 
doi:10.1002/14651858.CD011227.pub2. 
10. Latter S, Blenkinsopp A. Non-medical prescribing: current and future 
contribution of pharmacists and nurses. Int J Pharm Pract. 2011;19(6):381-2. 
doi:10.1111/j.2042-7174.2011.00183.x. 
11. Carey N, Stenner K. Does non-medical prescribing make a difference to 
patients? Nurs Times. 2010;107(26):14-6.  
12. Hoti K, Hughes J, Sunderland B. An expanded prescribing role for pharmacists–
an Australian perspective. Australas Med J. 2011;4(4):236-42.  
202 
 
13. Department of Health. Improving patients' access to medicines: A guide to 
implementing nurse and pharmacist independent prescribing within the NHS in 
England. London. . April 2006. 
http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.go
v.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasse
t/dh_4133747.pdf. Accessed 15 February 2016. 
14. Pharmaceutical Services Negotiating Committee. Who can prescribe what? 
2016. http://psnc.org.uk/dispensing-supply/receiving-a-prescription/who-can-
prescribe-what/. Accessed 15 February 2016. 
15. Tonna AP, Stewart D, McCaig D. An international overview of some pharmacist 
prescribing models. J Malta Coll Pharm Pract. 2008;14:20-6.  
16. Emmerton L, Marriott J, Bessell T, Nissen L, Dean L. Pharmacists and 
prescribing rights: review of international developments. J Pharm Pharm Sci. 
2005;8(2):217-25.  
17. Stewart D, MacLure K, George J. Educating nonmedical prescribers. Br J Clin 
Pharmacol. 2012;74(4):662-7.  
18. Kamarudin G, Penm J, Chaar B, Moles R. Educational interventions to improve 
prescribing competency: a systematic review. BMJ Open. 2013;3(8):e003291.  
19. Aronson JK. A prescription for better prescribing. Br J Clin Pharmacol. 
2006;61(5):487-91. doi:10.1111/j.1365-2125.2006.02649.x. 
20. De Vries T, Henning RH, Hogerzeil H, Fresle D. Guide to good prescribing: a 
practical manual. Geneva: World Health Organization; 1994. 
21. Hogerzeil HV, Barnes KI, Henning R, Kocabasoglu YE, Möller H, Smith AJ et al. 
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Supplementary material 2: 
 
Word version of discrete choice experiment questionnaire: 
 
 
School of Pharmacy Research Project 
 
Identifying community pharmacist preferences for prescribing models in primary care: a 
discrete choice experiment 
 
INFORMATION SHEET FOR PARTICIPANTS 
 
Thank you for showing an interest in this project. This participant information sheet contains 
detailed information about the research project. Its purpose is to explain to you as clearly as 
possible what the project involves before you decide whether to take part in it or not. 
Please read this sheet carefully before deciding whether to participate. If you decide to 
participate we thank you. If you decide not to take part there will be no disadvantage to you and 
we thank you for considering our request. 
 
What is the aim of the project? 
You are invited to take part in a project being undertaken by Rakhee Raghunandan, a PhD 
candidate at the School of Pharmacy, University of Otago, as part of the requirements for her 
PhD. The purpose of the project is to better understand community pharmacist’s preferences for 
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certain aspects (e.g. prescribing practice model, qualifications required, etc.) that would 
encourage them to provide a pharmacist prescribing service in primary care. 
 
Who is conducting the research? 
A research team based at the School of Pharmacy, University of Otago will be conducting the 
study. The research team consists of the PhD candidate (Rakhee Raghunandan) and her 
supervisors (Dr Alesha Smith, Associate Professor June Tordoff and Professor Carlo Marra).  
 
What type of participants are being sought? 
We are inviting practising New Zealand community pharmacists to participate in this project. 
 
What participants will be asked to do? 
Should you agree to take part, you will be asked to complete a 10–15 minute paper or online 
survey, which will help us identify your preferences for these variables. Completing the survey 
will imply consent to participate in the project. 
 
Do I have to take part? 
No, you may decide not to take part in this project without any disadvantage to yourself. It is up 
to you to decide whether or not to take part. If you do not wish to take part, you may discard this 
survey now. 
 
What data or information will be collected and what use will be made of it? 
The project involves questions where you will be asked to compare between different “profiles” 
(where different levels of the variables are linked to different prescribing practice models), and 
then choose the option that you most prefer for each question. Some of the information 
contained in the profiles may be hypothetical. We will also ask you for some demographic 
details about you and your pharmacy. These details will be used for statistical purposes only. 
Any e-mail addresses that are collected will be removed from the data set and will not be used 
to identify participants. E-mail addresses will only be used to identify and communicate with 
winners of the vouchers offered in this project. All data will be anonymised and cannot be 
linked back to you. 
 
The data collected will be securely stored in such a way that only those on the research team 
will be able to gain access to it. The results of the project may be published and will be 
available in the University of Otago Library (Dunedin, New Zealand). Please be assured that 
every attempt will be made to preserve your anonymity, and you or your workplace will not be 
identified by name in any publications. 
 
At the end of the project any personal information will be destroyed immediately except that, as 
required by the University's research policy, any raw data on which the results of the project 
depend will be retained in secure storage for five years, after which it will be destroyed. 
 
What are the possible benefits of taking part? 
This study will help us understand the importance community pharmacist’s assign to certain 
variables that might encourage them to provide a pharmacist prescribing service in primary 
care. It may help guide workforce and policy development.  
 
Participants who complete the survey and provide their e-mail address are eligible to enter a 
prize draw to win one a $500 New World voucher. 
 
Will my taking part in the study be kept confidential? 
Yes. All the information about your participation in this study will be kept anonymous and 
confidential. Any e-mail addresses that are collected will be removed from the data set and will 
not be used to identify participants. E-mail addresses will only be used to identify and 
communicate with winners of the vouchers offered in this project. All data from the study will 
263 
 
be kept securely locked in a filing cabinet and/or password protected computer file in a 
restricted access part of the research team’s premises. 
 
Can participants change their mind and withdraw from the project? 
Yes. You may withdraw from participating in the project any time during completion of the 
survey without any disadvantage to yourself. However, once you have completed the survey, 
your survey results will not be identifiable and cannot be withdrawn from the data set. 
 
What if participants have any questions? 
If you have any questions about our project, either now or in the future, please feel free to 
contact: 
Dr Alesha Smith 
School of Pharmacy, University of Otago, PO Box 56, Dunedin, 9054 






School of Pharmacy, University of Otago, PO Box 56, Dunedin, 9054 
E-mail: rakhee.raghunandan@postgrad.otago.ac.nz 
 
This study has been approved by the School of Pharmacy Ethics Committee, University of 
Otago. If you have any concerns about the ethical conduct of the research you may contact the 
Committee through the Human Ethics Committee Administrator (ph. 03 479-8256). Any issues 
you raise will be treated in confidence and investigated and you will be informed of the 
outcome. 
 
By completing this survey, I give my consent to participate in this research 
                  Yes 
                  No 
 
 
PROJECT INCLUSION QUESTION: 















Section 1: Choice tasks 
Instructions: 
This is the most important part of the survey. 
This section contains 10 questions that require you to make a choice in each question. In each 
question you will be shown three side-by-side profiles of practice models for providing a 
pharmacist prescribing service in primary care. Each of the three profiles will contain the 
prescribing practice model listed at the top of each alternative and the combination of variables 
(i.e. attributes and attribute levels) for each alternative—see explanatory figure below. Some of 
the variables may be hypothetical. You will need to choose the practice model that you prefer 




The models may appear repetitive, but each one is unique. When making your choice, assume 
that you have sufficient technical support, liability insurance and documentation systems to 
provide these. No model in the side-by-side profile is perfect. Each time you make a choice, you 











These are the definitions for the terms used for the variables in each question. The definitions 
will help ensure that you understand the alternatives that you are choosing between. Please use 
these definitions when you answer the choice task questions. 
1). Prescribing model attribute levels:  
• Independent prescribing: Pharmacist prescriber independently diagnoses and 
prescribes prescription medicines within their area of competence. 
• Collaborative prescribing: Initial diagnosis by GP/authorised prescriber, then 
pharmacist prescriber independently prescribes from a list of specified medicines for 
that condition only. 
• Delegated prescribing: Initial diagnosis and patient treatment plan by GP/authorised 
prescriber, then pharmacist prescriber only prescribes specified medicines within agreed 
patient treatment plan parameters. 
• Minor ailments prescribing: Pharmacist prescriber independently diagnoses, 
prescribes, and dispenses from a specified list of medicines for specified minor ailments 
seen in primary health. 
• Pharmacist only prescribing: Pharmacist prescribes prescription medicines that have 
been re-classified to pharmacist-only and can be prescribed via specified algorithm and 
dispensed by a pharmacist who has completed appropriate training. 
 
2). Education requirement for prescribing attribute levels:  
• Within BPharm: Pharmacist-prescriber training to be included in the future 
undergraduate pharmacy programme. We understand that this could not be an option for 
a currently registered pharmacist but we have included it as we are looking at the 
preference for the education requirement in a broader sense. 
• Accredited learning module: Self-directed and/or workshop learning module with 
assessment, accredited by regulatory organisation e.g. Pharmaceutical Society of NZ. 
The modules are condition/medicine-specific education modules—level of content will 
vary. 
• PGCertPres: Postgraduate certificate in prescribing which consists of 2 x 30 point 
papers that include: Clinical module, Principles of prescribing & prescribing 
practicum—this is a hypothetical option. 
• PGDipPres: Postgraduate diploma that consists of 4 x 30 point papers that include: 
Medicines Information & medicines management, Clinical module, Principles of 
prescribing, Prescribing practicum. This is a hypothetical option and is similar in 
structure to the current education requirements for nurse prescribers in NZ. 
• PGCertPharmPres + PGDipClinPharm: Current pharmacist-prescriber training 
programme which consists of the postgraduate prescribing certificate with current 
prerequisite of the postgraduate diploma in clinical pharmacy. The postgraduate 
prescribing certificate consists of 2 x 30 point papers that include: Principles of 
prescribing, Prescribing practicum. The prerequisite postgraduate diploma in clinical 
pharmacy consists of 4 x 30 point papers and include: Medicines information, 
Medicines management, and 2 more papers (of which both can be Clinical pharmacy 
papers or 1 can be the Pharmaceutical policy paper or equivalent). 
3). Professional service fee attribute: Please note that charging of the professional service fee 








1. Scenario A1 
If these were your only options, which practice model would you choose to provide a 
pharmacist prescribing service? [Assume that you have sufficient technical support, liability 
insurance and documentation systems to provide the pharmacist prescribing service] 
  Pharmacist only 
prescribing    
Independent 
prescribing     
Minor ailments 
prescribing    
Location of prescribing 
service     
Walk in consultation 
at community 
pharmacy     
Appointment at GP 
practice     
Appointment at 
community 
pharmacy    
Education requirement 
for prescribing     
PGDipPres     Accredited learning 
module     
PGCertPres     
Professional service 
fee     
$0 per hour     $50 per hour     $100 per hour     
Change in pharmacist 
prescriber's personal 
income     
Increases by 15%     Increases by 30%     No change in 
income     
 





2. Scenario A2 
If these were your only options, which practice model would you choose to provide a 
pharmacist prescribing service? [Assume that you have sufficient technical support, liability 
insurance and documentation systems to provide the pharmacist prescribing service] 
   Pharmacist only 
prescribing    
Minor ailments 
prescribing    
Collaborative 
prescribing    
Location of prescribing 
service     
Appointment at 
community 
pharmacy     
Appointment at 
community 
pharmacy     
Walk in consultation 
in community 
pharmacy     
Education requirement 
for prescribing     
PGCertPharmPres + 
PGDipClinPharm     
Within BPharm     Accredited learning 
module     
Professional service 
fee     
$0 per hour     $50 per hour     $100 per hour     
Change in pharmacist 
prescriber's personal 
income     
Increases by 30%     No change in 
income     
Increases by 15%     
 







prescribing    
Independent 
prescribing     
Minor ailments 
prescribing    
Pharmacist only 
prescribing    
Minor ailments 
prescribing    
Collaborative 
prescribing    
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3. Scenario A3 
If these were your only options, which practice model would you choose to provide a 
pharmacist prescribing service? [Assume that you have sufficient technical support, liability 
insurance and documentation systems to provide the pharmacist prescribing service] 
  Minor ailments 
prescribing     
Collaborative 
prescribing    
Pharmacist only 
prescribing    
Location of prescribing 
service     
Appointment at 
community 
pharmacy   
Walk in consultation 
at community 
pharmacy   
Walk in consultation 
at community 
pharmacy   
Education requirement 
for prescribing     
Accredited learning 
module     
PGCertPharmPres + 
PGDipClinPharm     
Within BPharm     
Professional service 
fee     
$0 per hour     $100 per hour     $50 per hour     
Change in pharmacist 
prescriber's personal 
income     
Increases by 15%     Increases by 30%     No change in 
income     
 





4. Scenario A4 
If these were your only options, which practice model would you choose to provide a 
pharmacist prescribing service? [Assume that you have sufficient technical support, liability 
insurance and documentation systems to provide the pharmacist prescribing service] 
  Minor ailments 
prescribing    
Pharmacist only 
prescribing    
Collaborative 
prescribing    
Location of prescribing 
service     
Appointment at 
community 
pharmacy     
Walk in consultation 
in community 
pharmacy     
Appointment at GP 
practice     
Education requirement 
for prescribing     
Within BPharm     Accredited learning 
module     
PGDipPres    
Professional service 
fee     
$50 per hour     $0 per hour     $100 per hour     
Change in pharmacist 
prescriber's personal 
income     
Increases by 30%     No change in 
income     
Increases by 15%     
 










prescribing     
Collaborative 
prescribing    
Pharmacist only 
prescribing    
Minor ailments 
prescribing    
Pharmacist only 
prescribing    
Collaborative 
prescribing    
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5. Scenario A5 
If these were your only options, which practice model would you choose to provide a 
pharmacist prescribing service? [Assume that you have sufficient technical support, liability 
insurance and documentation systems to provide the pharmacist prescribing service] 
  Independent 




prescribing    
Location of prescribing 
service     
Appointment at 
community 
pharmacy     
Walk in consultation 
in community 
pharmacy     
Appointment at GP 
practice     
Education requirement 
for prescribing     
PGDipPres     Within BPharm     PGCertPres     
Professional service 
fee     
$50 per hour     $100 per hour     $0 per hour     
Change in pharmacist 
prescriber's personal 
income     
No change in 
income     
Increases by 15%     Increases by 30%     
 
Which of the 3 
alternatives listed 
above you prefer? 
 
 
6. To help us better understand decision making in this questionnaire, can you please briefly 
























7. Scenario A6 
If these were your only options, which practice model would you choose to provide a 
pharmacist prescribing service? [Assume that you have sufficient technical support, liability 
insurance and documentation systems to provide the pharmacist prescribing service] 
  Independent 




prescribing    
Location of prescribing 
service     
Walk in consultation 
in community 
pharmacy     
Appointment at 
community 
pharmacy     
Appointment at GP 
practice     
Education requirement 
for prescribing     
PGCertPres     PGCertPharmPres + 
PGDipClinPharm     
Within BPharm     
Professional service 
fee     
$100 per hour     $0 per hour     $50 per hour     
Change in pharmacist 
prescriber's personal 
income     
No change in 
income     
Increases by 30%     Increases by 15%     
  
Which of the 3 
alternatives listed 
above you prefer? 
 
8. Scenario A7 
If these were your only options, which practice model would you choose to provide a 
pharmacist prescribing service? [Assume that you have sufficient technical support, liability 
insurance and documentation systems to provide the pharmacist prescribing service] 
  Minor ailments 
prescribing     
Collaborative 
prescribing   
Independent 
prescribing   
Location of prescribing 
service     
Walk in consultation 
in community 
pharmacy     
Appointment at 
community 
pharmacy     
Appointment at GP 
practice     
Education requirement 
for prescribing     
PGCertPres     Within BPharm     PGDipPres    
Professional service 
fee     
$50 per hour     $0 per hour     $100 per hour     
Change in pharmacist 
prescriber's personal 
income     
Increases by 15%     No change in 
income     
Increases by 30%     
 












prescribing    
Minor ailments 
prescribing     
Collaborative 
prescribing   
Independent 
prescribing   
270 
 
9. Scenario A8 
If these were your only options, which practice model would you choose to provide a 
pharmacist prescribing service? [Assume that you have sufficient technical support, liability 
insurance and documentation systems to provide the pharmacist prescribing service] 
  Independent 
prescribing 
Collaborative 
prescribing     
Delegated 
prescribing 
Location of prescribing 
service     
Appointment at 
community 
pharmacy     
Appointment at GP 
practice     
Walk in consultation 
at community 
pharmacy     
Education requirement 
for prescribing     
Within BPharm     PGCertPharmPres + 
PGDipClinPharm     
PGCertPres     
Professional service 
fee     
$100 per hour     $0 per hour     $50 per hour     
Change in pharmacist 
prescriber's personal 
income     
Increases by 15%     Increases by 30%     No change in 
income     
 
Which of the 3 
alternatives listed 
above you prefer? 
 
 
10. Scenario A9 
If these were your only options, which practice model would you choose to provide a 
pharmacist prescribing service? [Assume that you have sufficient technical support, liability 
insurance and documentation systems to provide the pharmacist prescribing service] 
  Delegated 
prescribing 
Minor ailments 
prescribing    
Collaborative 
prescribing    
Location of prescribing 
service     
Walk in consultation 
in community 
pharmacy     
Appointment at GP 
practice     
Appointment at 
community 
pharmacy     
Education requirement 
for prescribing     
Accredited learning 
module     
PGDipPres     PGCertPharmPres + 
PGDipClinPharm     
Professional service 
fee     
$50 per hour     $100 per hour     $0 per hour     
Change in pharmacist 
prescriber's personal 
income     
Increases by 30%     No change in 
income     
Increases by 15%     
 
Which of the 3 
alternatives listed 













prescribing    
Collaborative 
prescribing    
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11. Scenario A10 
If these were your only options, which practice model would you choose to provide a 
pharmacist prescribing service? [Assume that you have sufficient technical support, liability 
insurance and documentation systems to provide the pharmacist prescribing service] 
  Independent 
prescribing    
Collaborative 
prescribing    
Delegated 
prescribing    
Location of prescribing 
service     
Appointment at GP 
practice     
Walk in consultation 
at community 
pharmacy     
Appointment at 
community 
pharmacy     
Education requirement 
for prescribing     
PGCertPres    Within BPharm     PGDipPres     
Professional service 
fee     
$100 per hour     $50 per hour     $0 per hour     
Change in pharmacist 
prescriber's personal 
income     
Increases by 15%     No change in 
income     
Increases by 30%     
 
Which of the 3 
alternatives listed 
above you prefer? 
 
12. Please indicate how easy you found it to complete the 10 choice task questions in this 
section: 
 Extremely easy 
 Moderately easy 
 Moderately difficult 












prescribing    
Collaborative 
prescribing    
Delegated 





1. Scenario B1 
If these were your only options, which practice model would you choose to provide a 
pharmacist prescribing service? [Assume that you have sufficient technical support, liability 
insurance and documentation systems to provide the pharmacist prescribing service] 
     Delegated 
prescribing     
Collaborative 
prescribing   
Independent 
prescribing     
Location of prescribing 
service     
Appointment at 
community 
pharmacy     
Appointment at GP 
practice     
Walk in consultation 
in community 
pharmacy     
Education requirement 
for prescribing     
PGCertPharmPres + 
PGDipClinPharm     
PGCertPres     Within BPharm     
Professional service 
fee     
$50 per hour     $0 per hour     $100 per hour     
Change in pharmacist 
prescriber's personal 
income     
Increases by 15%     No change in 
income      
Increases by 30%     
 
Which of the 3 
alternatives listed 
above you prefer? 
 
 
2. Scenario B2 
If these were your only options, which practice model would you choose to provide a 
pharmacist prescribing service? [Assume that you have sufficient technical support, liability 
insurance and documentation systems to provide the pharmacist prescribing service] 
    Collaborative 
prescribing 
Pharmacist only 
prescribing    
Independent 
prescribing     
Location of prescribing 
service     
Appointment at GP 
practice     
Appointment at 
community 
pharmacy     
Walk in consultation 
at community 
pharmacy     
Education requirement 
for prescribing     
PGCertPharmPres + 
PGDipClinPharm     
Accredited learning 
module     
PGDipPres    
Professional service 
fee     
$100 per hour     $50 per hour     $0 per hour     
Change in pharmacist 
prescriber's personal 
income     
No change in 
income     
Increases by 30%     Increases by 15%     
 
Which of the 3 
alternatives listed 




prescribing     
Collaborative 
prescribing   
Independent 




prescribing    
Independent 
prescribing     
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3. Scenario B3 
If these were your only options, which practice model would you choose to provide a 
pharmacist prescribing service? [Assume that you have sufficient technical support, liability 
insurance and documentation systems to provide the pharmacist prescribing service] 
  Minor ailments 
prescribing    
Independent 
prescribing     
Delegated 
prescribing 
Location of prescribing 
service     
Appointment at GP 
practice     
Appointment at 
community 
pharmacy     
Walk in consultation 
in community 
pharmacy     
Education requirement 
for prescribing     
Within BPharm     Accredited learning 
module     
PGCertPres     
Professional service 
fee     
$100 per hour     $50 per hour     $0 per hour     
Change in pharmacist 
prescriber's personal 
income     
Increases by 30%     Increases by 15%     No change in 
income     
 





4. Scenario B4 
If these were your only options, which practice model would you choose to provide a 
pharmacist prescribing service? [Assume that you have sufficient technical support, liability 
insurance and documentation systems to provide the pharmacist prescribing service] 
  Collaborative 




prescribing   
Location of prescribing 
service     
Appointment at GP 
practice     
Walk in consultation 
in community 
pharmacy     
Appointment at 
community 
pharmacy     
Education requirement 
for prescribing     
Within BPharm     PGDipPres    PGCertPharmPres + 
PGDipClinPharm     
Professional service 
fee     
$50 per hour     $0 per hour     $100 per hour     
Change in pharmacist 
prescriber's personal 
income     
Increases by 15%     Increases by 30%     No change in 
income     
 
Which of the 3 
alternatives listed 





prescribing    
Independent 
prescribing     
Delegated prescribing 
Collaborative 




prescribing   
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5. Scenario B5 
If these were your only options, which practice model would you choose to provide a 
pharmacist prescribing service? [Assume that you have sufficient technical support, liability 
insurance and documentation systems to provide the pharmacist prescribing service] 
  Delegated 
prescribing 
Minor ailments 
prescribing     
Pharmacist only 
prescribing     
Location of prescribing 
service     
Appointment at GP 
practice     
Walk in consultation 
in community 
pharmacy     
Appointment at 
community 
pharmacy     
Education requirement 
for prescribing     
PGCertPres    PGCertPharmPres + 
PGDipClinPharm     
PGDipPres     
Professional service 
fee     
$0 per hour     $100 per hour     $50 per hour     
Change in pharmacist 
prescriber's personal 
income     
Increases by 15%     Increases by 30%     No change in 
income     
 
Which of the 3 
alternatives listed 
above you prefer? 
 
 
6. To help us better understand decision making in this questionnaire, can you please briefly 






























prescribing     
Pharmacist only 




7. Scenario B6 
If these were your only options, which practice model would you choose to provide a 
pharmacist prescribing service? [Assume that you have sufficient technical support, liability 
insurance and documentation systems to provide the pharmacist prescribing service] 
  Collaborative 
prescribing    
Pharmacist only 
prescribing     
Minor ailments 
prescribing    
Location of prescribing 
service     
Appointment at 
community 
pharmacy     
Appointment at 
community 
pharmacy     
Walk in consultation 
in community 
pharmacy     
Education requirement 
for prescribing     
Accredited learning 
module     
Within BPharm     PGCertPharmPres + 
PGDipClinPharm     
Professional service 
fee     
$100 per hour     $0 per hour     $50 per hour     
Change in pharmacist 
prescriber's personal 
income     
No change in 
income     
Increases by 30%     Increases by 15%     
 
Which of the 3 
alternatives listed 
above you prefer? 
 
 
8. Scenario B7 
If these were your only options, which practice model would you choose to provide a 
pharmacist prescribing service? [Assume that you have sufficient technical support, liability 
insurance and documentation systems to provide the pharmacist prescribing service] 
  Pharmacist only 




prescribing    
Location of prescribing 
service     
Appointment at 
community 
pharmacy     
Appointment at 
community 
pharmacy     




for prescribing     
PGCertPres    PGCertPharmPres + 
PGDipClinPharm     
PGDipPres     
Professional service 
fee     
$0 per hour     $100 per hour     $50 per hour     
Change in pharmacist 
prescriber's personal 
income     
Increases by 15%     No change in 
income     
Increases by 30%     
 
Which of the 3 
alternatives listed 





prescribing    
Pharmacist only 
prescribing     
Minor ailments 
prescribing    
Pharmacist only 
prescribing     
Delegated prescribing Minor ailments 
prescribing    
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9. Scenario B8 
If these were your only options, which practice model would you choose to provide a 
pharmacist prescribing service? [Assume that you have sufficient technical support, liability 
insurance and documentation systems to provide the pharmacist prescribing service] 
  Collaborative 
prescribing    
Pharmacist only 
prescribing    
Independent 
prescribing     
Location of prescribing 
service     
Appointment at 
community 
pharmacy     
Walk in consultation 
in community 
pharmacy     
Appointment at GP 
practice     
Education requirement 
for prescribing     
PGCertPharmPres + 
PGDipClinPharm     
PGCertPres    Accredited learning 
module     
Professional service 
fee     
$50 per hour     $100 per hour     $0 per hour     
Change in pharmacist 
prescriber's personal 
income     
No change in 
income     
Increases by 30%     Increases by 15%     
 





10. Scenario B9 
If these were your only options, which practice model would you choose to provide a 
pharmacist prescribing service? [Assume that you have sufficient technical support, liability 
insurance and documentation systems to provide the pharmacist prescribing service] 
  Delegated 
prescribing 
Independent 
prescribing     
Pharmacist only 
prescribing    
Location of prescribing 
service     
Walk in consultation 
at community 
pharmacy     
Appointment at GP 
practice     
Appointment at 
community 
pharmacy     
Education requirement 
for prescribing     
PGDipPres    PGCertPharmPres + 
PGDipClinPharm     
Within BPharm     
Professional service 
fee     
$0 per hour     $50 per hour     $100 per hour     
Change in pharmacist 
prescriber's personal 
income     
No change in 
income     
Increases by 15%     Increases by 30%     
 
Which of the 3 
alternatives listed 





prescribing    
Pharmacist only 
prescribing    
Independent 




prescribing     
Pharmacist only 
prescribing    
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11. Scenario B10 
If these were your only options, which practice model would you choose to provide a 
pharmacist prescribing service? [Assume that you have sufficient technical support, liability 
insurance and documentation systems to provide the pharmacist prescribing service] 
  Pharmacist only 
prescribing    
Collaborative 
prescribing    
Minor ailments 
prescribing    
Location of prescribing 
service     
Walk in consultation 
in community 
pharmacy     
Appointment at 
community 
pharmacy     
Appointment at GP 
practice     
Education requirement 
for prescribing     
PGCertPharmPres + 
PGDipClinPharm     
PGDipPres    Within BPharm     
Professional service 
fee     
$50 per hour     $100 per hour     $0 per hour     
Change in pharmacist 
prescriber's personal 
income     
Increases by 30%     No change in 
income     
Increases by 15%     
 
Which of the 3 
alternatives listed 
above you prefer? 
 
12. Please indicate how easy you found it to complete the 10 choice task questions in this 
section 
 Extremely easy 
 Moderately easy 
 Moderately difficult 












prescribing    
Collaborative 
prescribing    
Minor ailments 





1. Scenario C1 
If these were your only options, which practice model would you choose to provide a 
pharmacist prescribing service? [Assume that you have sufficient technical support, liability 
insurance and documentation systems to provide the pharmacist prescribing service] 
  Pharmacist only 
prescribing 
Independent 
prescribing     
Delegated 
prescribing 
Location of prescribing 
service     
Appointment at 
community 
pharmacy     
Walk in consultation 
at community 
pharmacy     
Appointment at GP 
practice     
Education requirement 
for prescribing     
PGDipPres     PGCertPres    Accredited learning 
module     
Professional service 
fee     
$50 per hour     $0 per hour     $100 per hour     
Change in pharmacist 
prescriber's personal 
income     
No change in 
income     
Increases by 15%     Increases by 30%     
 
Which of the 3 
alternatives listed 
above you prefer? 
 
 
2. Scenario C2 
If these were your only options, which practice model would you choose to provide a 
pharmacist prescribing service? [Assume that you have sufficient technical support, liability 
insurance and documentation systems to provide the pharmacist prescribing service] 
  Pharmacist only 
prescribing    
Minor ailments 
prescribing    
Collaborative 
prescribing  
Location of prescribing 
service     
Walk in consultation 
in community 
pharmacy     
Appointment at GP 
practice     
Appointment at 
community 
pharmacy     
Education requirement 
for prescribing     
PGCertPharmPres + 
PGDipClinPharm     
PGDipPres    Accredited learning 
module     
Professional service 
fee     
$100 per hour     $50 per hour     $0 per hour     
Change in pharmacist 
prescriber's personal 
income     
Increases by 15%     No change in 
income     
Increases by 30%     
 
Which of the 3 
alternatives listed 












prescribing    
Minor ailments 





3. Scenario C3 
If these were your only options, which practice model would you choose to provide a 
pharmacist prescribing service? [Assume that you have sufficient technical support, liability 
insurance and documentation systems to provide the pharmacist prescribing service] 
    Minor ailments 
prescribing  
Independent 
prescribing     
Delegated 
prescribing 
Location of prescribing 
service     
Appointment at GP 
practice     
Walk in consultation 
in community 
pharmacy     
Appointment at 
community 
pharmacy     
Education requirement 
for prescribing     
Accredited learning 
module     
PGCertPres    Within BPharm     
Professional service 
fee     
$0 per hour     $50 per hour     $100 per hour     
Change in pharmacist 
prescriber's personal 
income     
No change in 
income     
Increases by 30%     Increases by 15%     
 
Which of the 3 
alternatives listed 
above you prefer? 
 
 
4. Scenario C4 
If these were your only options, which practice model would you choose to provide a 
pharmacist prescribing service? [Assume that you have sufficient technical support, liability 
insurance and documentation systems to provide the pharmacist prescribing service] 
  Collaborative 
prescribing     
Delegated 
prescribing    
Pharmacist only 
prescribing    
Location of prescribing 
service     
Walk in consultation 
at community 
pharmacy     
Appointment at GP 
practice     
Appointment at 
community 
pharmacy     
Education requirement 
for prescribing     
PGDipPres     Within BPharm     Accredited learning 
module     
Professional service 
fee     
$0 per hour     $50 per hour     $100 per hour     
Change in pharmacist 
prescriber's personal 
income     
Increases by 30%     Increases by 15%     No change in 
income     
 
Which of the 3 
alternatives listed 











prescribing     
Delegated 
prescribing    
Pharmacist only 
prescribing    
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5. Scenario C5 
If these were your only options, which practice model would you choose to provide a 
pharmacist prescribing service? [Assume that you have sufficient technical support, liability 
insurance and documentation systems to provide the pharmacist prescribing service] 
  Independent 
prescribing   
Pharmacist only 
prescribing    
Delegated 
prescribing 
Location of prescribing 
service     
Walk in consultation 
in community 
pharmacy     
Appointment at 
community 
pharmacy     
Appointment at GP 
practice     
Education requirement 
for prescribing     
Within BPharm     PGDipPres     Accredited learning 
module     
Professional service 
fee     
$0 per hour     $100 per hour     $50 per hour     
Change in pharmacist 
prescriber's personal 
income     
Increases by 30%     Increases by 15%     No change in 
income     
 
Which of the 3 
alternatives listed 
above you prefer? 
 
 
6. To help us better understand decision making in this questionnaire, can you please briefly 




























prescribing   
Pharmacist only 





7. Scenario C6 
If these were your only options, which practice model would you choose to provide a 
pharmacist prescribing service? [Assume that you have sufficient technical support, liability 
insurance and documentation systems to provide the pharmacist prescribing service] 
  Collaborative 
prescribing 
Pharmacist only 
prescribing    
Independent 
prescribing     
Location of prescribing 
service     
Walk in consultation 
in community 
pharmacy     
Walk in consultation 
in community 
pharmacy     
Appointment at 
community 
pharmacy     
Education requirement 
for prescribing     
Within BPharm     Accredited learning 
module     
PGCertPres    
Professional service 
fee     
$0 per hour     $100 per hour     $50 per hour     
Change in pharmacist 
prescriber's personal 
income     
No change in 
income     
Increases by 15%     Increases by 30%     
 
Which of the 3 
alternatives listed 
above you prefer? 
 
 
8. Scenario C7 
If these were your only options, which practice model would you choose to provide a 
pharmacist prescribing service? [Assume that you have sufficient technical support, liability 
insurance and documentation systems to provide the pharmacist prescribing service] 
  Delegated 
prescribing 
Independent 
prescribing     
Pharmacist only 
prescribing   
Location of prescribing 
service     




pharmacy     
Walk in consultation 
in community 
pharmacy     
Education requirement 
for prescribing     
PGDipPres    PGCertPres    PGCertPharmPres + 
PGDipClinPharm     
Professional service 
fee     
$50 per hour     $100 per hour     $0 per hour     
Change in pharmacist 
prescriber's personal 
income     
Increases by 30%     No change in 
income     
Increases by 15%     
 
Which of the 3 
alternatives listed 







prescribing    
Independent 




prescribing     
Pharmacist only 
prescribing   
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9. Scenario C8 
If these were your only options, which practice model would you choose to provide a 
pharmacist prescribing service? [Assume that you have sufficient technical support, liability 
insurance and documentation systems to provide the pharmacist prescribing service] 
  Minor ailments 





Location of prescribing 
service     
Walk in consultation 
in community 
pharmacy     
Appointment at GP 
practice     
Appointment at 
community 
pharmacy     
Education requirement 
for prescribing     
Accredited learning 
module     
PGCertPres     PGCertPharmPres + 
PGDipClinPharm     
Professional service 
fee     
$100 per hour     $50 per hour     $0 per hour     
Change in pharmacist 
prescriber's personal 
income     
No change in 
income     
Increases by 15%     Increases by 30%     
 
Which of the 3 
alternatives listed 
above you prefer? 
 
 
10. Scenario C9 
If these were your only options, which practice model would you choose to provide a 
pharmacist prescribing service? [Assume that you have sufficient technical support, liability 
insurance and documentation systems to provide the pharmacist prescribing service] 
  Delegated 
prescribing     
Minor ailments 
prescribing    
Pharmacist only 
prescribing 
Location of prescribing 
service     
Appointment at 
community 
pharmacy     
Walk in consultation 
in community 
pharmacy     
Walk in consultation 
in community 
pharmacy     
Education requirement 
for prescribing     
PGCertPres     Accredited learning 
module     
PGCertPharmPres + 
PGDipClinPharm     
Professional service 
fee     
$100 per hour     $0 per hour     $50 per hour     
Change in pharmacist 
prescriber's personal 
income     
Increases by 30%     Increases by 15%     No change in 
income     
 
Which of the 3 
alternatives listed 





prescribing    
Delegated prescribing Independent 
prescribing  
Delegated 
prescribing     
Minor ailments 





11. Scenario C10  
If these were your only options, which practice model would you choose to provide a 
pharmacist prescribing service? [Assume that you have sufficient technical support, liability 
insurance and documentation systems to provide the pharmacist prescribing service] 
  Independent 
prescribing     
Minor ailments 
prescribing    
Collaborative 
prescribing     
Location of prescribing 
service     
Appointment at GP 
practice     
Appointment at 
community 
pharmacy     
Walk in consultation 
at community 
pharmacy     
Education requirement 
for prescribing     
Accredited learning 
module     
PGDipPres     PGCertPres     
Professional service 
fee     
$100 per hour     $0 per hour     $50 per hour     
Change in pharmacist 
prescriber's personal 
income     
Increases by 30%     Increases by 15%     No change in 
income     
 
Which of the 3 
alternatives listed 
above you prefer? 
 
12. Please indicate how easy you found it to complete the 10 choice task questions in this 
section 
 Extremely easy 
 Moderately easy 
 Moderately difficult 












prescribing     
Minor ailments 
prescribing    
Collaborative 
prescribing     
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Section 2: Attribute-related questions: 
13. Please rank the attributes (i.e. each row) below in order of their importance to you when you 
were deciding which alternatives to choose in the 10 choice tasks, with 1 being most 
important to 5 being least important.  
Please circle one rank option per attribute row and do not assign the same rank to 
more than one row below.  
 
1 2 3 4 5 
 Pharmacist prescribing model  
              (e.g. collaborative prescribing etc.)       
 
 Location of pharmacist prescribing service      
 Education requirement for prescribing       
Professional service fee charge        
Change in pharmacist prescriber’s income      
 
14. Did you ignore any of the 5 attributes listed above when choosing between the alternatives 
in the 10 choice tasks in the previous section? 


































15. Please rank the pharmacist prescribing models below in order from 1 (most preferred) to 5 
(least preferred) 
Please circle one rank option per attribute row and do not assign the same rank to 
more than one row below. 
 
1 2 3 4 5 
 Pharmacist only prescribing        
 Minor ailments prescribing        
 Delegated prescribing         
 Collaborative prescribing        
 Independent prescribing         
 
16. Please briefly explain why you ranked the pharmacist prescribing model selected in 
















17. Please briefly explain why you ranked the pharmacist prescribing model selected in 












Section 3: Sociodemographic questions 
18. What is your age (in years)? 
 
 




20. Please indicate your ethnicity (please select only one option) 




Middle Eastern/Latin American/African 
Other 
 
21. What is your highest level of pharmacy education? 
 BPharm 
 Diploma from CIT 
 PharmD  
 PGCertPharm 
PGDipClinPharm 
PGCertPharmPres/PGCertClinPharm in Prescribing 
MClinPharm/MPharm 
PhD 







22. What extra qualifications do you have to provide added pharmacist services? (Please tick all 
that apply to you) 
Community Pharmacy Anticoagulation Monitoring Service (CPAMS) 
Pharmacist vaccinator 
Pharmacist-only medicines that require completion of authorised training modules (e.g. 
emergency contraceptive pill, trimethoprim, sildenafil, etc.) 
Medicines Use Review (MUR) 
Medicines Therapy Assessment (MTA) 
Pharmacist prescriber (PGCertPharmPres/PGCertClinPharm in Prescribing) 










24. What is your current employment status in your primary pharmacy practice location (i.e. 
where you spend most of your time)?  
Please note that the employee category includes locum pharmacists. 
 Pharmacy owner of independent store 
 Pharmacy owner of a banner store 
 Employee pharmacist in independent store 
 Employee pharmacist in banner store 
 
25. Select what type of employment applies to you 
 Full time (≥ 37.5 hours/week) 






26. How many staff do you have working during a usual shift at your usual pharmacy practice 
location (type "0" if none apply)? 
 Number of pharmacists 
 Number of pharmacy technicians 
 Number of pharmacy assistants 
 Number of other staff 
 
27. What area is your pharmacy located in? 
Please select only one option. 
Major city (urban area with population > 50 000 people e.g. Auckland, Wellington, 
Christchurch, Dunedin, Hamilton, etc.)        
Provincial city (urban area with population > 30 000 people e.g. Nelson, New 
Plymouth, Napier, Gisborne etc.)  
Provincial town (urban area with a population between 1 000 and 30 000 people e.g. 
Levin, Gore, etc.) 
Rural (non-urban areas such as rural centres with population under 1 000 people)     
 
28. Which district health board (DHB) does your pharmacy fall under: 
Auckland DHB 
Bay of Plenty DHB 
Canterbury DHB 
Capital and Coast DHB 
Counties Manukau DHB 
Hawkes Bay DHB 
Hutt Valley DHB 
Lakes DHB 

















West Coast DHB 
 
29. On average how many prescription items does your pharmacy dispense per day? 
 < 100 
 100 – 200 
 201 – 300 
 301 – 400 
 401 – 500 
>500 
 Don’t know 
 
30. What are the demographics of the people who access services in your usual pharmacy 
practice location (please select all that apply)? 
 Chronic conditions 
 Elderly patients in their own homes 
 Elderly residential care facilities 
              Other residential care facilities 
 Low socioeconomic status 
 Young families 








31. Currently, how satisfied are you with your job overall? 
 Extremely satisfied 
 Somewhat satisfied 
 Somewhat dissatisfied 
 Extremely dissatisfied 
 
32. If you would like to go into the draw for one $500 New World voucher, please provide your 
e-mail address below. 
Please note that your e-mail address will only be used for purposes of the prize draw and 







We thank you for your time spent taking this survey. 
Your response has been recorded. 






Appendix 6: Ethics approval for Project 4—Identifying NZ public 
preferences for pharmacist prescribers in primary care—a 














Appendix 7: Online Supplementary File 3—Word version of NZ 
public DCE questionnaire 
Journal name: The Patient – Patient Centered Outcomes Research 
Article title: Identifying New Zealand public preferences for pharmacist 
prescribers in primary care—a discrete choice experiment 
Author names: Rakhee Raghunandan, Kirsten Howard, Carlo A Marra, June 
Tordoff, Alesha Smith  
Corresponding author: Rakhee Raghunandan; School of Pharmacy, University of 
Otago, Dunedin, New Zealand; rakhee.raghunandan@postgrad.otago.ac.nz  
 
 






Identifying patient preferences for pharmacist prescribers in primary care in NZ: a discrete choice 
experiment 
 
INFORMATION SHEET FOR  
PARTICIPANTS 
Thank you for showing an interest in this project. This participant information sheet contains detailed 
information about the research project. Its purpose is to explain to you as clearly as possible what the 
project involves before you decide whether to take part in it or not. 
Please read this sheet carefully before deciding whether to participate. If you decide to participate, we 
thank you. If you decide not to take part there will be no disadvantage to you and we thank you for 
considering our request. 
 
What is the aim of the project? 
You are invited to take part in a project being undertaken by Rakhee Raghunandan, a PhD candidate at 
the School of Pharmacy, University of Otago, as part of the requirements for her PhD. The purpose of the 
project is to better understand patient preferences for certain variables (e.g. location, cost, and operation 
hours of a prescribing service, the health professional that provides the prescribing service, etc.) that 
would encourage them to use a prescribing service (e.g. GPs, pharmacist prescribers, registered nurse 
prescribers) in primary care in New Zealand. 
 
Who is conducting the research? 
A research team based at the School of Pharmacy, University of Otago will be conducting the study. The 
research team consists of the PhD candidate (Rakhee Raghunandan) and her supervisors (Dr Alesha 
Smith, Associate Professor June Tordoff and Professor Carlo Marra).  
 
What type of participants are being sought? 
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We are inviting people from the New Zealand general public, who are 18 years old and over, to 
participate in this project. 
 
What participants will be asked to do? 
Should you agree to take part, you will be asked to complete a 15 minute online survey, which will help 
us identify your preferences for these variables. Completing the survey will imply consent to participate 
in the project. 
Do I have to take part? 
No, you may decide not to take part in this project without any disadvantage to yourself. It is up to you to 
decide whether or not to take part. If you do not wish to take part, you may discard this survey now. 
 
What data or information will be collected and what use will be made of it? 
The project involves a set of choices questions where you will be asked to compare between different 
“profiles” of prescribers (e.g. GPs, pharmacist prescribers, registered nurse prescribers). The profiles will 
contain different combinations of the variables that are linked to their prescribing service, and then you 
choose the option that you most prefer for each choice question. Some of the information contained in the 
profiles may be hypothetical.  
This questionnaire will also collect a variety of data including information that relates to: 
• your views on GP prescribers, pharmacist prescribers and registered nurse prescribers;  
• how you access your GP services; 
• what services you access from you community pharmacy; 
• what we can do to improve the questionnaire.  
We will also ask you for some sociodemographic details about yourself. These details will be used for 
statistical purposes only.  
All collected data will be anonymous and cannot be linked back to you. No material that could personally 
identify you will be used in any reports on this study.  The results of the project may be published and 
will be available in the University of Otago Library (Dunedin, New Zealand), and every attempt will be 
made to preserve your anonymity. 
 
Data obtained as a result of the research will be securely stored by the research team and retained for at 
least 5 years, as required by the University's research policy, after which it will be destroyed. 
 
What are the possible benefits of taking part? 
This study will help us understand the importance patients assign to certain variables that might 
encourage them to use a prescribing service in primary care. It may help to develop prescribing services 
that allow better use of health professionals who can prescribe prescription medicines, thereby ensuring 
that NZ patients have efficient access to their medicines.  
 
Will my taking part in the study be kept confidential? 
Yes. All the information about your participation in this study will be kept anonymous and confidential. 
All data from the study will be kept securely locked in a filing cabinet and/or password protected 
computer file in a restricted access part of the research team’s premises. 
 
Can participants change their mind and withdraw from the project? 
Yes. You may withdraw from participating in the project any time during completion of the survey 
without any disadvantage to yourself. However, once you have completed the survey, your survey results 
will not be identifiable and cannot be withdrawn from the data set. 
 
What if participants have any questions? 
If you have any questions about our project, please feel free to contact: 
Dr Alesha Smith 
School of Pharmacy, University of Otago, PO Box 56, Dunedin, 9054 








School of Pharmacy, University of Otago, PO Box 56, Dunedin, 9054 
E-mail: rakhee.raghunandan@postgrad.otago.ac.nz  
 
This study has been approved by the Human Ethics Committee, University of Otago (Reference 
D19/019). If you have any concerns about the ethical conduct of the research you may contact the 
Committee through the Human Ethics Committee Administrator (ph. 03 479-8256). Any issues you raise 

























***Please read this as it will help you understand and answer the questions in this questionnaire to the 
best of your ability*** 
Before starting this questionnaire, it would be useful to provide you with background information about 
the three prescribing NZ health professionals we want to include in our questionnaire, i.e. general 
practitioner prescribers (GP prescribers), pharmacist prescribers, and registered nurse prescribers. 
Most people are not aware that in NZ we have prescribing health professionals known as pharmacist 
prescribers, and registered nurse prescribers.  
• Pharmacist prescribers and registered nurse prescribers are different from usual pharmacists and 
registered nurses.  
• Pharmacist prescribers and registered nurse prescribers are qualified pharmacists and registered 
nurses in NZ, who have completed additional postgraduate training in their specialist areas, to 
be able to prescribe some prescription medicines that your GP prescribes for you.  
• Generally GP prescribers can prescribe almost all prescription medicines, while pharmacist 
prescribers and registered nurse prescribers can only prescribe specific prescription medicines 
from an approved list and these medicines must relate to their scope of practice (e.g. heart 
health, asthma, diabetes, kidney disease etc.).  
• During a consultation with a pharmacist prescriber or a registered nurse prescriber, they will 
assess your condition, decide if and how your medicines need adjusting, and then write and sign 



















Section 1: Screening questions: 





Q2). Please indicate the gender that you identify with 
 Male 
 Female 




(Please note: you do not have to specify any information here if you are not comfortable with 
this). 
 
Q3). Please indicate the ethnicity that you mainly identify with (please select only one option) 




Middle Eastern/Latin American/African 








Section 2: Cost variable reference question: 
Q4). What is the usual cost (to the nearest dollar) of your GP consultation? 
Please note: The cost value entered cannot be a zero value. If your usual GP consultation is free, 



















Section 3: Choice questions  
Instructions: 
 
How to answer the choice questions in this section: 
 
We ask you to IMAGINE the scenario where you have had a particular health problem for some time 
i.e. hypertension (high blood pressure), and you need to see a prescriber who can assess your current 
health condition, decide if and how your medicines need adjusting, and then write and sign your 
prescription for your medicines.  
 
You then have 5 choice questions to answer. 
 
For each choice question you are offered 3 different options (shown side-by-side) for your 
consultation, which vary according to: 
• Who you see 
• Location of consultation 
• How long you have to wait for the next available consultation 
• Cost of the consultation 
• Type of service your consultation covers 
• Type of consultation 
• Prescribing service operating hours 
 
We then ask that you choose which of the 3 options you MOST PREFER for each choice question, 
even if none seem ideal. There is no right or wrong answer—this is only your personal opinion. Each 
time you make a choice, you will have to make trade-offs. Some of the variables in the questions may 
not exist yet. The 5 choice questions may appear repetitive, but each one is unique.  
 
We also ask you to make the following assumptions when making your choice: 
• All the prescribers listed in the 3 options have completed all the clinical and legal training 
requirements to provide the prescribing service (i.e. they can write and sign the prescription for 
your required high blood pressure medicines).  
• All the prescribers listed in the 3 options have appropriate access to your medical records to make 
clinical decisions.  
• The prescriber will assess your current health condition, and may perform some screening and/or 
request additional laboratory testing as required. 
• You will see a GP prescriber for a review of your condition at least once a year. 
• The $5 per prescription item charge that you pay when your medicines are dispensed at the 
pharmacy is a separate charge. It is not included in any costs within this questionnaire. 
 
 
The next part of this section contains: 
− 1 example question with an explanation,  
− 1 practice question where you make a choice, and  


















Example Choice Question: 
 
Here is an example with the health scenario displayed first.  
This is followed by the example choice question, which shows 3 consultation options with the 3 
different prescribers displayed side-by-side.  
The example choice question also shows which box has been ticked.  
We then include an explanation for the choice made (i.e. the box that was ticked in the example).  
As this is an example question, you do not have to tick a box for this question only. 
 
HEALTH SCENARIO: 
IMAGINE you have had hypertension (i.e. high blood pressure) for some time and you need to 
see a prescriber who can assess your current health condition, decide if and how your medicines 
need adjusting, and then write and sign your prescription for your medicines. 
 
IF these were the only options available at the time, which option would you choose for each 
choice question? 
 
Make the following assumptions when making your choice: 
• All the prescribers listed in the 3 options have completed all the clinical and legal training 
requirements to provide the prescribing service (i.e. they can write and sign the prescription for 
your required high blood pressure medicines).  
• All the prescribers listed in the 3 options have appropriate access to your medical records to make 
clinical decisions.  
• The prescriber will assess your current health condition, and may perform screening and/or 
request additional laboratory testing as required. 
• You will see a GP prescriber for a review of your condition at least once a year. 
• The $5 per prescription item charge that you pay when your medicines are dispensed at a 


































EXAMPLE CHOICE QUESTION: 
 Pharmacist 
prescriber 
GP prescriber Registered Nurse 
prescriber 
Location of consultation At community 
pharmacy 
At GP practice At GP practice 
Next available 
consultation is 
Within 1 day from 
now 
7 days from now 5 days from now 
Cost of the consultation $24 $20 $16 
Type of service your 
consultation covers 
• Assessment of 
health 
condition. 









dose changes as 





• Assessment of 
















• Assessment of 
health condition. 








Type of consultation Walk-in and wait 
clinic 
By appointment Walk-in and wait clinic 
Prescribing service 
operating hours 
16 hours a day (e.g. 
7am-11pm) 
8 hours a day (e.g. 
9am—5pm) 
8 hours a day (e.g. 
9am—5pm) 
Which option would you 
choose?  
Tick one box only 




Explanation of the choice made above: In the above example, the person ticked the box for the first 
option, to show they most preferred to see a: 
• pharmacist prescriber  
• within 1 day from now  
• at a walk-in and wait clinic  
• in a community pharmacy  
• that is open for 16 hours a day  
• to get their updated prescription that included only dose changes to their current medicines 















IMAGINE you have had hypertension (i.e. high blood pressure) for some time and you need to 
see a prescriber who can assess your current health condition, decide if and how your medicines 
need adjusting, and then write and sign your prescription for your medicines. 
 
IF these were the only options available at the time, which option would you choose for each 
choice question? 
 
Make the following assumptions when making your choice: 
• All the prescribers listed in the 3 options have completed all the clinical and legal training 
requirements to provide the prescribing service (i.e. they can write and sign the prescription for 
your required high blood pressure medicines).  
• All the prescribers listed in the 3 options have appropriate access to your medical records to make 
clinical decisions.  
• The prescriber will assess your current health condition, and may perform screening and/or 
request additional laboratory testing as required. 
• You will see a GP prescriber for a review of your condition at least once a year. 
• The $5 per prescription item charge that you pay when your medicines are dispensed at a 




PRACTICE CHOICE QUESTION: 




Location of consultation At GP practice At community 
pharmacy  
At GP practice 
Next available consultation 
is 
Within 1 day from 
now  
3 days from now 5 days from now 
Cost of the consultation $16 $20 $20 
Type of service your 
consultation covers 
• Assessment of 









changing doses of 
current medicines, 
stopping a current 
medicine, starting 
new medicines. 










changing doses of 
current medicines, 
stopping a current 
medicine, starting 
new medicines. 
• Assessment of 
health 
condition. 













24 hours a day Open 16 hours a day 
(e.g. 7am-11pm) 
8 hours a day (e.g. 
9am—5pm) 
Which option would you 
choose?  
Tick one box only 
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Choice questions—BLOCK A: 
Choice Questions for this questionnaire: 
 
Please consider the health scenario listed below and answer the 5 choice questions that follow by ticking 




IMAGINE you have had hypertension (i.e. high blood pressure) for some time and you need to 
see a prescriber who can assess your current health condition, decide if and how your medicines 
need adjusting, and then write and sign your prescription for your medicines. 
 
IF these were the only options available at the time, which option would you choose for each 
choice question? 
 
Make the following assumptions when making your choice: 
• All the prescribers listed in the 3 options have completed all the clinical and legal training 
requirements to provide the prescribing service (i.e. they can write and sign the prescription for 
your required high blood pressure medicines).  
• All the prescribers listed in the 3 options have appropriate access to your medical records to make 
clinical decisions.  
• The prescriber will assess your current health condition, and may perform screening and/or 
request additional laboratory testing as required. 
• You will see a GP prescriber for a review of your condition at least once a year. 
• The $5 per prescription item charge that you pay when your medicines are dispensed at a 






































Choice question A1: 
 GP prescriber  Registered Nurse 
prescriber 
Pharmacist prescriber 




7 days from now 3 days from now 5 days from now 
Cost of the consultation usual GP cost plus 
20% 
usual GP cost minus 
20% 
usual GP cost minus 
20% 
Type of service your 
consultation covers 
• Assessment of 
health 
condition. 









dose changes as 





• Assessment of 
health 
condition.  









• Assessment of 
health condition.  




• Issue repeat 
prescription for 
current medicines. 
Type of consultation By appointment  Walk-in and wait 
clinic 
 Walk-in and wait clinic 
Prescribing service 
operating hours 
Open 16 hours a day 
(e.g. 7am-11pm) 
Open 24 hours day Open 8 hours a day 
(e.g. 9am-5pm)  
Which option would you 
choose? 
 Tick one box only 






























Choice question A2: 
 GP prescriber  Registered Nurse 
prescriber 
Pharmacist prescriber 
Location of consultation At GP practice At community 
pharmacy 
At GP practice 
Next available 
consultation is 
7 days from now 3 days from now Within 1 day from now 
Cost of the consultation usual GP cost minus 
20% 
usual GP cost plus 
20%  
usual GP cost minus 
20% 
Type of service your 
consultation covers 










































• Assessment of 
health condition.  




• Issue prescription 
for current 
medicines with 
dose changes as 
needed, but no 
stoppages or 
additions to current 
medicines. 
Type of consultation By appointment By appointment  Walk-in and wait clinic 
Prescribing service 
operating hours 
Open 8 hours a day 
(e.g. 9am-5pm)  
Open 16 hours a day 
(e.g. 7am-11pm) 
Open 24 hours day 
Which option would you 
choose?  
Tick one box only 




























Choice question A3: 




Location of consultation At GP practice At community 
pharmacy 
At GP practice 
Next available consultation 
is 
5 days from now Within 1 day from 
now 
7 days from now 
Cost of the consultation usual GP cost 
minus 100% 
usual GP cost minus 
20% 
usual GP cost plus 
20%  
Type of service your 
consultation covers 
•  Assessment of 
health 
condition. 














this consultation.  




changing doses of 
current 
medicines, 
stopping a current 
medicine, starting 
new medicines. 
• Assessment of 
health condition.  




• Issue prescription 
for current 
medicines with 
dose changes as 










Open 16 hours a 
day (e.g. 7am-
11pm) 
Open 8 hours a day 
(e.g. 9am-5pm)  
Open 24 hours day 
Which option would you 
choose?  
Tick one box only 































Choice question A4: 
 GP prescriber  Registered Nurse 
prescriber 
Pharmacist prescriber 
Location of consultation At GP practice At community 
pharmacy 
At GP practice 
Next available 
consultation is 
Within 1 day from 
now 
5 days from now 7 days from now 
Cost of the consultation same as usual GP 
cost 
usual GP cost minus 
100% 
usual GP cost minus 
100% 
Type of service your 
consultation covers 
• Assessment of 
health 
condition. 






























• Assessment of 
health condition. 




• Issue prescription 
for current 
medicines with 
dose changes as 
needed, but no 
stoppages or 
additions to current 
medicines. 
Type of consultation  Walk-in and wait 
clinic 
By appointment  Walk-in and wait clinic 
Prescribing service 
operating hours 
Open 8 hours a day 
(e.g. 9am-5pm)  
Open 24 hours day Open 16 hours a day 
(e.g. 7am-11pm) 
Which option would you 
choose?  
Tick one box only 



























Choice question A5: 








Within 1 day from 
now 
3 days from now 7 days from now 
Cost of the consultation usual GP cost plus 
20%  
usual GP cost minus 
100% 
same as usual GP 
cost 
Type of service your 
consultation covers 





this consultation.  




changing doses of 
current 
medicines, 
stopping a current 
medicine, starting 
new medicines. 
• Assessment of 
health condition. 




• Issue prescription 
for current 
medicines with dose 
changes as needed, 
but no stoppages or 
additions to current 
medicines. 














as needed, but 
no stoppages 
or additions to 
current 
medicines. 




Open 16 hours a day 
(e.g. 7am-11pm) 
Open 24 hours day Open 8 hours a day 
(e.g. 9am-5pm)  
Which option would you 
choose?  
Tick one box only 
   
 
Q11.A6). To help us better understand decision making in this questionnaire, can you please briefly 
explain why and how you made your choice in choice question A5 above? 
You can see what you chose for choice question 5 by clicking on the “prev” button and then the “next” 











Choice questions—BLOCK B: 
Choice Questions for this questionnaire: 
 
Please consider the health scenario listed below and answer the 5 choice questions that follow by ticking 
the option you most prefer for each choice question: 
 
HEALTH SCENARIO: 
IMAGINE you have had hypertension (i.e. high blood pressure) for some time and you need to 
see a prescriber who can assess your current health condition, decide if and how your medicines 
need adjusting, and then write and sign your prescription for your medicines. 
 
IF these were the only options available at the time, which option would you choose for each 
choice question? 
 
Make the following assumptions when making your choice: 
• All the prescribers listed in the 3 options have completed all the clinical and legal training 
requirements to provide the prescribing service (i.e. they can write and sign the prescription for 
your required high blood pressure medicines).  
• All the prescribers listed in the 3 options have appropriate access to your medical records to make 
clinical decisions.  
• The prescriber will assess your current health condition, and may perform screening and/or 
request additional laboratory testing as required. 
• You will see a GP prescriber for a review of your condition at least once a year. 
• The $5 per prescription item charge that you pay when your medicines are dispensed at a 




Choice question B1: 
 GP prescriber  Registered Nurse 
prescriber 
Pharmacist prescriber 
Location of consultation At GP practice At community 
pharmacy 
At GP practice 
Next available 
consultation is 
3 days from now 7 days from now 3 days from now 
Cost of the consultation usual GP cost plus 
20%  
usual GP cost minus 
100% 
usual GP cost minus 
20% 
Type of service your 
consultation covers 
• Assessment of 
health condition. 




• Issue prescription 
for current 
medicines with 
dose changes as 





•  Assessment of 
health condition.  








• Assessment of 




this consultation.  
• Issue prescription 
for optimisation of 
medicines, which 
includes changing 
doses of current 
medicines, 
stopping a current 
medicine, starting 
new medicines. 
Type of consultation  Walk-in and wait 
clinic 




Open 24 hours day Open 8 hours a day 
(e.g. 9am-5pm)  
Open 16 hours a day 
(e.g. 7am-11pm) 
Which option would you 
choose?  
Tick one box only 
   





Choice question B2: 








3 days from now 7 days from now 5 days from now 
Cost of the consultation usual GP cost minus 
100% 
usual GP cost plus 20%  same as usual GP 
cost 
Type of service your 
consultation covers 
• Assessment of 
health condition. 








dose changes as 





•  Assessment of 
health condition.  




• Issue repeat 
prescription for 
current medicines. 





















Type of consultation  Walk-in and wait 
clinic 
By appointment By appointment 
Prescribing service 
operating hours 
Open 8 hours a day 
(e.g. 9am-5pm)  
Open 16 hours a day 
(e.g. 7am-11pm) 
Open 24 hours day 
Which option would you 
choose?  
Tick one box only 



























Choice question B3: 








3 days from now 5 days from now Within 1 day from 
now 
Cost of the consultation usual GP cost plus 
20%  
usual GP cost minus 
100% 
usual GP cost 
minus 20% 
Type of service your 
consultation covers 
•  Assessment of 
health condition.  








•  Assessment of 
health condition.  




• Issue repeat 
prescription for 
current medicines. 
• Assessment of 
health 
condition.  










as needed, but 
no stoppages 
or additions to 
current 
medicines. 
Type of consultation By appointment  Walk-in and wait clinic By appointment 
Prescribing service 
operating hours 
Open 16 hours a day 
(e.g. 7am-11pm) 
Open 8 hours a day (e.g. 
9am-5pm)  
Open 24 hours day 
Which option would you 
































Choice question B4: 








7 days from now 5 days from now 3 days from now 
Cost of the consultation usual GP cost minus 
100% 
usual GP cost plus 20%  usual GP cost 
minus 100% 
Type of service your 
consultation covers 
•  Assessment of 
health condition. 








• Assessment of 
health condition.  
• Medicine 
optimisation 
required during this 
consultation. 
• Issue prescription 
for optimisation of 
medicines, which 
includes changing 
doses of current 
medicines, stopping 
a current medicine, 
starting new 
medicines. 
•  Assessment of 
health 
condition.  









Type of consultation  Walk-in and wait 
clinic 
By appointment By appointment 
Prescribing service 
operating hours 
Open 24 hours day Open 8 hours a day (e.g. 
9am-5pm)  
Open 16 hours a 
day (e.g. 7am-
11pm) 
Which option would you 
choose?  
Tick one box only 
































Choice question B5: 




Location of consultation At GP practice At community 
pharmacy 
At GP practice 
Next available consultation is 5 days from now 7 days from now 3 days from now 
Cost of the consultation usual GP cost minus 
100% 
usual GP cost plus 20%  usual GP cost 
plus 20%  
Type of service your 
consultation covers 





















•  Assessment of 
health condition.  




























Type of consultation  Walk-in and wait 
clinic 
 Walk-in and wait 
clinic 
By appointment 
Prescribing service operating 
hours 
Open 16 hours a day 
(e.g. 7am-11pm) 
Open 8 hours a day 
(e.g. 9am-5pm)  
Open 8 hours a 
day (e.g. 9am-
5pm)  
Which option would you 
choose?  
Tick one box only 




Q11.B6). To help us better understand decision making in this questionnaire, can you please briefly 
explain why and how you made your choice in choice question B5 above? 
You can see what you chose for choice question 5 by clicking on the “prev” button and then the “next” 















Choice questions—BLOCK C: 
Choice Questions for this questionnaire: 
 
Please consider the health scenario listed below and answer the 5 choice questions that follow by ticking 




IMAGINE you have had hypertension (i.e. high blood pressure) for some time and you need to 
see a prescriber who can assess your current health condition, decide if and how your medicines 
need adjusting, and then write and sign your prescription for your medicines. 
 
IF these were the only options available at the time, which option would you choose for each 
choice question? 
 
Make the following assumptions when making your choice: 
• All the prescribers listed in the 3 options have completed all the clinical and legal training 
requirements to provide the prescribing service (i.e. they can write and sign the prescription for 
your required high blood pressure medicines).  
• All the prescribers listed in the 3 options have appropriate access to your medical records to make 
clinical decisions.  
• The prescriber will assess your current health condition, and may perform screening and/or 
request additional laboratory testing as required. 
• You will see a GP prescriber for a review of your condition at least once a year. 
• The $5 per prescription item charge that you pay when your medicines are dispensed at a 





































Choice question C1: 
 GP prescriber  Registered Nurse 
prescriber 
Pharmacist prescriber 
Location of consultation At GP practice At community 
pharmacy 
At GP practice 
Next available 
consultation is 
Within 1 day from 
now 
7 days from now 5 days from now 
Cost of the consultation usual GP cost 
minus 20% 
usual GP cost minus 
20% 
usual GP cost minus 
100% 
Type of service your 
consultation covers 
•  Assessment of 
health 
condition. 









•  Assessment of 
health 
condition. 









• Assessment of health 
condition.  




• Issue prescription for 
current medicines 
with dose changes as 
needed, but no 
stoppages or 
additions to current 
medicines. 
Type of consultation  Walk-in and wait 
clinic 
By appointment By appointment 
Prescribing service 
operating hours 
Open 16 hours a 
day (e.g. 7am-
11pm) 
Open 24 hours day Open 8 hours a day (e.g. 
9am-5pm)  
Which option would you 
choose?  
Tick one box only 


































Choice question C2: 




Location of consultation At GP practice At community 
pharmacy 
At GP practice 
Next available 
consultation is 
5 days from now 5 days from now Within 1 day from 
now 
Cost of the consultation usual GP cost plus 
20%  
usual GP cost minus 
100% 
usual GP cost plus 
20%  
Type of service your 
consultation covers 
•  Assessment of 
health condition.  








• Assessment of 
health condition. 









dose changes as 





• Assessment of 




this consultation.  
• Issue prescription 
for optimisation of 
medicines, which 
includes changing 
doses of current 
medicines, 
stopping a current 
medicine, starting 
new medicines. 
Type of consultation By appointment  Walk-in and wait 
clinic 




Open 24 hours day Open 16 hours a day 
(e.g. 7am-11pm) 
Open 8 hours a day 
(e.g. 9am-5pm)  
Which option would you 
choose?  
Tick one box only 































Choice question C3: 




Location of consultation At GP practice At community 
pharmacy 
At GP practice 
Next available 
consultation is 
5 days from now 5 days from now 7 days from now 
Cost of the consultation usual GP cost plus 
20%  
usual GP cost plus 
20%  
usual GP cost minus 
100% 
Type of service your 
consultation covers 
• Assessment of 
health condition.  








dose changes as 





• Assessment of 
health condition. 









dose changes as 





• Assessment of 




this consultation.  
• Issue prescription 
for optimisation of 
medicines, which 
includes changing 
doses of current 
medicines, 
stopping a current 
medicine, starting 
new medicines. 





Open 8 hours a day 
(e.g. 9am-5pm)  
Open 24 hours day Open 16 hours a day 
(e.g. 7am-11pm) 
Which option would you 
choose?  
Tick one box only 































Choice question C4: 




Location of consultation At GP practice At GP practice At GP practice 
Next available 
consultation is 
3 days from now 5 days from now Within 1 day from 
now 
Cost of the consultation usual GP cost minus 
100% 
usual GP cost plus 
20%  
same as usual GP cost 
Type of service your 
consultation covers 



















• Assessment of 
health 
condition. 









dose changes as 





•  Assessment of 
health condition.  




• Issue repeat 
prescription for 
current medicines. 




Open 24 hours day Open 16 hours a day 
(e.g. 7am-11pm) 
Open 8 hours a day 
(e.g. 9am-5pm)  
Which option would you 
choose?  
Tick one box only 






























Choice question C5: 








5 days from now Within 1 day from 
now 
3 days from now 
Cost of the consultation usual GP cost minus 
100% 
same as usual GP 
cost 
usual GP cost plus 
20%  
Type of service your 
consultation covers 
•  Assessment of 
health condition. 





























• Assessment of 




this consultation.  




changing doses of 
current medicines, 
stopping a current 
medicine, starting 
new medicines. 




Open 8 hours a day 
(e.g. 9am-5pm)  
Open 24 hours day Open 16 hours a day 
(e.g. 7am-11pm) 
Which option would you 
choose?  
Tick one box only 
   
 
 
Q11.C6). To help us better understand decision making in this questionnaire, can you please briefly 
explain why and how you made your choice in choice question C5 above? 
 
You can see what you chose for choice question 5 by clicking on the “prev” button and then the “next” 


















Choice questions—BLOCK D: 
Choice Questions for this questionnaire: 
 
Please consider the health scenario listed below and answer the 5 choice questions that follow by ticking 
the option you most prefer for each choice question: 
 
HEALTH SCENARIO: 
IMAGINE you have had hypertension (i.e. high blood pressure) for some time and you need to 
see a prescriber who can assess your current health condition, decide if and how your medicines 
need adjusting, and then write and sign your prescription for your medicines. 
 
IF these were the only options available at the time, which option would you choose for each 
choice question? 
 
Make the following assumptions when making your choice: 
• All the prescribers listed in the 3 options have completed all the clinical and legal training 
requirements to provide the prescribing service (i.e. they can write and sign the prescription for 
your required high blood pressure medicines).  
• All the prescribers listed in the 3 options have appropriate access to your medical records to make 
clinical decisions.  
• The prescriber will assess your current health condition, and may perform screening and/or 
request additional laboratory testing as required. 
• You will see a GP prescriber for a review of your condition at least once a year. 
• The $5 per prescription item charge that you pay when your medicines are dispensed at a 







































Choice question D1: 
 GP prescriber  Registered Nurse 
prescriber 
Pharmacist prescriber 
Location of consultation At GP practice At community 
pharmacy 
At GP practice 
Next available 
consultation is 
5 days from now 3 days from now 7 days from now 
Cost of the consultation usual GP cost plus 
20%  
usual GP cost minus 
100% 
usual GP cost plus 20%  
Type of service your 
consultation covers 
•  Assessment of 
health condition. 





























• Assessment of 
health condition.  




• Issue prescription 
for current 
medicines with 
dose changes as 
needed, but no 
stoppages or 
additions to current 
medicines. 
Type of consultation  Walk-in and wait 
clinic 





Open 24 hours day Open 8 hours a day 
(e.g. 9am-5pm)  
Open 16 hours a day 
(e.g. 7am-11pm) 
Which option would you 
choose?  
Tick one box only 



























Choice question D2: 
 GP prescriber  Registered Nurse 
prescriber 
Pharmacist prescriber 




7 days from now Within 1 day from 
now 
5 days from now 
Cost of the consultation usual GP cost plus 20%  usual GP cost 
minus 100% 
usual GP cost plus 20%  
Type of service your 
consultation covers 
• Assessment of 
health condition. 




• Issue prescription 
for current 
medicines with 
dose changes as 




•  Assessment of 
health 
condition. 









• Assessment of 
health condition.  
• Medicine 
optimisation 
required during this 
consultation.  
• Issue prescription 
for optimisation of 
medicines, which 
includes changing 
doses of current 
medicines, stopping 
a current medicine, 
starting new 
medicines. 
Type of consultation  Walk-in and wait 
clinic 
By appointment  Walk-in and wait clinic 
Prescribing service 
operating hours 
Open 8 hours a day 
(e.g. 9am-5pm)  
Open 24 hours day Open 24 hours day 
Which option would you 
choose?  
Tick one box only 

































Choice question D3: 
 GP prescriber  Registered Nurse 
prescriber 
Pharmacist prescriber 




Within 1 day from now 5 days from now 3 days from now 
Cost of the consultation usual GP cost minus 
100% 
usual GP cost plus 
20%  
usual GP cost minus 
100% 
Type of service your 
consultation covers 
• Assessment of 
health condition. 




• Issue prescription 
for current 
medicines with 
dose changes as 

























•  Assessment of 
health condition.  




• Issue repeat 
prescription for 
current medicines. 
Type of consultation By appointment  Walk-in and wait 
clinic 
 Walk-in and wait clinic 
Prescribing service 
operating hours 
Open 8 hours a day 
(e.g. 9am-5pm)  
Open 24 hours day Open 16 hours a day 
(e.g. 7am-11pm) 
Which option would you 
choose?  
Tick one box only 



























Choice question D4: 
 GP prescriber  Registered Nurse 
prescriber 
Pharmacist prescriber 




3 days from now 5 days from now 7 days from now 
Cost of the consultation same as usual GP cost usual GP cost 
minus 20% 
usual GP cost minus 
100% 
Type of service your 
consultation covers 
•  Assessment of 
health condition. 




• Issue repeat 
prescription for 
current medicines. 
• Assessment of 
health 
condition. 










as needed, but 
no stoppages 
or additions to 
current 
medicines. 
• Assessment of 
health condition.  
• Medicine 
optimisation 
required during this 
consultation.  
• Issue prescription 
for optimisation of 
medicines, which 
includes changing 
doses of current 
medicines, stopping 
a current medicine, 
starting new 
medicines. 
Type of consultation By appointment By appointment  Walk-in and wait clinic 
Prescribing service 
operating hours 
Open 8 hours a day 
(e.g. 9am-5pm)  
Open 16 hours a 
day (e.g. 7am-
11pm) 
Open 24 hours day 
Which option would you 
choose?  
Tick one box only 






























Choice question D5: 
 GP prescriber  Registered Nurse 
prescriber 
Pharmacist prescriber 
Location of consultation At GP practice At community 
pharmacy 
At GP practice 
Next available 
consultation is 
7 days from now Within 1 day from 
now 
3 days from now 
Cost of the consultation usual GP cost minus 
20% 
usual GP cost 
minus 20% 
usual GP cost minus 
100% 
Type of service your 
consultation covers 
• Assessment of 




this consultation.  
• Issue prescription 
for optimisation of 
medicines, which 
includes changing 
doses of current 
medicines, 
stopping a current 
medicine, starting 
new medicines. 
• Assessment of 
health 
condition. 










as needed, but 
no stoppages 
or additions to 
current 
medicines. 
•  Assessment of 
health condition.  




• Issue repeat 
prescription for 
current medicines. 
Type of consultation  Walk-in and wait 
clinic 





Open 24 hours day Open 16 hours a 
day (e.g. 7am-
11pm) 
Open 8 hours a day (e.g. 
9am-5pm)  
Which option would you 
choose?  
Tick one box only 
   
 
 
Q11.D6). To help us better understand decision making in this questionnaire, can you please briefly 
explain why and how you made your choice in choice question D5 above? 
 
You can see what you chose for choice question 5 by clicking on the “prev” button and then the “next” 



















Section 4: Attribute-related questions: 
12). Please indicate how easy you found it to complete the 5 choice task questions in the previous section: 
 Extremely easy 
 Moderately easy 
 Moderately difficult 
 Extremely difficult 
 
13). From the 3 prescribers listed below, please choose which prescriber is your most preferred and which 






GP prescriber                    
Pharmacist prescriber    
Nurse prescriber   
 
  
















16).  Before completing this questionnaire, did you know that pharmacist prescribers in New Zealand 
are pharmacists who complete additional training and can prescribe some prescription medicines (i.e. 
during a consultation with them, they assess your condition and can write and sign your prescription, 
just like your GP does, for specific approved prescription medicines)? 
   Yes 
    No 
 
17).  Before completing this questionnaire, did you know that registered nurse prescribers in New 
Zealand are registered nurses who complete additional training and can prescribe some prescription 
medicines (i.e. during a consultation with them, they assess your condition and can write and sign 
your prescription, just like your GP does, for specific approved prescription medicines)? 
   Yes 






18).   Currently, how satisfied are you with your ACCESS to a GP overall (i.e. you can see/make an 
appointment with your GP when you want to)?   
Extremely satisfied 
 Somewhat satisfied 
 Somewhat dissatisfied 



























Section 5: Sociodemographic questions 
19).  What is your highest level of education? 
 Finished primary school 
 Finished high school 
 Any university qualification 
 Apprenticeship (and no university or polytechnic qualification) 
 Any polytechnic qualification 




20).  What is your household income per year, in NZ dollars before tax?  
Less than $25 000 per year 
More than $25 000 to $50 000 per year 
More than $50 000 to $80 000 per year 
More than $80 000 to $100 000 per year 
More than $100 000 per year 
 
21).  Select what type of employment applies to you 
Full time (≥ 30 hours/week) 
 Part time (< 30 hours/week) 
 Unemployed 
 
22).  What type of area do you live in?  
   Major city (urban area with population > 50 000 people e.g. Auckland, Wellington,      
              Christchurch, Dunedin, Hamilton, etc.)       
  
Provincial city (urban area with population > 30 000 people e.g. Nelson, New Plymouth, Napier, 
Gisborne etc.)  
Provincial town (urban area with a population between 1 000 and 30 000 people e.g. Levin, 
Gore, etc.) 





















Other, please specify 
 
 
24).  When you visit your GP practice to see a doctor, do you usually 
 See the same GP each time (i.e. your own GP) 
 See any available GP 
 
25).  How often do you visit the GP?  
 Never 
Once a year 
Once every 6 months 
Once every 3 months 
 Once a month 




26).  When you visit a community pharmacy, do you 
Visit the same community pharmacy most of the time 
Use different community pharmacies most of the time due to convenience 
 
27).  How often do you visit a community pharmacy?  
Never 
Once a year 
Once every 6 months 
Once every 3 months 
 Once a month 
         More often than once a month   
 











Please click the button on the bottom right to submit your answers and finish the questionnaire. 
We thank you for your time spent completing this questionnaire. 
 
 
 
 
 
